# National Clinical Guideline Centre

# Drug allergy

## Diagnosis and management of drug allergy in adults, children and young people

*Clinical guideline <...>*

*Methods, evidence and recommendations*

*April 2014*

*Commissioned by the National Institute for Health and Care Excellence*

Royal College of Physicians

The Royal College of Surgeons of England

RCGP Royal College of General Practitioners

Royal College of Nursing

NICE accredited
www.nice.org.uk/accreditation

1

# Contents

## 1 Guideline Development Group members

| Name | Role |
|------|------|
| Mike Arden Jones | Consultant Dermatologist |
| David Cousins | Pharmacist |
| Matthew Doyle | General Practitioner |
| George Du Toit | Consultant Paediatrician |
| Mandy East | Patient or carer member |
| Pamela Ewan | Consultant Allergist |
| James Larcombe | General Practitioner |
| Nicola Mundy | Patient or carer member |
| Shuaib Nasser | Chair, Consultant Allergist |
| Alice Oborne | Pharmacist |
| Paul Whittaker | Specialist respiratory consultant |
| Andrew Williams | Specialist Nurse |

## 2 NCGC technical team members

| Name | Role |
|------|------|
| Lee Yee Chong | Senior Research Fellow (until May 2013) |
| Margaret Constanti | Health Economist (until March 2013) |
| Kathleen DeMott | Research Fellow (until August 2013) |
| Tamara Diaz | Project Manager |
| Katharina Dworzynski | Senior Research Fellow |
| Martin Harker | Health Economist (from April 2013) |
| Kate Kelley | Guideline Lead, Associate Director (until January 2013) |
| Grace Marsden | Senior Health Economist (from April 2013) |
| Su Park | Research Fellow (from August 2013) |
| Vicki Pollit | Senior Health Economist (until March 2013) |
| Gill Ritchie | Guideline Lead, Associate Director |
| Carlos Sharpin | Information Scientist |

## 3 Co-optees

| Name | Role |
|------|------|
| M Thirumala Krishna | Co-optee, Laboratory Pathologist and Consultant Allergist |
| Nigel J N Harper | Co-optee, Consultant Anaesthetist |
| Nick Brown | Co-optee, Dentist |

4

1 # Acknowledgements

2 The development of this guideline was greatly assisted by the following people:

| Name | Role |
| --- | --- |
| Elisabetta Fenu | NCGC, Health Economic Lead |
| Jill Cobb | NCGC, Information Scientist |
| Tom Kenny | NIHR Evaluation Trials and Studies Coordinating Centre (NETS CC), Director, External Relations, |
| Maggie Westby | NCGC, Clinical Lead |
| Pamela Young | NIHR Evaluation Trials and Studies Coordinating Centre (NETS CC), Scientific Adviser (Identification) - External Relations |

3

4

# 1 Introduction

All drugs have the potential to cause side effects, also known as 'adverse drug reactions', but not all of these are allergic in nature. Other reactions are caused by drug intolerance, idiosyncratic reactions and pseudo-allergic reactions. The British Society for Allergy and Clinical Immunology (BSACI) defines drug allergy as an adverse drug reaction with an established immunological mechanism. The mechanism at presentation may not be apparent from the clinical history and it cannot always be established whether a drug reaction is allergic or non-allergic without investigation. Therefore, this guideline has defined drug allergy as any reaction caused by a drug with clinical features compatible with an immunological mechanism.

Hospital Episode Statistics from 1996 to 2000 reported that drug allergies and adverse drug reactions accounted for approximately 62,000 hospital admissions in England each year. There is also evidence that these reactions are increasing: between 1998 and 2005, serious adverse drug reactions rose 2.6-fold. Up to 15% of inpatients have their hospital stay prolonged as a result of an adverse drug reaction.

Almost one million people admitted to NHS hospitals each year have a diagnostic 'label' of drug allergy, with the most common being penicillin allergy. About 10% of the general population claim to have a penicillin allergy;[76,76] this has often been because of a skin rash that occurred during a course of penicillin in childhood. Fewer than 10% of people who think they are allergic to penicillin are truly allergic.[76,76] Therefore, penicillin allergy can potentially be excluded in 9% of the population.[36,59]

Hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, diclofenac, naproxen and aspirin,[59,75] is common, affecting 1 in 1000 of the general population and 5–10% of people who have asthma. In these people, fatal reactions can occur with small doses of NSAIDs. Up to one-third of people with chronic urticaria have severe reactions to NSAIDs, involving angioedema and anaphylaxis after administration of NSAIDs.[34,109]

Anaphylaxis during general anaesthesia occurs in between 1 in 10,000–20,000 anaesthetics. These patients may be denied general anaesthesia in the future unless a safe combination of drugs can be identified.

Major issues identified by this guideline include poor clinical documentation of drug allergy and a lack of patient information. Computerised primary care record systems are often unable to distinguish between intolerance and drug allergy and this can lead to a false label of drug allergy, particularly if the person's reaction took place many years previously and details about their reaction have been lost. Furthermore, there is no routine system in place for people to keep a record of their own drug allergies. This can lead to confusion over which drugs can be taken safely and can result in people inadvertently taking a drug they are allergic to, particularly when buying over-the-counter drugs from a pharmacy.

Analysis of patient safety incidents reported to the National Reporting and Learning System between 2005 and 2013 identified 18,079 incidents involving drug allergy. These included 6 deaths, 19 'severe harms', 4,980 'other harms' and 13,071 'near-misses'. The majority of these incidents involved a drug that was prescribed, dispensed or administered to a patient with a previously known allergy to that drug or drug class.

Diagnosing drug allergy can be challenging and there is considerable variation both in how drug allergy is managed and in geographical access to treatment. This can lead to underdiagnosis, misdiagnosis and self-diagnosis. This variation may be caused by insufficient awareness of available services or by a lack of local provision of drug allergy centres. Some people are never offered referral to specialist services and instead stay in primary care while others have their drug allergy managed in

1  other disciplines. Therefore, only a small proportion of people are treated in specialist allergy
2  centres.

3  In view of the variation in provision of care for people with drug allergy, the scope of this guideline
4  identified a need for guidance to improve clinical management for people affected by drug allergy.
5  This guideline has been developed for use by healthcare professionals at all levels of healthcare and
6  offers best practice advice on the diagnosis, documentation and communication of drug allergy in
7  adults, children and young people.

8

# 2 Development of the guideline

## 2.1 What is a NICE clinical guideline?

NICE clinical guidelines are recommendations for the care of individuals in specific clinical conditions or circumstances within the NHS – from prevention and self-care through primary and secondary care to more specialised services. We base our clinical guidelines on the best available research evidence, with the aim of improving the quality of healthcare. We use predetermined and systematic methods to identify and evaluate the evidence relating to specific review questions.

NICE clinical guidelines can:
- provide recommendations for the treatment and care of people by health professionals
- be used to develop standards to assess the clinical practice of individual health professionals
- be used in the education and training of health professionals
- help patients to make informed decisions
- improve communication between patient and health professional.

While guidelines assist the practice of healthcare professionals, they do not replace their knowledge and skills.

We produce our guidelines using the following steps:
- Guideline topic is referred to NICE from the Department of Health.
- Stakeholders register an interest in the guideline and are consulted throughout the development process.
- The scope is prepared by the National Clinical Guideline Centre (NCGC).
- The NCGC establishes a Guideline Development Group.
- A draft guideline is produced after the group assesses the available evidence and makes recommendations.
- There is a consultation on the draft guideline.
- The final guideline is produced.

The NCGC and NICE produce a number of versions of this guideline:
- the 'full guideline' contains all the recommendations, plus details of the methods used and the underpinning evidence
- the 'NICE guideline' lists the recommendations
- 'information for the public' is written using suitable language for people without specialist medical knowledge
- NICE Pathways brings together all connected NICE guidance.

This version is the full version. The other versions can be downloaded from NICE at www.nice.org.uk.

## 2.2 Remit

NICE received the remit for this guideline from the Department of Health. They commissioned the NCGC to produce the guideline.

The remit for this guideline is:

**Drug allergy: the diagnosis and management of drug allergy in adults, children and young people**

## 2.3 Who developed this guideline?

A multidisciplinary Guideline Development Group (GDG) comprising health professionals and researchers as well as lay members developed this guideline (see the list of Guideline Development Group members and the acknowledgements).

The National Institute for Health and Care Excellence (NICE) funds the National Clinical Guideline Centre (NCGC) and thus supported the development of this guideline. The GDG was convened by the NCGC and chaired by Dr Shuaib Nasser in accordance with guidance from NICE.

The group met every 5 to 6 weeks during the development of the guideline. At the start of the guideline development process all GDG members declared interests including consultancies, fee-paid work, share-holdings, fellowships and support from the healthcare industry. At all subsequent GDG meetings, members declared arising conflicts of interest.

Members were either required to withdraw completely or for part of the discussion if their declared interest made it appropriate. The details of declared interests and the actions taken are shown in Appendix B.

Staff from the NCGC provided methodological support and guidance for the development process. The team working on the guideline included a project manager, systematic reviewers, health economists and information scientists. They undertook systematic searches of the literature, appraised the evidence, conducted meta-analysis and cost-effectiveness analysis where appropriate and drafted the guideline in collaboration with the GDG.

**(a) What this guideline covers**

This guideline covers the diagnosis and management of drug allergies. For further details please refer to the scope in Appendix A and the review questions in Section 3.1.

**(a) What this guideline does not cover**

This guideline does not cover other allergies (for example food allergies), treatment of the acute phase including anaphylaxis, investigation of allergies to individual drugs or in specific populations (unless specified in the scope), or treatment of non-allergic adverse drug reactions.

**(b) Relationships between the guideline and other NICE guidance**

This guideline is related to NICE clinical guideline 134 (2011) on Anaphylaxis, NICE clinical guideline 76 (2009) on Medicines adherence, NICE patient safety guidance 1 (2007) on Medicines reconciliation on admission of adults to hospital and a NICE clinical guideline on Medicines optimisation (in development).

# 3 Methods

This chapter sets out in detail the methods used to review the evidence and to generate the recommendations that are presented in subsequent chapters. This guidance was developed in accordance with the methods outlined in the NICE guidelines manual 2012.[117]

## 3.1 Developing the review questions and outcomes

Review questions were developed in a PICO framework (patient, intervention, comparison and outcome) for intervention reviews; in a framework of population, index tests, reference standard and target condition for reviews of diagnostic test accuracy; and using population, presence or absence of factors under investigation (for example prognostic factors) and outcomes for prognostic reviews. The experience of information provision for people with suspected or confirmed drug allergies was reviewed using qualitative information to capture preferences and perceptions (including factors which improve or act as a barrier to optimal care).

This use of a framework guided the literature searching process, critical appraisal and synthesis of evidence, and facilitated the development of recommendations by the GDG. The review questions were drafted by the NCGC technical team and refined and validated by the GDG. The questions were based on the key clinical areas identified in the scope (Appendix A).

A total of 11 review questions were identified.

Full literature searches, critical appraisals and evidence reviews were completed for all the specified review questions.

Table 1:    Review questions

| Chapter | Type of review | Review questions | Outcomes |
|---------|----------------|------------------|----------|
| Assessment | Review of commonalities across drug allergies assessment scores and algorithms | What is the clinical and cost effectiveness of clinical probability scores or algorithms in identifying or excluding drug allergies? | • Commonalities and differences across algorithms and probability scores<br>• Features that assess likelihood of people having drug allergies |
| Measuring serum tryptase after suspected anaphylaxis | Diagnostic accuracy review | What is the clinical and cost effectiveness of serum tryptase testing compared with reference standard tests for the diagnosis of an anaphylactic reaction due to suspected drug allergy? | • Test accuracy measures:<br>• Pre-test probability<br>• Sensitivity<br>• Specificity<br>• Positive predictive value<br>• Negative predictive value<br>• Number of cases missed |
| Measuring serum specific immunologulin E (IgE) | Diagnostic accuracy review | What is the clinical and cost effectiveness of serum specific IgE testing compared with reference standard tests in the diagnosis of drug allergy for the following drugs? amoxicillin | • Test accuracy measures:<br>• Pre-test probability<br>• Sensitivity<br>• Specificity |

| Chapter | Type of review | Review questions | Outcomes |
|---------|----------------|------------------|----------|
| | | ampicillin<br>cofactor<br>chlorhexidine<br>morphine<br>penicillin G<br>penicillin V<br>suxemethonium. | • Positive predictive value<br>• Negative predictive value<br>• Number of cases missed<br>• Number of cases mislabelled |
| Documenting and sharing information with other healthcare professionals | Intervention review | What are the most clinically and cost effective documentation strategies for communicating drug allergy information across all NHS services to prevent patients from receiving drugs to which they are allergic? | • Medication errors (inappropriate prescription or administration of drugs)<br>• Number of repeat drug allergic reactions (including patient-reported episodes)<br>• Inappropriate avoidance of drugs<br>• Health-related quality of life |
| Providing information and support to patients | Qualitative review | What information and support should individuals with suspected drug allergy or their parents and carers receive?<br>What information and support should individuals who have had specialist investigations or their parents and carers receive? | • Patient experiences<br>• Preferences or perceptions, including factors which improve or act as barrier to optimal care<br>• Clinical and quality of life outcomes related to diagnosis and management of drug allergy |
| Non-specialist management | Prognostic review | In patients who have had allergic reactions to NSAIDs what are the factors that indicate whether they can or cannot tolerate selective COX-2 inhibitors? | • Incidence and severity of reaction to selective COX-2 inhibitors, such as asthma, angioedema or urticaria<br>• Incidence of other adverse events |
| Referral to specialist drug allergy services | Intervention review | What is the clinical and cost effectiveness of referral to specialist drug allergy services for people with suspected drug allergy to beta-lactam antibiotics?<br><br>What is the clinical and cost effectiveness of referral to specialist drug allergy services for people with suspected allergy to NSAIDs?<br><br>What is the clinical and cost effectiveness of referral to specialist drug allergy services for people with suspected allergy to local | • Mortality<br>• Number of repeat drug allergic reactions (including patient reported episodes)<br>• Length of hospital stay<br>• Inappropriate avoidance of drugs.<br>• Health-related quality of life |

| Chapter | Type of review | Review questions | Outcomes |
|---|---|---|---|
| | | anaesthetics? | |
| | | What is the clinical and cost effectiveness of referral to specialist drug allergy services for people with suspected anaphylaxis due to drug allergy during general anaesthesia?(a) | |

1   (a) This question was phrased different to the other 3 review questions regarding referral – it relates to people with
2       suspected anaphylaxis rather than people with suspected drug allergy – since it refers to an immediate severe reaction
3       during general anaesthesia.

## 3.2   Searching for evidence

### 3.2.1   Clinical literature search

Systematic literature searches were undertaken to identify all published clinical evidence relevant to the review questions. Searches were undertaken according to the parameters stipulated within the NICE guidelines manual 2012.[117] Databases were searched using relevant medical subject headings, free-text terms and study-type filters where appropriate. Studies published in languages other than English were not reviewed. Where possible, searches were restricted to articles published in English. All searches were conducted in MEDLINE, Embase, and The Cochrane Library. In additional Cinahl was used for the information and support review. All searches were updated on 10 January 2014. No papers published after this date were considered.

Search strategies were quality assured by cross-checking reference lists of highly relevant papers, analysing search strategies in other systematic reviews, and asking GDG members to highlight any additional studies. The questions, the study types applied, the databases searched and the years covered can be found in Appendix G.

The titles and abstracts of records retrieved by the searches were sifted for relevance, with potentially significant publications obtained in full text. These were assessed against the inclusion criteria.

During the scoping stage, a search was conducted for guidelines and reports on the websites listed below from organisations relevant to the topic. Searching for unpublished literature was not undertaken. All references sent by stakeholders were considered.

- Guidelines International Network database (http://www.g-i-n.net/)
- National Guideline Clearing House (http://www.guideline.gov/)
- National Institute for Health and Care Excellence (NICE) (http://www.nice.org.uk/)
- National Institutes of Health Consensus Development Program (http://consensus.nih.gov/)
- NHS Evidence Search (http://www.evidence.nhs.uk/)
- British Society for Allergy & Clinical Immunology (BSACI) (http://www.bsaci.org/)
- American Academy of Allergy, Asthma & Immunology (AAAAI) (http://www.aaaai.org/home.aspx).

### 3.2.2   Health economic literature search

Systematic literature searches were also undertaken to identify health economic evidence within published literature relevant to the review questions. The evidence was identified by conducting a broad search relating to drug allergy in the NHS Economic Evaluation Database (NHS EED), the Health Technology Assessment database (HTA) and the Health Economic Evaluations Database (HEED) with

no date restrictions. Additionally, the search was run on MEDLINE and Embase using a specific economic filter, from 2011, to ensure recent publications that had not yet been indexed by the economic databases were identified. Studies published in languages other than English were not reviewed. For databases, where it was possible, searches were restricted to articles published in English.

The health economic search strategies are included in Appendix G. All searches were updated on 15 January 2014. No papers published after this date were considered.

## 3.3 Evidence of effectiveness

The evidence was reviewed following the steps shown schematically in Figure 1:

- Potentially relevant studies were identified for each review question from the relevant search results by reviewing titles and abstracts. Full papers were then obtained.

- Full papers were reviewed against pre-specified inclusion and exclusion criteria to identify studies that addressed the review question in the appropriate population (review protocols are included in Appendix C).

- Relevant studies were critically appraised using the appropriate checklist as specified in The guidelines manual (2012).[117] For diagnostic questions, the QUADAS-2 checklist[155,163] was followed (see Appendix F of The guidelines manual (2012)).

- Key information was extracted on the study's methods, PICO factors and results. These were presented in summary tables (in each review chapter) and evidence tables (in Appendix H).

- Summaries of evidence were generated by outcome (included in the relevant review chapters) and were presented in GDG meetings:

    o Randomised studies: data were meta-analysed where appropriate and reported in GRADE profiles (for intervention reviews).

    o Observational studies: data were presented as a range of values in GRADE profiles.

    o Prognostic studies: data were presented as a range of values, usually in terms of the relative effect as reported by the authors.

    o Diagnostic studies were presented as measures of diagnostic test accuracy (sensitivity, specificity, positive and negative predictive value). Coupled values of sensitivity and specificity were summarised in paired (sensitivity and specificity side by side) forest plots to allow visual comparison between different index tests and to investigate heterogeneity more effectively (given data were reported at the same thresholds).

    o Qualitative studies: each study was summarised in a table where possible, otherwise presented in a narrative.

A 20% sample of each of the above stages of the reviewing process was quality assured by a second reviewer to eliminate any potential of reviewer bias or error.

**Figure 1:    Step-by-step process of review of evidence in the guideline**



### 3.3.1    Inclusion and exclusion criteria

The inclusion and exclusion of studies was based on the review protocols, which can be found in Appendix C. Excluded studies by review question (with the reasons for their exclusion) are listed in Appendix K. The GDG was consulted about any uncertainty regarding inclusion or exclusion.

The guideline population was defined to be people with suspected or confirmed drug allergies. For some review questions, the review population was defined by the drug or drug class the person was allergic to (for example beta-lactam antibiotics, non-steroidal anti-inflammatories, local anaesthetics or general anaesthetics in review questions 8 to 11).

In the diagnostic chapter serum IgE testing was reviewed for a list of drugs that was prioritised by the GDG: amoxicillin, ampicillin, cofactor, chlorhexidine, morphine, penicillin G, penicillin V, and suxamethonium.

The diagnostic serum tryptase review was restricted to patients with signs and symptoms of anaphylaxis.

Even though the prognostic review (to examine if there were certain characteristics of people with an allergy to NSAIDs who could take selective COX-2 inhibitors) had identified specific characteristics as prognostic factors, studies that were not designed to directly address these factors were not excluded. Studies that investigated the safety of taking selective COX-2 inhibitors for people with an allergy to NSAIDs more generally were included as indirect evidence. These studies were then divided by the study population (people with asthma or people with cutaneous reactions) to address the prognostic aspect of the question. For details of the approach to this review please refer to Chapter 10.

1 Randomised trials, non-randomised trials, and observational studies (including diagnostic or
2 prognostic studies) were included in the evidence reviews as appropriate.

3 Conference abstracts were not automatically excluded from the review but were initially assessed
4 against the inclusion criteria and then further processed only if no other full publication was available
5 for that review question, in which case the authors of the selected abstracts were contacted for
6 further information. None of the reviews in this guideline included conference abstracts as part of
7 the evidence.

8 Literature reviews, posters, letters, editorials, comment articles, unpublished studies and studies not
9 in English were excluded.

10 The review protocols are presented in Appendix C.

## 3.3.2 Methods of combining clinical studies

### 3.3.2.1 Data synthesis for intervention reviews

13 Where possible, meta-analyses were conducted to combine the results of studies for each review
14 question using Cochrane Review Manager (RevMan5) software. Fixed-effects (Mantel-Haenszel)
15 techniques were used to calculate risk ratios (relative risk) for the binary outcomes, such as number
16 of patients being treated with alternative beta-lactam antibiotics, or number of patients with
17 medication errors.

18 For continuous outcomes, measures of central tendency (mean) and variation (standard deviation)
19 were required for meta-analysis. Data for continuous outcomes (such as prescription errors) were
20 analysed using an inverse variance method for pooling weighted mean differences and, where the
21 studies had different scales, standardised mean differences were used. A generic inverse variance
22 option in RevMan5 was used if any studies reported solely the summary statistics and 95%
23 confidence interval (95% CI) or standard error; this included any hazard ratios reported. However, in
24 cases where standard deviations were not reported per intervention group, the standard error (SE)
25 for the mean difference was calculated from other reported statistics (p values or 95% CIs); meta-
26 analysis was then undertaken for the mean difference and SE using the generic inverse variance
27 method in RevMan5. When the only evidence was based on studies that summarised results by
28 presenting medians (and interquartile ranges), or only p values were given, this information was
29 assessed in terms of the study's sample size and was included in the GRADE tables without
30 calculating the relative or absolute effects. Consequently, aspects of quality assessment such as
31 imprecision of effect could not be assessed for evidence of this type.

32 Statistical heterogeneity was assessed by visually examining the forest plots, and by considering the
33 chi-squared test for significance at $p < 0.1$ or an I-squared inconsistency statistic (with an I-squared
34 value of more than 50% indicating considerable heterogeneity). Where considerable heterogeneity
35 was present, we carried out predefined subgroup analyses for type of drug allergy and age group
36 (children or adults).

37 The means and standard deviations of continuous outcomes were required for meta-analysis.
38 However, in cases where standard deviations were not reported, the standard error was calculated if
39 the p values or 95% CIs were reported and meta-analysis was undertaken with the mean and
40 standard error using the generic inverse variance method in RevMan5. Where p values were
41 reported as 'less than', a conservative approach was undertaken. For example, if p value was
42 reported as 'p≤0.001', the calculations for standard deviations will be based on a p value of 0.001.

43 For interpretation of the binary outcome results, differences in the absolute event rate were
44 calculated using the GRADEpro software, for the median event rate across the control arms of the

individual studies in the meta-analysis. Absolute risk differences were presented in the GRADE profiles and in clinical summary of findings tables, for discussion with the GDG.

For binary outcomes, absolute event rates were also calculated using the GRADEpro software using event rate in the control arm of the pooled results.

### 3.3.2.2 Data synthesis for prognostic factor reviews

Odds ratios (ORs), risk ratios (RRs) or hazard ratios (HRs), with their 95% confidence intervals (95% CIs) for the effect of the pre-specified prognostic factors were extracted from the papers when reported. For the purpose of the review question on tolerance of selective COX-2 inhibitors, factors that indicated whether the drug was safe to prescribe regardless of prognostic factors were also noted, such as the type of allergic reaction and the rate of severe reactions in response to the selective COX-2 inhibitor.

### 3.3.2.3 Data synthesis for diagnostic test accuracy reviews

#### Data and outcomes

For the reviews of diagnostic test accuracy, a positive result on the index test was found if the patient had values of the measured quantity above a threshold value, and different thresholds could be used. Diagnostic test accuracy measures used in the analysis were: sensitivity, specificity, positive and negative predictive value. The threshold of a diagnostic test is defined as the value at which the test can best differentiate between those with and without the target condition (for instance different thresholds were used in the serum tryptase review) and, in practice, it varies amongst studies. For this guideline, sensitivity and specificity were considered equally important. A high sensitivity (true positives) of a test can pick up the majority of the correct cases with drug allergy; conversely, a high specificity (true negatives) can correctly exclude people without drug allergy.

#### Data synthesis

Coupled forest plots of sensitivity and specificity with their 95% CIs across studies (at various thresholds) were produced for each test, using RevMan5. In order to do this, 2×2 tables (the number of true positives, false positives, true negatives and false negatives) were directly taken from the study if given, or else were derived from raw data or calculated from the set of test accuracy statistics.

Heterogeneity or inconsistency amongst studies was visually inspected in the forest plots where appropriate (only when there were similar thresholds). A diagnostic meta-analysis was not carried out because studies were not homogenous enough to assume a single underlying level of sensitivity and specificity (due to differences in population, type of index test or reference standard).

### 3.3.2.4 Data synthesis for qualitative study review

Where possible a meta-synthesis was conducted to combine qualitative study results. The main aim of the synthesis of qualitative data was a description of the main topics that may influence the experience of care of the person with suspected or confirmed drug allergy or their parents or carers, rather than build new theories or reconceptualise the topic under review. Whenever studies identified a qualitative theme, this was extracted and the main characteristics were summarised. When all themes were extracted from studies, common concepts were categorised and tabulated. This included information on how many studies had identified this theme. A frequently identified theme may indicate an important issue for the review, but frequency of theme is not the only indicator of importance. Study type and population in qualitative research can differ widely meaning that themes that may only be identified by one or a few studies can provide important new

information. Therefore for the purpose of the qualitative review in this guideline the categorisation of themes was exhaustive, that is all themes were accounted for in the synthesis. The GDG could then draw conclusions on the relative merits of each of the themes and how they may help in forming recommendations.

### 3.3.2.5 Data synthesis for the algorithm and probability score review

The aim of this review was to summarise evidence on issues that clinicians need to consider when assessing a person with a suspected drug allergy and the signs and symptoms that the person would present with. Assessments should be suitable for the primary care setting. It was decided that this topic would be best addressed with a review of already published assessment methods (that is, algorithms and probability scores) because of the multitude of individual features that may indicate a potential drug allergy. After a top-level search on this topic a published systematic review was identified (Agbabiaka 2008[3]). This review was edited (studies restricted to adverse drug events without drug allergies were excluded) and updated. For a full description of this specific data synthesis approach please see Chapter 5.

### 3.3.2.6 Data synthesis for the documentation review

The aim of this review was to summarise evidence on the effectiveness of documentation strategies in preventing people with suspected or confirmed allergies receiving the drug they are allergic to. Study types considered for this review were randomised trials, and systematic reviews. Prospective and retrospective cohort studies, before and after studies, case series, surveys and qualitative studies were also considered, with the caveat that if a lot of evidence was identified for a particular documentation intervention then only the higher-level evidence be included in the review.

Due to the multitude of populations, study designs, interventions and reported outcomes an exception was made to the usual effectiveness reviews described above. The following approach was used:

- Evidence was classified according to the broad documentation category (for example, computerised systems or structured charts).
- Features of different documentation categories were then extracted.
- Outcomes (such as prescribing errors or alerts that were overwritten) were summarised and where possible related to the features of the documentation strategy.
- Study quality was assessed individually and then by the majority of evidence for a particular intervention and outcome.
- Overall quality was then assessed by documentation category.

Further details of this approach are described in Chapter 8.

## 3.3.3 Type of studies

For most intervention reviews in this guideline, parallel randomised controlled trials (RCTs) were included because they are considered the most robust type of study design that could produce an unbiased estimate of the intervention effects. If the GDG believed RCT data were not appropriate or there was limited evidence from RCTs, well-conducted non-randomised studies were included. Please refer to Appendix C for full details on the study design of studies selected for each review question. For example in the questions on referral to specialist drug allergy services it was decided to include non-randomised trials since randomisation might not always be possible or appropriate.

For the diagnostic reviews and the algorithm and probability score review, cross-sectional and retrospective studies were included. For prognostic reviews, prospective and retrospective cohort studies were included.

Where data from observational studies were included, the GDG decided that the results for each outcome should be presented separately for each study and meta-analysis was not conducted.

### 3.3.4 Appraising the quality of evidence by outcomes

The evidence for outcomes from the included RCTs and, where appropriate, observational studies were evaluated and presented using an adaptation of the 'Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox' developed by the international GRADE working group (http://www.gradeworkinggroup.org/). The software developed by the GRADE working group (GRADEpro) was used to assess the quality of each outcome, taking into account individual study quality factors and the meta-analysis results. Results were presented in GRADE profiles ('GRADE tables'), which consist of 2 sections: the 'Clinical evidence profile' table includes details of the quality assessment while the 'Clinical evidence summary of findings' table includes pooled outcome data, where appropriate, an absolute measure of intervention effect and the summary of quality of evidence for that outcome. In this table, the columns for intervention and control indicate summary measures and measures of dispersion (such as mean and standard deviation or median and range) for continuous outcomes and frequency of events (n/N: the sum across studies of the number of patients with events divided by sum of the number of completers) for binary outcomes. Reporting or publication bias was only taken into consideration in the quality assessment and included in the 'Clinical evidence profile' table if it was apparent.

The evidence for each outcome was examined separately for the quality elements listed and defined in Table 2. Each element was graded using the quality levels listed in Table 3. The main criteria considered in the rating of these elements are discussed below (see Section 3.3.5 Grading of evidence). Footnotes were used to describe reasons for grading a quality element as having serious or very serious problems. The ratings for each component were summed to obtain an overall assessment for each outcome (Table 4).

The GRADE toolbox is currently designed only for randomised trials and observational studies but we adapted the quality assessment elements and outcome presentation for diagnostic accuracy studies.

**Table 2:    Description of the elements in GRADE used to assess the quality of intervention and diagnostic studies**

| Quality element | Description |
|---|---|
| Risk of bias ('Study limitations') | Limitations in the study design and implementation may bias the estimates of the treatment effect. High risk of bias for the majority of the evidence decreases confidence in the estimate of the effect |
| Inconsistency | Inconsistency refers to an unexplained heterogeneity, as assessed by the I-squared or Chi-squared statistic in intervention reviews or visual inspection of paired sensitivity and specificity forest plots in diagnostic reviews (that is, when point estimates in sensitivity and specificity vary widely across studies). |
| Indirectness | Indirectness refers to differences in study population, intervention or diagnostic index test, comparator or diagnostic comparator test and outcomes between the available evidence and the review question, or recommendation made, such that the effect estimate is changed |
| Imprecision | Intervention reviews: Results are imprecise when studies include relatively few patients and few events and thus have wide confidence intervals around the estimate of the effect. Imprecision results if the confidence interval includes the clinically important threshold but ranges from appreciable benefit to no effect or possible harm. Diagnostic reviews: Results are considered to be imprecise if the confidence interval around either the pooled sensitivity or specificity (or if not pooled the confidence interval of the median) ranges between 10–20% (serious) or above 20% (very serious). |
| Publication bias | Publication bias is a systematic underestimate or an overestimate of the underlying |

| Quality element | Description |
|---|---|
| | beneficial or harmful effect due to the selective publication of studies. This aspect was not assessed in the diagnostic test accuracy reviews. |

**Table 3:    Levels of quality elements in GRADE**

| Level | Description |
|---|---|
| None | There are no serious issues with the evidence |
| Serious | The issues are serious enough to downgrade the outcome evidence by 1 level |
| Very serious | The issues are serious enough to downgrade the outcome evidence by 2 levels |

**Table 4:    Overall quality of outcome evidence in GRADE**

| Level | Description |
|---|---|
| High | Further research is very unlikely to change our confidence in the estimate of effect |
| Moderate | Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate |
| Low | Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate |
| Very low | Any estimate of effect is very uncertain |

### 3.3.5    Grading the quality of clinical evidence

After results were pooled, the overall quality of evidence for each outcome was considered. The following procedure was adopted when using GRADE:

1. A quality rating was assigned, based on the study design. RCTs start as High, observational studies as Low, and uncontrolled case series as Low or Very low.

2. The rating was then downgraded for the specified criteria: risk of bias (study limitations), inconsistency, indirectness, imprecision and publication bias. These criteria are detailed below. Evidence from observational studies (which had not previously been downgraded) was upgraded if there was: a large magnitude of effect, a dose–response gradient, and if all plausible confounding would reduce a demonstrated effect or suggest a spurious effect when results showed no effect. Each quality element considered to have 'serious' or 'very serious' risk of bias was rated down by 1 or 2 points respectively.

3. The downgraded or upgraded marks were then summed and the overall quality rating was revised. For example, all RCTs started as High and the overall quality became Moderate, Low or Very low if 1, 2 or 3 points were deducted respectively.

4. The reasons or criteria used for downgrading were specified in the footnotes.

The details of the criteria used for each of the main quality element are discussed further in the following Sections 3.3.6 to 3.3.9.

### 3.3.6    Risk of bias

Bias can be defined as anything that causes a consistent deviation from the truth. Bias can be perceived as a systematic error, for example, if a study was to be carried out several times and there was a consistently wrong answer, the results would be inaccurate.

The risk of bias for a given study and outcome is associated with the risk of over- or underestimation of the true effect.

The risks of bias are listed in Table 5.

1 A study with a poor methodological design does not automatically imply high risk of bias; the bias is
2 considered individually for each outcome and it is assessed whether this poor design will impact on
3 the estimation of the intervention effect.

4 **Table 5:    Risk of bias in randomised controlled trials**

| Risk of bias | Explanation |
|---|---|
| Allocation concealment | Those enrolling patients are aware of the group to which the next enrolled patient will be allocated (this is a major problem in 'pseudo' or 'quasi' randomised trials with, for example, allocation by day of week, birth date, chart number) |
| Lack of blinding | Patient, caregivers, those recording outcomes, those adjudicating outcomes, or data analysts are aware of the arm to which patients are allocated |
| Incomplete accounting of patients and outcome events | Missing data not accounted for and failure of the trialists to adhere to the intention-to-treat principle when indicated |
| Selective outcome reporting | Reporting of some outcomes and not others on the basis of the results |
| Other risks of bias | For example: Stopping early for benefit observed in randomised trials, in particular in the absence of adequate stopping rules Use of unvalidated patient-reported outcomes Recruitment bias in cluster-randomised trials |

5 **3.3.6.1   Diagnostic studies**

6 For diagnostic accuracy studies, the Quality Assessment of Diagnostic Accuracy Studies version 2
7 (QUADAS-2) checklist was used (see Appendix F of The guidelines manual (2012)[117]). Risk of bias and
8 applicability in primary diagnostic accuracy studies in QUADAS-2 consists of 4 domains (see Figure 2):

9 • patient selection
10 • index test
11 • reference standard
12 • flow and timing.

Figure 2: Summary of QUADAS-2 checklist

| DOMAIN | PATIENT SELECTION | INDEX TEST | REFERENCE STANDARD | FLOW AND TIMING |
|---|---|---|---|---|
| Description | Describe methods of patient selection: Describe included patients (prior testing, presentation, intended use of index test and setting): | Describe the index test and how it was conducted and interpreted: | Describe the reference standard and how it was conducted and interpreted: | Describe any patients who did not receive the index test(s) and/or reference standard or who were excluded from the 2x2 table (refer to flow diagram): Describe the time interval and any interventions between index test(s) and reference standard: |
| Signalling questions (yes/no/unclear) | Was a consecutive or random sample of patients enrolled? | Were the index test results interpreted without knowledge of the results of the reference standard? | Is the reference standard likely to correctly classify the target condition? | Was there an appropriate interval between index test(s) and reference standard? |
| | Was a case-control design avoided? | If a threshold was used, was it pre-specified? | Were the reference standard results interpreted without knowledge of the results of the index test? | Did all patients receive a reference standard? |
| | Did the study avoid inappropriate exclusions? | | | Did all patients receive the same reference standard? |
| | | | | Were all patients included in the analysis? |
| Risk of bias: High/low/unclear | Could the selection of patients have introduced bias? | Could the conduct or interpretation of the index test have introduced bias? | Could the reference standard, its conduct, or its interpretation have introduced bias? | Could the patient flow have introduced bias? |
| Concerns regarding applicability: High/low/unclear | Are there concerns that the included patients do not match the review question? | Are there concerns that the index test, its conduct, or interpretation differ from the review question? | Are there concerns that the target condition as defined by the reference standard does not match the review question? | |

*Source:   QUADAS-2 website, University of Bristol[155]*

Optional domain, multiple test accuracy is applicable when a single study examined more than 1 diagnostic test (head-to-head comparison between 2 or more index tests reported within the same study). This optional domain contains 3 questions relating to risk of bias:

- Did all patients undergo all index tests or were the index tests appropriately randomised amongst the patients?
- Were index tests conducted within a short time interval?
- Are index test results unaffected when undertaken together on the same patient?

### 3.3.6.2  Prognostic studies

For prognostic studies, quality was assessed using the checklist for prognostic studies (Appendix I in The guidelines manual (2012)[117]). The quality rating (Low, High, Unclear) was derived by assessing the risk of bias across 6 domains: selection bias, attrition bias, prognostic factor bias, outcome measurement bias, control for confounders and appropriate statistical analysis, with the last 4 domains being assessed for each outcome. A summary table on the quality of prognostic studies is presented at the beginning of each review to summarise the risk of bias across the 5 domains. More details about the quality assessment for prognostic studies are shown below:

- The study sample represents the population of interest with regard to key characteristics
- Missing data are unrelated to key characteristics, sufficient to limit potential bias – reasons for missing data are adequately described.
- The prognostic factor of interest is adequately measured in study participants.
- The outcome of interest is adequately measured in study participants.
- Important potential confounders are accounted for appropriately.
- The statistical analysis is appropriate for the design of the study, limiting potential for the presentation of valid results.

Many of the studies in the prognostic review were safety studies, that is, they did not directly investigate particular factor and in these cases the checklist for non-randomised studies was used.

### 3.3.6.3 Qualitative studies

For qualitative studies, quality was assessed using the checklist for qualitative studies (Appendix I in The guidelines manual (2012)[117]). The quality rating (Low, High, Unclear) was derived by assessing the risk of bias across 6 domains:

- theoretical approach
- study design
- data collection
- validity
- analysis
- ethics.

### 3.3.6.4 Algorithm and probability score studies

For these studies none of the checklists adequately addressed the specific quality criteria deemed important by the GDG. A checklist was therefore designed for these studies to assess risk of bias across 9 criteria:

These criteria were based on factors that were considered in the narrative assessment of the algorithms within the systematic review[3] included in the chapter (see 6.3):

1. design of the tool:

How the tool was designed in a systematic way (i.e. using a statistical method or by way of literature review)

2. factors that are considered:

Whether or not a sufficient number of features were considered

3. applicability to clinical practice (primary care):

The aim of the review was to find an assessment that could be carried out in general practice and was therefore applicable to current practice.

4. definition of condition:

Whether the tool was based on a clear definition of the condition for which it was going to be used.

5. number of evaluators or assessors:

Whether in the design of the tool separate independent evaluators were used and their assessments were analysed for consistency.

6. prior probabilities:

Whether the group that was assessed was generalisable to the general population of people with drug allergies or whether only high risk participants were assessed by the tool.

7. validation in independent studies:

Whether this test has been further used as a reference standard in other test comparisons

8. confounders or alternative conditions:

Whether plausible alternative conditions or factors that may affect the result of the algorithm were considered

9. ease of interpretation:

Whether the test could be easily and quickly scored and also whether the result or 'score' could be easily interpreted in primary care.

This quality checklist was used by two reviewers independently and differences in assessments were discussed and agreed.

### 3.3.7  Inconsistency

Inconsistency refers to an unexplained heterogeneity of results. When estimates of the treatment effect across studies differ widely (that is, there is heterogeneity or variability in results), this suggests true differences in underlying treatment effect.

Heterogeneity in meta-analyses was examined and sensitivity and subgroup analyses performed as pre-specified in the protocols (Appendix C).

When heterogeneity exists (chi-squared p<0.1, I-squared inconsistency statistic of >50%, or evidence from examining forest plots), but no plausible explanation can be found (for example, duration of intervention or different follow-up periods), the quality of evidence was downgraded by 1 or 2 levels, depending on the extent of uncertainty to the results contributed by the inconsistency in the results. In addition to the I-squared and chi-squared values, the decision for downgrading was also dependent on factors such as whether the intervention is associated with benefit in all other outcomes or whether the uncertainty about the magnitude of benefit (or harm) of the outcome showing heterogeneity would influence the overall judgment about net benefit or harm (across all outcomes).

### 3.3.8  Indirectness

Directness refers to the extent to which the populations, intervention, comparisons and outcome measures are similar to those defined in the inclusion criteria for the reviews. Indirectness is important when these differences are expected to contribute to a difference in effect size, or may affect the balance of harms and benefits considered for an intervention.

### 3.3.9  Imprecision

Imprecision in guidelines concerns whether the uncertainty (confidence interval) around the effect estimate means that it is not clear whether there is a clinically important difference between interventions or not. Therefore, imprecision differs from the other aspects of evidence quality, in that it is not really concerned with whether the point estimate is accurate or correct (has internal or external validity) instead it is concerned with the uncertainty about what the point estimate is. This uncertainty is reflected in the width of the confidence interval.

The 95% confidence interval (95% CI) is defined as the range of values that contain the population value with 95% probability. The larger the trial, the smaller the 95% CI and the more certain the effect estimate.

Imprecision in the evidence reviews was assessed by considering whether the width of the 95% CI of the effect estimate is relevant to decision-making, considering each outcome in isolation. Figure 3 considers a positive outcome for the comparison of treatment A versus B. Three decision-making zones can be identified, bounded by the thresholds for clinical importance (minimal important difference – MID) for benefit and for harm. The MID for harm for a positive outcome means the threshold at which drug A is less effective than drug B by an amount that is clinically important to patients (favours B).

Figure 3:    Illustration of precise and imprecise outcomes based on the confidence interval of
             outcomes in a forest plot



When the confidence interval of the effect estimate is wholly contained in one of the 3 zones (for example, clinically important benefit), we are not uncertain about the size and direction of effect (whether there is a clinically important benefit, or the effect is not clinically important, or there is a clinically important harm), so there is no imprecision.

When a wide confidence interval lies partly in each of 2 zones, it is uncertain in which zone the true value of effect estimate lies, and therefore there is uncertainty over which decision to make (based on this outcome alone). The confidence interval is consistent with 2 decisions and so this is considered to be imprecise in the GRADE analysis and the evidence is downgraded by 1 level ('serious imprecision').

If the confidence interval of the effect estimate crosses into 3 zones, this is considered to be very imprecise evidence because the confidence interval is consistent with 3 clinical decisions and there is a considerable lack of confidence in the results. The evidence is therefore downgraded by 2 levels in the GRADE analysis ('very serious imprecision').

Implicitly, assessing whether the confidence interval is in, or partially in, a clinically important zone, requires the GDG to estimate an MID or to say whether they would make different decisions for the 2 confidence limits.

The literature was searched for established MIDs for the selected outcomes in the evidence reviews. In addition, the GDG was asked whether they were aware of any acceptable MIDs in the clinical community. Finally, the GDG considered it clinically acceptable to use the GRADE default MID to assess imprecision: a 25% relative risk reduction or relative risk increase was used, which corresponds to clinically important thresholds for a risk ratio of 0.75 and 1.25 respectively. This default MID was used for all the outcomes in the interventions evidence reviews.

### 3.3.10   Evidence statements

Evidence statements are summary statements that are presented after the GRADE profiles, summarising the key features of the clinical effectiveness evidence presented. The wording of the evidence statements reflects the certainty or uncertainty in the estimate of effect. The evidence statements are presented by outcome and encompass the following key features of the evidence:

- the number of studies and the number of participants for a particular outcome
- a brief description of the participants
- an indication of the direction of effect (if one treatment is beneficial or harmful compared to the other, or whether there is no difference between the 2 tested treatments)
- a description of the overall quality of evidence (GRADE overall quality).

# 3.4 Evidence of cost effectiveness

The GDG is required to make decisions based on the best available evidence of both clinical and cost effectiveness. Guideline recommendations should be based on the expected costs of the different options in relation to their expected health benefits (that is, their 'cost effectiveness') rather than the total implementation cost.[117] Thus, if the evidence suggests that a strategy provides significant health benefits at an acceptable cost per patient treated, it should be recommended even if it would be expensive to implement across the whole population.

Evidence on cost effectiveness related to the key clinical issues being addressed in the guideline was sought. The health economists:

- Undertook a systematic review of the published economic literature.

- Undertook new cost-effectiveness analysis in priority areas.

## 3.4.1 Literature review

The health economist:

- Identified potentially relevant studies for each review question from the economic search results by reviewing titles and abstracts. Full papers were then obtained.

- Reviewed full papers against pre-specified inclusion and exclusion criteria to identify relevant studies (see below for details).

- Critically appraised relevant studies using the economic evaluations checklist as specified in The guidelines manual (2012).[117]

- Extracted key information about the studies' methods and results into evidence tables (included in Appendix I).

- Generated summaries of the evidence in NICE economic evidence profiles (included in the relevant chapter for each review question) – see below for details.

### 3.4.1.1 Inclusion and exclusion criteria

Full economic evaluations (studies comparing costs and health consequences of alternative courses of action: cost–utility, cost-effectiveness, cost–benefit and cost–consequence analyses) and comparative costing studies that addressed the review question in the relevant population were considered potentially includable as economic evidence.

Studies that only reported cost per hospital (not per patient), or only reported average cost effectiveness without disaggregated costs and effects, were excluded. Literature reviews, abstracts, posters, letters, editorials, comment articles, unpublished studies and studies not in English were excluded.

Remaining studies were prioritised for inclusion based on their relative applicability to the development of this guideline and the study limitations. For example, if a high quality, directly applicable UK analysis was available, then other less relevant studies may not have been included. Where exclusions occurred on this basis, this is noted in the relevant section.

For more details about the assessment of applicability and methodological quality see the economic evaluation checklist (Appendix F of The guidelines manual (2012),[117] and the health economics review protocol in Appendix C).

When no relevant economic studies were found from the economic literature review, relevant UK NHS unit costs related to the compared interventions were presented to the GDG to inform the possible economic implications of the recommendations.

1 **3.4.1.2 NICE economic evidence profiles**

2 When relevant economic studies are identified a NICE economic evidence profile is used to
3 summarise cost and cost-effectiveness estimates. The economic evidence profile shows an
4 assessment of applicability and methodological quality for each economic evaluation, with footnotes
5 indicating the reasons for the assessment. These assessments are made by the health economist
6 using the economic evaluation checklist from The guidelines manual (2012).[117] It also shows the
7 incremental costs, incremental effects (for example, quality-adjusted life years [QALYs]) and
8 incremental cost-effectiveness ratio for the base case analysis in the evaluation, as well as
9 information about the assessment of uncertainty in the analysis. See Table 6 for more details.

10 If a non-UK study is included in the profile, the results are converted into pounds sterling using the
11 appropriate purchasing power parity.[123]

12 **Table 6:    Content of NICE economic evidence profile**

| Item | Description |
|---|---|
| Study | First author name, reference, date of study publication and country perspective. |
| Applicability | An assessment of applicability of the study to the clinical guideline, the current NHS situation and NICE decision-making(a): |
| | Directly applicable – the study meets all applicability criteria, or fails to meet one or more applicability criteria but this is unlikely to change the conclusions about cost effectiveness. |
| | Partially applicable – the study fails to meet one or more applicability criteria, and this could change the conclusions about cost effectiveness. |
| | Not applicable – the study fails to meet one or more of the applicability criteria, and this is likely to change the conclusions about cost effectiveness. Such studies would usually be excluded from the review. |
| Limitations | An assessment of methodological quality of the study(a): |
| | Minor limitations – the study meets all quality criteria, or fails to meet one or more quality criteria, but this is unlikely to change the conclusions about cost effectiveness. |
| | Potentially serious limitations – the study fails to meet one or more quality criteria, and this could change the conclusions about cost effectiveness. |
| | Very serious limitations – the study fails to meet one or more quality criteria, and this is highly likely to change the conclusions about cost effectiveness. Such studies would usually be excluded from the review. |
| Other comments | Particular issues that should be considered when interpreting the study. |
| Incremental cost | The mean cost associated with one strategy minus the mean cost of a comparator strategy. |
| Incremental effects | The mean QALYs (or other selected measure of health outcome) associated with one strategy minus the mean QALYs of a comparator strategy. |
| Cost effectiveness | Incremental cost-effectiveness ratio (ICER): the incremental cost divided by the incremental effects. |
| Uncertainty | A summary of the extent of uncertainty about the ICER reflecting the results of deterministic or probabilistic sensitivity analyses, or stochastic analyses of trial data, as appropriate. |

13 *(a) Applicability and limitations were assessed using the economic evaluation checklist in Appendix G of The guidelines*
14 *manual (2012)[117]*

15 No published economic studies were identified which met the inclusion criteria for this guideline, and
16 consequently no economic evidence profiles are included in this guideline.

### 3.4.2 Undertaking new health economic analysis

As well as reviewing the published economic literature for each review question, as described above, new economic analysis was undertaken by the health economists in selected areas. Priority areas for new health economic analysis were agreed by the GDG after formation of the review questions and consideration of the available health economic evidence.

The GDG identified referral to specialist drug allergy services or alternative management strategies within primary care for patients who are not referred as the highest priority area for original economic analysis. The GDG believed that economic modelling in this area would be informative if feasible, but concluded that modelling was unfortunately not feasible as information was not available on the relative effectiveness of referral or non-specialist management on outcomes such as the number of future allergic reactions or the number of occasions alternative drugs are used. This was due both to the fact that as specialist management is outside the scope of this guideline the referral pathway is undefined, and to the lack of applicable published economic research on the areas that are within the scope. Therefore any model would necessarily have to be built largely upon estimates and assumptions. In particular, sufficient data were not available to allow modelling of different subgroups, which would be necessary to identify which individuals should or should not be referred to specialist drug allergy services.

Instead of conducting a full economic evaluation, 4 cost-effectiveness scenarios were constructed for the case of suspected allergy to beta-lactam antibiotics. These calculated the potential costs of both referral to specialist drug allergy services and of non-specialist management for multiple frequencies of future need for antibiotics. They presented the magnitude of difference in quality of life (measured in quality-adjusted life years [QALYs] or life days [QALDs]) which referral would need to be expected to yield for it to be cost effective compared to non-specialist management. The GDG used these scenarios to inform their recommendations regarding which people should and should not be referred to specialist drug allergy services.

The following general principles were adhered to in developing the cost-effectiveness scenarios:

- Methods were consistent with the NICE reference case.[118]
- The GDG was involved in the design of the scenarios, selection of conditions and drugs examined and interpretation of the results.
- Costs were based on routine NHS data sources.
- Inputs and assumptions were reported fully and transparently, and their limitations were discussed.

Full methods for the cost-effectiveness scenarios for referral to specialist drug allergy services are described in Chapter 11.

### 3.4.3 Cost-effectiveness criteria

NICE's report 'Social value judgements: principles for the development of NICE guidance' sets out the principles that GDGs should consider when judging whether an intervention offers good value for money.[115] In general, an intervention was considered to be cost effective if either of the following criteria applied (given that the estimate was considered plausible):

- the intervention dominated other relevant strategies (that is, it was both less costly in terms of resource use and more clinically effective compared with all the other relevant alternative strategies), or
- the intervention cost less than £20,000 per QALY gained compared with the next best strategy.

If the GDG recommended an intervention that was estimated to cost more than £20,000 per QALY gained, or did not recommend one that was estimated to cost less than £20,000 per QALY gained,

the reasons for this decision are discussed explicitly in the 'Recommendations and link to evidence' section of the relevant chapter, with reference to issues regarding the plausibility of the estimate or to the factors set out in 'Social value judgements: principles for the development of NICE guidance'.[115]

When QALYs or life years gained are not used in an analysis, results are difficult to interpret unless one strategy dominates the others with respect to every relevant health outcome and cost.

### 3.4.4 In the absence of economic evidence

When no relevant published studies were found, and a new analysis was not prioritised, the GDG made a qualitative judgement about cost effectiveness by considering expected differences in resource use between options and relevant UK NHS unit costs, alongside the results of the clinical review of effectiveness evidence.

## 3.5 Developing recommendations

Over the course of the guideline development process, the GDG was presented with:

- Evidence tables of the clinical and economic evidence reviewed from the literature. All evidence tables are in Appendices H and I.
- Summaries of clinical and economic evidence and quality (as presented in Chapters 5–11).
- Forest plots (Appendix J).

Recommendations were drafted on the basis of the GDG's interpretation of the available evidence, taking into account the balance of benefits, harms and costs between different courses of action. Firstly, the net benefit over harm (clinical effectiveness) was considered, focusing on the critical outcomes. When this was done informally, the GDG took into account the clinical benefits and harms when one intervention was compared with another. The assessment of net benefit was moderated by the importance placed on the outcomes (the GDG's values and preferences), and the confidence the GDG had in the evidence (evidence quality). Secondly, whether the net benefit justified any differences in costs was assessed.

When clinical and economic evidence was of poor quality, conflicting or absent, the GDG drafted recommendations based on their expert opinion. The considerations for making consensus-based recommendations include the balance between potential harms and benefits, the economic costs compared to the economic benefits, current practices, recommendations made in other relevant guidelines, patient preferences and equality issues. The consensus recommendations were agreed through discussions in the GDG. The GDG also considered whether the uncertainty was sufficient to justify delaying making a recommendation to await further research, taking into account the potential harm of failing to make a clear recommendation (see Section 3.5.1 below).

The GDG considered the 'strength' of recommendations. This takes into account the quality of the evidence but is conceptually different. Some recommendations are 'strong' in that the GDG believes that the vast majority of healthcare and other professionals and patients would choose a particular intervention if they considered the evidence in the same way that the GDG has. This is generally the case if the benefits clearly outweigh the harms for most people and the intervention is likely to be cost effective. However, there is often a closer balance between benefits and harms, and some patients would not choose an intervention whereas others would. This may happen, for example, if some patients are particularly averse to some side effect and others are not. In these circumstances the recommendation is generally weaker, although it may be possible to make stronger recommendations about specific groups of patients.

The GDG focused on the following factors in agreeing the wording of the recommendations:

- The actions health professionals need to take.
- The information readers need to know.
- The strength of the recommendation (for example the word 'offer' was used for strong recommendations and 'consider' for weak recommendations).
- The involvement of patients (and their carers if needed) in decisions on treatment and care.
- Consistency with NICE's standard advice on recommendations about drugs, waiting times and ineffective interventions (see Section 9.3 in The guidelines manual (2012)[117]).

The main considerations specific to each recommendation are outlined in the 'Recommendations and link to evidence' sections within each chapter.

### 3.5.1   Research recommendations

When areas were identified for which good evidence was lacking, the GDG considered making recommendations for future research. Decisions about inclusion were based on factors such as:

- the importance to patients or the population
- national priorities
- potential impact on the NHS and future NICE guidance
- ethical and technical feasibility.

### 3.5.2   Validation process

This guidance is subject to a 6-week public consultation and feedback as part of the quality assurance and peer review of the document. All comments received from registered stakeholders are responded to in turn and posted on the NICE website.

### 3.5.3   Updating the guideline

A formal review of the need to update a guideline is usually undertaken by NICE after its publication. NICE will conduct a review to determine whether the evidence base has progressed significantly to alter the guideline recommendations and warrant an update.

### 3.5.4   Disclaimer

Healthcare providers need to use clinical judgement, knowledge and expertise when deciding whether it is appropriate to apply guidelines. The recommendations cited here are a guide and may not be appropriate for use in all situations. The decision to adopt any of the recommendations cited here must be made by practitioners in light of individual patient circumstances, the wishes of the patient, clinical expertise and resources.

The National Clinical Guideline Centre disclaims any responsibility for damages arising out of the use or non-use of this guideline and the literature used in support of this guideline.

### 3.5.5   Funding

The National Clinical Guideline Centre was commissioned by the National Institute for Health and Care Excellence to undertake the work on this guideline.

# Algorithm

## SUSPECTED DRUG ALLERGY

### ASSESSMENT

**SIGNS AND ALLERGIC PATTERNS OF SUSPECTED DRUG ALLERGY WITH TIMING OF ONSET AFTER EXPOSURE TO DRUG.**

When assessing a person presenting with possible drug allergy, take a history and undertake a clinical examination, use the following when deciding whether to suspect drug allergy:

**Immediate, rapidly evolving reactions:**
- Anaphylaxis – a severe multi-system reaction usually with erythema, urticaria or angioedema in combination with hypotension and/or bronchospasm
- Urticaria or angioedema without systemic features
- Exacerbation of asthma, for example with non-steroidal anti-inflammatory drugs (NSAIDs)

*Onset usually under 1 hour, previous exposure not always confirmed*

**Non-immediate reactions without systemic involvement**
- Widespread red macules or papules (exanthem-like)
- Fixed drug eruption (localised inflamed skin)

*Onset usually on day 6–10 of first drug exposure (reaction to first exposure may be more prolonged), or day 1–3 of second exposure*

**Non-immediate reactions with systemic involvement**
- Widespread red macules, papules or erythroderma with systemic involvement. For example, drug reaction with eosinophilia and systemic symptoms (DRESS) or drug hypersensitivity syndrome (DHS) – characterised by fever, lymphadenopathy, liver dysfunction and platelets below the laboratory limits

*Onset usually 2-6 weeks after first drug exposure, or 24–48 hours after second exposure*

*N.B. this list describes common and important presenting features of drug allergy but other presentations are also recognised.*

**Non-immediate reactions with systemic involvement (continued)**
- Toxic epidermal necrolysis or Stevens Johnson syndrome – characterised by mucosal or cutaneous erosions, vesicles, blistering or epidermal detachment, and red purpuric macules or erythema multiforme. Painful rash and fever are often early signs

*Onset usually 7–14 days after first drug exposure, or 24–48 hours after second exposure*

- Acute generalised exanthematous pustulosis – widespread pustules, usually with a fever and neutrophilia *Onset 3–5 days after first drug exposure*

- Common disorders caused, rarely, by drug allergy:
  - eczema
  - hepatitis
  - photosensitivity
  - vasculitis *Time of onset variable*

**Be aware that the person's reaction is more likely to be caused by drug allergy if:**
- the reaction occurred while the person was being treated with the drug or
- the drug is known to cause that type of reaction or
- the person has had a similar reaction to that drug or class of drug in a previous exposure.

**Be aware that the person's reaction is less likely to be caused by drug allergy if:**
- there is a possible non-drug cause for the person's symptoms, for example, they have had similar symptoms when not taking the drug, **or**
- the person has gastrointestinal symptoms only.

*N.B. this list describes common and important presenting features of drug allergy but other presentations are also recognised.*

**SERUM TRYPTASE**

After a suspected drug-related anaphylactic reaction, take blood samples for mast cell tryptase in line with recommendations in Anaphylaxis (NICE clinical guideline 134).

Record in the person's notes and on the pathology request form, the exact timing of both blood samples taken for mast cell tryptase after onset of suspected anaphylaxis.

Ensure that tryptase sampling tubes are included in emergency anaphylaxis kits.

**SERUM IGE**

Do not use blood testing for specific IgE for diagnosing drug allergy in a non-specialist setting.

### NON-SPECIALIST MANAGEMENT AND REFERRAL TO SPECIALIST SERVICES

**GENERAL MANAGEMENT:**

**NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (INCLUDING SELECTIVE CYCLOOXYGENASE 2 INHIBITORS)**

**If drug allergy is suspected:**
- consider stopping the drug suspected to have caused the allergic reaction and advise the person to avoid that drug in future
- treat the symptoms arising from the acute reaction if needed; send people with severe reactions to hospital
- document details of the suspected drug allergy in the person's medical records (see recommendation 10)
- provide information to the person (see section 1.3).

**Refer to a specialist drug allergy service people who have had:**
a suspected anaphylactic reaction (also see Anaphylaxis, NICE clinical guideline 134) **or**
a severe non-immediate cutaneous reaction (for example, drug reaction with eosinophilia and systemic symptoms [DRESS], Stevens–Johnson Syndrome, toxic epidermal necrolysis).

Inform people with a suspected allergy to a non-selective non-steroidal anti-inflammatory drug (NSAID) (and their parents or carers if appropriate) that in future they need to avoid all other non-selective NSAIDs, including over-the-counter preparations.

Consider a selective cyclooxygenase 2 (COX-2) inhibitor for people who have had mild reactions to a non-selective NSAID if an anti-inflammatory is needed. Discuss the benefits and low risk of introducing a selective COX-2 inhibitor, and then offer the lowest starting dose and only give a single dose on the first day.

Do not offer a selective COX-2 inhibitor in a non-specialist setting to people who have had severe reactions, such as anaphylaxis, severe angioedema or asthmatic reactions, to non-selective NSAIDs.

### NON-SPECIALIST MANAGEMENT AND REFERRAL TO SPECIALIST SERVICES

**BETA LACTAMS**
Refer to a specialist drug allergy service people with a suspected allergy to beta-lactam antibiotics who:
- need treatment for a disease that can only be treated by a beta-lactam antibiotic **or**
- have a high likelihood of frequent future need for beta-lactam antibiotics, for example, people with recurrent bacterial infections or immune deficiency.

Consider referring to a specialist drug allergy service people who are not able to take beta-lactam antibiotics and at least 1 other class of antibiotic because of suspected allergy to these antibiotics.

**NSAIDS**
Refer to a specialist drug allergy service people who have had suspected allergic reactions to NSAIDs with symptoms such as severe angioedema or asthmatic reactions but who need treatment with an NSAID.

Be aware that people with asthma who also have nasal polyps are likely to have NSAID-sensitive asthma unless they are known to have tolerated NSAIDs in the last 12 months.

**LOCAL ANAESTHETICS**
Refer to a specialist drug allergy service people who need procedures involving local anaesthetics but are unable to have them because of previous suspected allergic reactions to local anaesthetics.

**GENERAL ANAESTHESIA**
Refer to a specialist drug allergy service people who have had a suspected allergic reaction or anaphylaxis during or immediately after general anaesthesia.

### DOCUMENTATION AND INFORMATION

**DOCUMENTATION AND SHARING INFORMATION WITH OTHER HEALTHCARE PROFESSIONALS**

**Recording drug allergy status**

Healthcare professionals should document people's drug allergy status in their healthcare records using 1 of the following:
- 'drug allergy'
- 'none known'
- 'unable to ascertain' (document it as soon as the information is available).

When documenting suspected or confirmed drug allergy status in routine care, record all of the following at a minimum:
- drug name
- nature of reaction
- the date when the reaction occurred.

**Documenting new suspected drug allergic reactions**

When a person presents with suspected drug allergy, document their reaction in a structured approach that includes:
- the generic and proprietary name of the drug taken
- a description of the reaction (see recommendation 1.1.1)
- the indication for the drug being taken (if there is no clinical diagnosis, describe the illness)
- date and time of the reaction
- the number of doses taken or number of days on the drug before onset of the reaction
- the route of administration
- which drug or drug classes to avoid in future.

**DOCUMENTATION AND SHARING INFORMATION WITH OTHER HEALTHCARE PROFESSIONALS**

**Maintaining and sharing drug allergy information**

Ensure that drug allergy status is documented separately from adverse drug reactions and that it is clearly visible to all healthcare professionals who are prescribing, administering and dispensing drugs.

Check drug allergy status and update, if needed, at every contact with the patient.

Check and update a person's documented drug allergy status and confirm it with the person (or their parents or carers if appropriate) before prescribing, dispensing or administering any drug.

Carry out medicines reconciliation for people admitted to hospital in line with recommendations in Technical patient safety solutions for medicines reconciliation on admission of adults to hospital (NICE patient safety solutions 1).

Ensure that information about drug allergy status is included in all:
- GP referral letters
- hospital discharge letters
- prescriptions issued in any healthcare setting.

**After specialist drug allergy investigations**

For recommendations on referral to specialist services see section 1.4.

After specialist drug allergy investigations, allergy specialists should document:
- the diagnosis – whether the person had an allergic or non-allergic reaction
- the investigations used to confirm or exclude the diagnosis
- drug or drug classes to avoid in future.

**PROVIDING INFORMATION AND SUPPORT TO PATIENTS**

Discuss the person's suspected drug allergy with them, and their parents or carers if appropriate, and provide written information (see recommendation 1.2.3). Record the name of the clinician and the date the information was given.

Ensure that the person (and their parents or carers if appropriate) is aware of the drug or drug classes that they need to avoid, and advise them to check with a pharmacist before taking any over-the-counter drugs.

Advise people (and their parents or carers if appropriate) to carry information they are given about their drug allergy at all times and to share this whenever they visit a healthcare professional or are prescribed, dispensed or are about to be administered a new drug.

Allergy specialists should give the following written information to people who have undergone specialist drug allergy investigation:
- the diagnosis – whether they had an allergic or non-allergic reaction
- the drug name and a description of their reaction
- the investigations used to confirm or exclude the diagnosis
- drugs to avoid in future
- any safe alternative drugs that may be used.

Inform people in whom allergy to a drug or drug class has been excluded by specialist investigation that they can now take this drug or drug class safely. Provide information in line with the recommendations in Patient experience in adult NHS services (NICE clinical guidance 138).

# 4 Guideline summary

## 4.1 Key priorities for implementation

From the full set of recommendations, the GDG selected 10 key priorities for implementation. The criteria used for selecting these recommendations are listed in detail in The guidelines manual (2012).[117] The reasons behind selection of each of these recommendations are shown in the table linking the evidence to the recommendation in the relevant chapter.

**Assessment**

1. When assessing a person presenting with possible drug allergy, take a history and undertake a clinical examination. Use the following tables as a guide when deciding whether to suspect drug allergy.

**Tables 1–3 Signs and allergic patterns of suspected drug allergy with timing of onset after exposure to drug**[a]

**1 Immediate, rapidly evolving reactions**

| | |
|---|---|
| Anaphylaxis – a severe multi-system reaction usually with erythema, urticaria or angioedema in combination with hypotension and/or bronchospasm | Onset usually under 1 hour, previous exposure not always confirmed |
| Urticaria or angioedema without systemic features | |
| Exacerbation of asthma, for example with non-steroidal anti-inflammatory drugs (NSAIDs) | |

**2 Non-immediate reactions without systemic involvement**

| | |
|---|---|
| Widespread red macules or papules (exanthem-like) | Onset usually on day 6–10 of first drug exposure (reaction to first exposure may be more prolonged), or day 1–3 of second exposure |
| Fixed drug eruption (localised inflamed skin) | |

**3 Non-immediate reactions with systemic involvement**

| | |
|---|---|
| Widespread red macules, papules or erythroderma with systemic involvement. For example, drug reaction with eosinophilia and systemic symptoms (DRESS) or drug hypersensitivity syndrome (DHS) – characterised by fever, lymphadenopathy, | Onset usually 2–6 weeks after first drug exposure, or 24–48 hours after second exposure |

---

[a] Note that these tables describe common and important presenting features of drug allergy but other presentations are also recognised

| | |
|---|---|
| liver dysfunction and low platelets | |
| Toxic epidermal necrolysis or Stevens–Johnson syndrome – characterised by mucosal or cutaneous erosions, vesicles, blistering or epidermal detachment, and red purpuric macules or erythema multiforme. Painful rash and fever are often early signs | Onset usually 7–14 days after first drug exposure, or 24–48 hours after second exposure |
| Acute generalised exanthematous pustulosis – widespread pustules, usually with a fever and neutrophilia | Onset 3–5 days after first drug exposure |
| Common disorders caused, rarely, by drug allergy:<br><br>eczema<br><br>hepatitis<br><br>photosensitivity<br><br>vasculitis | Time of onset variable |

1  **Documenting and sharing information with other healthcare professionals:**

2  **Documenting new suspected drug allergic reactions**

3  2. When a person presents with suspected drug allergy, document their reaction in a structured
4  approach that includes:

5  • the generic and proprietary name of the drug taken

6  • a description of the reaction (see recommendation 1)

7  • the indication for the drug being taken (if there is no clinical diagnosis, describe the illness)

8  • date and time of the reaction

9  • the number of doses taken or number of days on the drug before onset of the reaction

10  • the route of administration

11  • which drug or drug classes to avoid in future.

12

13  **Maintaining and sharing drug allergy information**

14  **3.** Check and update a person's documented drug allergy status and confirm it with the person (or
15  their parents or carers if appropriate) before prescribing, dispensing or administering any drug.

16

17  4. Ensure that information about drug allergy status is included in all:

18  • GP referral letters

19  • hospital discharge letters

20  • prescriptions issued in any healthcare setting.

21

22  **Providing information and support to patients**

5. Discuss the person's suspected drug allergy with them, and their parents or carers if appropriate, and provide written information (see recommendation 10). Record the name of the clinician and the date the information was given.

6. Ensure that the person (and their parents or carers if appropriate) is aware of the drug or drug classes that they need to avoid, and advise them to check with a pharmacist before taking any over-the-counter drugs.

7. Allergy specialists should give the following written information to people who have undergone specialist drug allergy investigation:

- the diagnosis – whether they had an allergic or non-allergic reaction

- the drug name and a description of their reaction

- the investigations used to confirm or exclude the diagnosis

- drugs to avoid in future

- any safe alternative drugs that may be used.

**Non-specialist management and referral to specialist services**

**General**

8. Refer to a specialist drug allergy service people who have had:

- a suspected anaphylactic reaction (also see Anaphylaxis, NICE clinical guideline 134) **or**

- a severe non-immediate cutaneous reaction (for example, drug reaction with eosinophilia and systemic symptoms [DRESS], Stevens–Johnson Syndrome, toxic epidermal necrolysis).

**Beta lactam antibiotics**

9. Refer to a specialist drug allergy service people with a suspected allergy to beta-lactam antibiotics who:

- need treatment for a disease that can only be treated by a beta-lactam antibiotic **or**

- have a high likelihood of frequent future need for beta-lactam antibiotics, for example, people with recurrent bacterial infections or immune deficiency.

**General anaesthesia**

10. Refer to a specialist drug allergy service people who have had a suspected allergic reaction or anaphylaxis during or immediately after general anaesthesia.

## 4.2 Full list of recommendations

**Assessment**

1. When assessing a person presenting with possible drug allergy, take a history and undertake a clinical examination. Use the following tables as a guide when deciding whether to suspect drug allergy.

**Tables 1–3 Signs and allergic patterns of suspected drug allergy with timing of onset after exposure to drug[b]**

**1 Immediate, rapidly evolving reactions**

| Anaphylaxis – a severe multi-system reaction usually with erythema, urticaria or angioedema in combination with hypotension and/or bronchospasm | Onset usually under 1 hour, previous exposure not always confirmed |
|---|---|

---

[b] Note that these tables describe common and important presenting features of drug allergy but other presentations are also recognised

| 1. Urticaria or angioedema without systemic features | |
| --- | --- |
| **Exacerbation of asthma, for example with non-steroidal anti-inflammatory drugs (NSAIDs)** | |

**2 Non-immediate reactions without systemic involvement**

| Widespread red macules or papules (exanthem-like) | Onset usually on day 6–10 of first drug exposure (reaction to first exposure may be more prolonged), or day 1–3 of second exposure |
| --- | --- |
| **Fixed drug eruption (localised inflamed skin)** | |

**3 Non-immediate reactions with systemic involvement**

| Widespread red macules, papules or erythroderma with systemic involvement. For example, drug reaction with eosinophilia and systemic symptoms (DRESS) or drug hypersensitivity syndrome (DHS) – characterised by fever, lymphadenopathy, liver dysfunction and low platelets | Onset usually 2–6 weeks after first drug exposure, or 24–48 hours after second exposure |
| --- | --- |
| Toxic epidermal necrolysis or Stevens–Johnson syndrome – characterised by mucosal or cutaneous erosions, vesicles, blistering or epidermal detachment, and red purpuric macules or erythema multiforme. Painful rash and fever are often early signs | Onset usually 7–14 days after first drug exposure, or 24–48 hours after second exposure |
| Acute generalised exanthematous pustulosis – widespread pustules, usually with a fever and neutrophilia | Onset 3–5 days after first drug exposure |
| Common disorders caused, rarely, by drug allergy: eczema hepatitis photosensitivity vasculitis | Time of onset variable |

2. Be aware that the reaction is more likely to be caused by drug allergy if it occurred during or after use of the drug and:

- the drug is known to cause that type of reaction or
- the person has had a similar reaction to that drug or class of drug in a previous exposure.

3. Be aware that the reaction is less likely to be caused by drug allergy if:

- there is a possible non-drug cause for the person's symptoms, for example, they have had similar symptoms when not taking the drug, or
- the person has gastrointestinal symptoms only.

**Measuring serum tryptase after suspected anaphylaxis**

4. After a suspected drug-related anaphylactic reaction, take blood samples for mast cell tryptase in line with recommendations in Anaphylaxis (NICE clinical guideline 134).

5.  Record in the person's notes and on the pathology request form, the exact timing of both blood samples taken for mast cell tryptase after onset of suspected anaphylaxis.

6.  Ensure that tryptase sampling tubes are included in emergency anaphylaxis kits.

**Measuring serum specific immunoglobulin E (IgE)**

7.  Do not use blood testing for specific IgE for diagnosing drug allergy in a non-specialist setting.

**Documenting and sharing information with other healthcare professionals**

**Recording drug allergy status**

8.  Healthcare professionals should document people's drug allergy status in their healthcare records using 1 of the following:

    • 'drug allergy'

    • 'none known'

    • 'unable to ascertain' (document it as soon as the information is available).

9.  When documenting suspected or confirmed drug allergy status in routine care, record all of the following at a minimum:

    • drug name

    • nature of reaction

    • the date when the reaction occurred.

**Documenting new suspected drug allergic reactions**

10. When a person presents with suspected drug allergy, document their reaction in a structured approach that includes:

    • the generic and proprietary name of the drug taken

    • a description of the reaction (see recommendation 1)

    • the indication for the drug being taken (if there is no clinical diagnosis, describe the illness)

    • date and time of the reaction

    • the number of doses taken or number of days on the drug before onset of the reaction

    • the route of administration

    • which drug or drug classes to avoid in future.

**Maintaining and sharing drug allergy information**

11. Ensure that drug allergy status is documented separately from adverse drug reactions and that it is clearly visible to all healthcare professionals who are prescribing, administering and dispensing drugs.

12. Check drug allergy status and update, if needed, at every contact with the patient.

13. Check and update a person's documented drug allergy status and confirm it with the person (or their parents or carers if appropriate) before prescribing, dispensing or administering any drug.

14.    Carry out medicines reconciliation for people admitted to hospital in line with recommendations in Technical patient safety solutions for medicines reconciliation on admission of adults to hospital (NICE patient safety solutions 1).

15.    Ensure that information about drug allergy status is included in all:

- GP referral letters

- hospital discharge letters

- prescriptions issued in any healthcare setting.

**After specialist drug allergy investigations**

For recommendations on referral to specialist services see section 12.

16.    After specialist drug allergy investigations, allergy specialists should document:

- the diagnosis – whether the person had an allergic or non-allergic reaction

- the investigations used to confirm or exclude the diagnosis

- drug or drug classes to avoid in future.

**Providing information and support to patients**

17.    Discuss the person's suspected drug allergy with them, and their parents or carers if appropriate, and provide written information (see recommendation 10). Record the name of the clinician and the date the information was given.

18.    Ensure that the person (and their parents or carers if appropriate) is aware of the drug or drug classes that they need to avoid, and advise them to check with a pharmacist before taking any over-the-counter drugs.

19.    Advise people (and their parents or carers if appropriate) to carry information they are given about their drug allergy at all times and to share this whenever they visit a healthcare professional or are prescribed, dispensed or are about to be administered a new drug.

20.    Allergy specialists should give the following written information to people who have undergone specialist drug allergy investigation:

- the diagnosis – whether they had an allergic or non-allergic reaction

- the drug name and a description of their reaction

- the investigations used to confirm or exclude the diagnosis

- drugs to avoid in future

- any safe alternative drugs that may be used.

21.    Inform people in whom allergy to a drug or drug class has been excluded by specialist investigation that they can now take this drug or drug class safely.

22.    Provide information in line with the recommendations in Patient experience in adult NHS services (NICE clinical guidance 138).

**Non Specialist management**

**General**

23.    If drug allergy is suspected:

- consider stopping the drug suspected to have caused the allergic reaction and advise the person to avoid that drug in future

- treat the symptoms arising from the acute reaction if needed; send people with severe reactions to hospital

- document details of the suspected drug allergy in the person's medical records (see recommendation 10)

- provide information to the person (see section 10).

24. Refer to a specialist drug allergy service people who have had:

  - a suspected anaphylactic reaction (also see Anaphylaxis, NICE clinical guideline 134) or

  - a severe non-immediate cutaneous reaction (for example, drug reaction with eosinophilia and systemic symptoms [DRESS], Stevens–Johnson Syndrome, toxic epidermal necrolysis).

**Selective cyclooxygenase 2 inhibitors**

25. Inform people with a suspected allergy to a non-selective non-steroidal anti-inflammatory drug (NSAID) (and their parents or carers if appropriate) that in future they need to avoid all other non-selective NSAIDs, including over-the-counter preparations.

26. Consider a selective cyclooxygenase 2 (COX-2) inhibitor for people who have had mild reactions to a non-selective NSAID if an anti-inflammatory is needed. Discuss the benefits and low risk of introducing a selective COX-2 inhibitor, and then offer the lowest starting dose and only give a single dose on the first day.

27. Do not offer a selective COX-2 inhibitor in a non-specialist setting to people who have had severe reactions, such as anaphylaxis, severe angioedema or asthmatic reactions, to non-selective NSAIDs.

**Referral to specialist services**

**Beta Lactams**

28. Refer to a specialist drug allergy service people with a suspected allergy to beta-lactam antibiotics who:

  - need treatment for a disease that can only be treated by a beta-lactam antibiotic or

  - have a high likelihood of frequent future need for beta-lactam antibiotics, for example, people with recurrent bacterial infections or immune deficiency.

29. Consider referring to a specialist drug allergy service people who are not able to take beta-lactam antibiotics and at least 1 other class of antibiotic because of suspected allergy to these antibiotics.

**Non-steroidal anti-inflammatory drugs**

30. Refer to a specialist drug allergy service people who have had suspected allergic reactions to NSAIDs with symptoms such as severe angioedema or asthmatic reactions but who need treatment with an NSAID.

31. Be aware that people with asthma who also have nasal polyps are likely to have NSAID-sensitive asthma unless they are known to have tolerated NSAIDs in the last 12 months.

**Local anaesthetics**

32.    Refer to a specialist drug allergy service people who need procedures
       involving local anaesthetics but are unable to have them because of previous
       suspected allergic reactions to local anaesthetics.

**General anaesthesia**

33.    Refer to a specialist drug allergy service people who have had a suspected
       allergic reaction or anaphylaxis during or immediately after general
       anaesthesia.

## 4.3 Key research recommendations

### 4.3.1 Designing systems for documenting drug allergy

Which documentation strategies would be most clinically and cost effective to minimise the number
of people who are re-exposed to drugs to which they have a suspected or confirmed allergy, looking
in particular at:

- electronic health records that include features specifically designed to record and alert clinicians
  to drug allergy information, compared with systems without such features, and
- different formats for patient-held, structured drug allergy documentation?

### 4.3.2 Communicating information about drug allergy

In people with suspected or confirmed drug allergies, are patient-focused information strategies
more effective than standard NHS practice in increasing people's likelihood of disclosing their drug
allergy (or their suspected drug allergy) and therefore reducing the risk of being re-exposed to the
affected drug?

### 4.3.3 Using selective cyclooxygenase 2 inhibitors in people with previous severe allergic reactions to non-selective non-steroidal anti-inflammatory drugs

Should all patients who have experienced a severe allergic reaction to a non-selective non-steroidal
anti-inflammatory drug (NSAID) be assessed by specialist drug allergy services or should they be
advised to take a selective cyclooxygenase 2 (COX-2) inhibitor without further investigations?

### 4.3.4 Oral antibiotic challenge for diagnosing antibiotic allergy in children

In children who have a suspected allergy to an antibiotic, is it clinically and cost effective to proceed
directly (without prior skin or intra-dermal tests) to a diagnostic oral antibiotic challenge rather than
refer to specialist drug allergy services?

# 5 Assessment

## 5.1 Introduction

When a new drug is started a patient may experience adverse symptoms for a variety of reasons. These may be related to the underlying disorder for which the patient was being treated, may be incidental and unrelated to the drug or disease, or they may be caused by the drug itself.

In cases of known non-immunologically mediated adverse reaction, for example, nausea or abdominal discomfort, the decision on whether to continue will be taken after discussion with the patient and assessment of the severity of the reaction and the length of the remaining prescription course will be taken into account. If the patient has suffered a hypersensitivity reaction, however, the drug will almost invariably be stopped and if necessary an alternative drug sought. There can be considerable overlap between symptoms recognised from the adverse reaction profile of the drug and those resulting from hypersensitivity reaction. Each drug has a specific pattern of expected non-allergic symptoms and even immunologically mediated symptoms can follow a familiar pattern seen in previous patients. A correct diagnosis differentiating an allergic from a non-allergic reaction at the time of presentation should therefore allow safe future prescription and avoidance of the specific drug or drug class. Detailed documentation of the adverse reaction will also allow a more accurate specialist assessment if the patient requires the same or similar drug in future.

## 5.2 Review question: What is the clinical and cost effectiveness of clinical probability scores or algorithms in identifying or excluding drug allergies?

For full details see review protocol in Appendix C.

**Table 7:    Characteristics of review question**

| | |
|---|---|
| **Population** | Patients presenting with signs and symptoms of suspected drug allergy; patients with a record of a suspected drug allergy |
| **Intervention** | Clinical algorithms or prediction rules that assess likelihood or class patients by likelihood of having a drug allergy |
| **Aim** | To identify any signs and symptoms that are consistently used to assess the likelihood of a person having a drug allergy across algorithms currently in use |
| **Study design** | In the absence of RCTs, cohorts studies will be considered, particularly any multivariate studies used to derive the algorithms |

## 5.3 Clinical evidence

### 5.3.1 Algorithms

We searched the literature for systematic reviews or any other study design that aimed to identify a set of signs and symptoms, usually in the form of a questionnaire or checklist (that is, an algorithm) to ascertain whether a person has a drug allergy. One systematic review (Agbabiaka et al. 2008[3]) was identified, as were 7 additional algorithm studies: Bousquet et al. 2009[18], Caimmi et al. 2012[23], Du et al. 2013[38], Gallagher et al. 2011[50] (also known as the Liverpool algorithm), Gonzalez et al. 1992[54] (which was missing from Agbagiaka's systematic review), Son et al. 2011[146] and Trewin et al. 1991[153] (also missing from Agbagiaka 2008's systematic review). Each of these studies describes the development of an algorithm in order to evaluate drug allergies. A further study was identified which

1     updated 1 of the included algorithms (Arimone et al. 2013[5] updating the French Begaud et al. 1985[12]
2     algorithm). This is added to the reference in Table 8.

3     The systematic review of algorithms by Agbabiaka et al. 2008[3] is considered to be at a moderate risk
4     of bias according to the NICE systematic review checklist (since the quality of the included algorithms
5     and probability scores was reported in a narrative manner and criteria for quality assessment were
6     not explicitly described),but it considered algorithms for both adverse drug reactions and drug
7     allergies. The authors included 26 algorithms in the systematic review. Six of these
8     algorithms[62,74,77,101,150,166] were excluded from this review on the basis that they focused on adverse
9     drug reactions (ADR) alone without the drug allergy being recorded as a subset of ADR.

10     The working definition of 'algorithm' from the identified systematic review was, "…a set of specific
11     questions with associated scores for calculating the likelihood of a cause–effect relationship". The
12     authors extracted criteria in the assessment of adverse drug reactions for 26 algorithms and
13     probability scores and these are shown in Table 8 below for each of the included algorithms. The 12
14     categories for assessment provide a starting point for this review but were not explained fully.
15     Therefore it was necessary in some cases to impute the meaning of individual categories.

16     The following categories were used (with brief explanations of how we interpreted them):

17     1. Time to onset or temporal sequence.

18       Measurement of the time elapsed between taking medication and a reaction to develop.

19     2. Previous experience or information on drug.

20       A previous experience with the drug or a previous reaction to the drug.

21     3. Alternative aetiological candidates.

22       Ruling out other reasons for the reaction to the drug.

23     4. Drug level or evidence of overdose.

24       Whether the correct dose was used.

25     5. Challenge.

26       Assessment of what happens when the drug is introduced.

27     6. Dechallenge.

28       Assessment of what happens when the person is taken off the drug.

29     7. Rechallenge.

30       Assessment of what happens when the drug is reintroduced.

31     8. Response pattern to drug (symptoms).
32       This point was unclear in the systematic review. We interpreted it to mean the clinical
33       manifestation of the signs and symptoms that would be specific to the drug under investigation.

34     9. Confirmed by laboratory evidence.

35       Whether laboratory tests have already been carried out.

36     10.Concomitant drugs.

37       Whether there could be a potential drug interaction.

38     11.Background epidemiological or clinical information.

39       For this category we focused on background epidemiology since clinical information was not
40       clearly defined in the review.

41     12. Characteristics or mechanisms of adverse drug reaction.

42       How this reaction is related to the drug under investigation and whether the reaction is plausible
43       in light of the drug's mechanisms.

44     We also searched the literature for systematic reviews or any other study design that aimed to
45     identify a set of signs and symptoms in the form of a probability score to ascertain whether a person

has a drug allergy. The systematic review by Agbabiaka et al.[3] reviewed 4 probabilistic or Bayesian approaches[68,89,91,103] to assessment of drug allergy. One further study was identified (Theophile et al. 2013[152]). This additional study also included a comparison with other algorithms.

Furthermore, Agbabiaka et al. 2008[3] reviewed comparisons of algorithms. These are studies in which people with suspected drug allergies are assessed with more than one algorithm and the level of agreement (that is, congruency) between the assessments is then calculated. Table 11 summarises results of 6 comparative studies[13,20,73,107,126,152] A further comparison study was added in the update of the systematic review.[152]

Agbabiaka et al. 2008[3] included a narrative analysis of 26 algorithms, but there was no explicit quality assessment of individual algorithms (they were appraised narratively). In the current review an explicit list of criteria was drawn up to assess the quality of the 6 additional algorithms that were identified from the search. In this checklist the quality of each of the following features was assessed (for these criteria please see section 3.3.6.4).

Using the format from Agbabiaka et al. 2008[3] used in Table 8, the 12 criteria were extracted for each of the 7 additional studies[18,23,38,50,54,146,153] included in the current review.

Table 8 below reproduces an amended version of the summary that is provided in Agbabiaka et al.[3] Studies which did not include drug allergy in the adverse drug reaction algorithms were excluded. Table 9 uses the same criteria to assess the additional algorithms identified in our search (with comments and quality assessment according to our checklist in the final 2 columns).

**Table 12** summarises the frequency of the criteria across algorithms. Please also see the study selection flow chart in Appendix E, study evidence tables in Appendix H and exclusion list in Appendix K.

1
2

**Table 8: Criteria to assess the association between a reaction and a drug: studies included in the systematic review (adapted from Agbabiaka et al. 2008[3])**

| Author | TTO or temp seq | Prev exp or drug info | Alter aetio-logies | Drug level or evidence of overdose | Chall-enge | Dechall-enge | Rechall-enge | Response pattern to drug | Confirm-ed lab evidence | Concom-itant drugs | Back-ground epi or clin info | ADR char or mech | Other |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Begaud et al. 1985,[12] updated by Arimone et al. 2013[5] | ✓ | ✗ | ✓ | ✓ | ✗ | ✓ | ✓ | ✓ | ✓ | ✓ | ✗ | ✓ | ✗ |
| Benichou and Danan 1992[14] | ✓ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✓ | ✓ | ✗ | ✓ | ✗ | ✗ |
| Blanc et al. 1979[16] | ✓ | ✗ | ✗ | ✗ | ✓ | ✗ | ✗ | ✗ | ✓ | ✗ | ✗ | ✗ | ✗ |
| Castle 1984[24] | ✓ | ✗ | ✓ | ✓ | ✗ | ✗ | ✗ | ✓ | ✗ | ✓ | ✓ | ✗ | ✗ |
| Cornelli 1984[30] | ✓ | ✗ | ✗ | ✓ | ✗ | ✗ | ✓ | ✓ | ✗ | ✓ | ✗ | ✗ | ✗ |
| Danan and Benichow 1993[31] | ✓ | ✗ | ✓ | ✗ | ✗ | ✗ | ✗ | ✓ | ✓ | ✗ | ✓ | ✗ | ✗ |
| Dangoumau et al. 1978[32] | ✗ | ✗ | ✓ | ✓ | ✗ | ✓ | ✓ | ✓ | ✗ | ✗ | ✗ | ✗ | ✗ |
| Emanueli and Sacchetti 1980[40] | ✓ | ✓ | ✓ | ✗ | ✓ | ✗ | ✓ | ✓ | ✗ | ✗ | ✗ | ✗ | ✗ |
| Evreux et al. 1982[45] | ✓ | ✓ | ✓ | ✗ | ✗ | ✓ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ |
| Hoskins and Mannino 1992[63] | ✓ | ✗ | ✗ | ✗ | ✗ | ✓ | ✓ | ✗ | ✗ | ✗ | ✓ | ✓ | ✗ |

| Author | TTO or temp seq | Prev exp or drug info | Alter aetio-logies | Drug level or evidence of overdose | Chall-enge | Dechall-enge | Rechall-enge | Response pattern to drug | Confirm-ed lab evidence | Concom-itant drugs | Back-ground epi or clin info | ADR char or mech | Other |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hsu and Stoll 1993[65] | ✗ | ✓ | ✗ | ✓ | ✗ | ✗ | ✓ | ✓ | ✗ | ✗ | ✗ | ✗ | ✗ |
| Iray 1976 | ✓ | ✗ | ✗ | ✓ | ✗ | ✓ | ✓ | ✓ | ✓ | ✗ | ✗ | ✗ | ✗ |
| Jones 1982[72] | ✗ | ✓ | ✗ | ✓ | ✗ | ✗ | ✓ | ✓ | ✗ | ✗ | ✗ | ✗ | ✗ |
| Koh and Shu 2005[79] | ✓ | ✗ | ✓ | ✓ | ✓ | ✗ | ✓ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ |
| Kramer et al. 1979[84] | ✓ | ✗ | ✓ | ✓ | ✓ | ✗ | ✓ | ✓ | ✗ | ✗ | ✗ | ✗ | ✗ |
| Lagier et al. 1983[88] | ✗ | ✗ | ✗ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✗ | ✓ | ✓ | ✓ |
| Naranjo et al. 1981[113] | ✗ | ✓ | ✓ | ✗ | ✓ | ✗ | ✓ | ✓ | ✓ | ✗ | ✗ | ✗ | ✗ |
| Stephens 1984[149] | ✗ | ✗ | ✓ | ✓ | ✗ | ✗ | ✓ | ✓ | ✓ | ✓ | ✗ | ✗ | ✗ |
| Turner 1984[154] | ✓ | ✗ | ✗ | ✗ | ✓ | ✓ | ✗ | ✗ | ✗ | ✗ | ✓ | ✗ | ✗ |
| Venulet et al. 1980[159] | ✗ | ✓ | ✗ | ✓ | ✗ | ✓ | ✓ | ✗ | ✗ | ✓ | ✗ | ✗ | ✓ |

Abbreviations: ADR char or mech: characteristics or mechanisms of adverse drug reaction; Alt aetiologies: alternative aetiological candidates (underlying illnesses, new illnesses, non-drug therapies and diagnostic tests and procedures); Background epi or clin info: background epidemiological or clinical information; Dechallenge: drug discontinued or reduced in dosage; Other: other factors; Prev exp or drug info: previous experience or information on drug; Response pattern to drug: clinical manifestation – symptoms improve with treatment; TTO or temp seq: time to onset or temporal sequence

1
2

**Table 9:** **Criteria to assess the association between a reaction and a drug: studies not included in the systematic review (adapted from Agbabiaka et al. 2008[3] with additional notes and quality ratings in the final 2 columns)**

| Author, population, setting | TTO or temp seq | Prev exp or drug info | Alter aetio-logies | Drug level or evid-ence of OD | Chall-enge | De-chall-enge | Re-chall-enge | Res-ponse pattern to drug | Confirm-ed lab evidence | Con-com-itant drugs | Back-ground epi or clin info | ADR char or mech | Other | Quality |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bousquet et al. 2009[18] – ENDA classification Setting: ENDA (European Network for Drug Allergy) collaboration | ✓ | ✓ | ✓ | ✗ | ✗ | ✗ | ✗ | ✓ | ✓ | ✓ | ✗ | ✓ | Acute (up to 24 hours) versus delayed reactions (more than 24 hours) | High |
| Caimmi et al. 2012[23] Population & setting: Consecutive patients referred to Allergy Department University Hospital, Montpelier, France | ✓ | ✓ | ✗ | ✗ | ✗ | ✗ | ✗ | ✓ | ✗ | ✗ | ✓ | ✓ | Immediate (up to 6 hours) or non-immediate (more than 6 hours) | High |
| Du et al. 2013[38]; Population: neonatal patients Setting: USA & Canada | ✓ | ✗ | ✓ | ✓ | ✗ | ✓ | ✓ | ✓ | ✗ | ✓ | ✓ | ✗ | Algorithm validated and performed better than Naranjo scale with Kappa and ICC scores of 0.76 and 0.62 compared to 0.31 and 0.43 | Moderate. Not appropriate for GP practice; no precise definition of DA |
| Gallagher et al. 2011[50] – Liverpool algorithm Based on case reports in children's hospitals in the UK | ✓ | ✓ | ✓ | ✗ | ✓ | ✗ | ✓ | ✓ | ✓ | ✓ | ✗ | ✗ | In comparison with the Naranjo algorithm more patients can be classified as 'definite' causal | High |

| Author, population, setting | TTO or temp seq | Prev exp or drug info | Alter aetio-logies | Drug level or evid-ence of OD | Chall-enge | De-chall-enge | Re-chall-enge | Res-ponse pattern to drug | Confirm-ed lab evidence | Con-com-itant drugs | Back-ground epi or clin info | ADR char or mech | Other | Quality |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | | | | | | relationship | |
| Gonzalez et al. 1992[54] Population: patients with suspected beta-lactam reaction Setting: Allergy Department, Hospital Universitario Reina Sofia, Cordoba, Spain | ✗ | ✗ | ✗ | ✗ | ✓ | ✗ | ✗ | ✓ | ✓ | ✗ | ✗ | ✗ | Scores based on 3 parameters only: clinical symptoms, aetiology and lab tests | Moderate. No validation; all factors not considered; no precise definition of DA |
| Son et al. 2011[146] Population: patients with cutaneous ADRs Setting: South Korea | ✓ | ✓ | ✓ | ✓ | ✗ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✗ | To evaluate the accuracy of a Korean algorithm which was developed because, '…algorithms used in foreign countries with different genetic backgrounds, investigation and level of awareness for ADRS and as such they might not be suitable for use in Korea.' This algorithm | High |

| Author, population, setting | TTO or temp seq | Prev exp or drug info | Alter aetio-logies | Drug level or evid-ence of OD | Chall-enge | De-chall-enge | Re-chall-enge | Res-ponse pattern to drug | Confirm-ed lab evidence | Con-com-itant drugs | Back-ground epi or clin info | ADR char or mech | Other | Quality |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | | | | | | correlated well with Naranjo. | |
| Trewin 1991[153] Population: elderly patients with suspected drug allergy Setting: Pharmacy Department, Royal Devon & Exeter Hospital | ✕ | ✕ | ✓ | ✕ | ✕ | ✓ | ✕ | ✓ | ✓ | ✕ | ✓ | ✕ | Included in this algorithm for the elderly was also 'medication compliance' and 'source of medication' details. In the number and type of ADRS identified only 2 were 'rash' and there was no reference to drug allergy. | Moderate Single author of algorithm; no validation; no precise definition of DA; all factors not considered. |

1 *Abbreviations: ADR char or mech: characteristics or mechanisms of adverse drug reaction; Alt aetiologies: alternative aetiological candidates (underlying illnesses, new illnesses, non-drug*
2 *therapies and diagnostic tests and procedures); Background epi or clin info: background epidemiological or clinical information; Dechallenge: drug discontinued or reduced in dosage; Other:*
3 *other factors; Prev exp or drug info: previous experience or information on drug; Response pattern to drug: clinical manifestation – symptoms improve with treatment; TTO or temp seq: time to*
4 *onset or temporal sequence*
5 *Quality Assessment: 9 criteria for quality assessment. Scoring of positive responses: 7–9 high quality; 4–6 moderate quality; 1–3 low quality.*

6 ### 5.3.2 Probability scores

7 Bayesian methods have been proposed to provide a formal inferential framework for causality in the assessment of drug allergy and adverse drug reactions.
8 It is mathematically based upon calculating a ratio (the posterior odds) between 2 probabilities both of which are conditional on the same background and
9 case information: that a given drug caused an adverse event versus that an alternative cause is responsible.

10 Despite the benefits of repeatability, transparency, explicitness, completeness, balancing of case data and no arbitrary limiting of information on the
11 assessment, this method of causation analysis can be time consuming and may require significant use of resources and complex calculations.

12 The same categories were used as those described for the algorithms.

Agbabiaka et al. 2008[3] included a narrative analysis of the probabilistic and Bayesian approaches, but there was no explicit quality assessment of individual algorithms.

Table 10 below is adapted from the summary that is provided in Agbabiaka et al.[3]

**Table 10: Probabilistic or Bayesian approaches to causation used**

| Author | TTO or temp seq | Prev exp or drug info | Alter aetio-logies | Drug level or evidence of overdose | Chall-enge | Dechall-enge | Rechall-enge | Response pattern to drug | Confirm-ed lab evidence | Concom-itant drugs | Back-ground epi or clin info | ADR char or mech | Other |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hutchinson et al. 1991[68] | ✓ | ✗ | ✗ | ✗ | ✗ | ✗ | ✓ | ✓ | ✓ | ✓ | ✗ | ✗ | ✗ |
| Lanctot et al. 1995[90] | ✓ | ✓ | ✗ | ✗ | ✗ | ✓ | ✓ | ✗ | ✗ | ✗ | ✓ | ✓ | ✗ |
| Lane et al. 1987[91] | ✓ | ✗ | ✗ | ✗ | ✗ | ✗ | ✓ | ✓ | ✓ | ✗ | ✗ | ✓ | ✗ |
| Mashford 1984 | ✓ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | ✓ | ✗ | ✗ | ✗ | ✓ |
| Theophile et al. 2013[152] | ✓ | ✗ | ✓ | ✗ | ✗ | ✓ | ✓ | ✓ | ✓ | ✓ | ✗ | ✗ | ✓ |

*Abbreviations: ADR char or mech: characteristics or mechanisms of adverse drug reaction; Alt aetiologies: alternative aetiological candidates (underlying illnesses, new illnesses, non-drug therapies and diagnostic tests and procedures); Background epi or clin info: background epidemiological or clinical information; Dechallenge: drug discontinued or reduced in dosage; Other: other factors; Prev exp or drug info: previous experience or information on drug; Response pattern to drug: clinical manifestation – symptoms improve with treatment; TTO or temp seq: time to onset or temporal sequence*

### 5.3.3 Comparative studies

The conclusion of the systematic review by Agbabiaka et al. 2008[3] was that "…no single algorithm is accepted as the 'gold standard,' because of the shortcomings and disagreements that exist between them." We have reviewed 6 studies[13,20,73,107,126,152] which compare the most commonly used algorithms for drug allergy and provide kappa statistics as a measure of congruency. A summary of the statistical conclusions of the comparative studies is provided in Table 11 below.

**Table 11: Studies comparing algorithms**

| Reference | Algorithms compared | Sensitivity | Specificity | Positive (negative) predictive values | Concordance with allergy diagnosis | Concordance with other algorithms |
|---|---|---|---|---|---|---|

| Reference | Algorithms compared | Sensitivity | Specificity | Positive (negative) predictive values | Concordance with allergy diagnosis | Concordance with other algorithms |
|---|---|---|---|---|---|---|
| Benahmed et al. 2005[13] | Begaud Jones Naranjo | Begaud: 8.3% Jones: 50% Naranjo: 0% | Begaud: 98.3% Jones: 53.3% Naranjo: 100% | Begaud: 50.9% (83.5%) Jones: 18.5% (83.4%) Naranjo: 0% (100%) | Begaud: No concordance, k=0.12 Jones: No concordance, k=0.14 Naranjo: No concordance, k=0.14 | Jones and Naranjo: perfect concordance (k=1) but the Jones method showed a substantial trend in favour of higher scores for the cases. Begaud: No concordance (k=0) |
| Busto et al. 1982[20] | Kramer (ASS) Naranjo (APS) | | | | | High inter-rater reliability when both methods were used: Scores obtained with APS were highly correlated with those obtained with ASS by both raters: r=0.86 and r=0.81 respectively. Time spent using the ASS was slightly but significantly longer than that using the APS (9.52 (±3.02) minutes versus 8.94 (±3.51) minutes) |
| Kane-Gill et al. 2012[73] | Jones Kramer Naranjo | | | | | The level of agreement between algorithms have kappa values all >0.7 between individual instruments with the Naranjo criteria versus Kramer algorithm having the highest kappa score, which is considered excellent agreement. |
| Michel & Knodel 1986[107] | Kramer Naranjo | | | | | Agreement between Kramer and Naranjo was 67% with kappa=0.43; Kramer versus Jones was 67% agreement with k=0.48; Naranjo versus Jones was 64% agreement with k=0.28. |
| Pere et al. 1986[126] | Begaud Emanueli Kramer Naranjo | Weightings of criteria: Criteria are not highly sensitive (0.41<Sens<0.70) | Weightings of criteria: Criteria are not highly specific | | | Concordance between methods is better than with chance but never more than moderately (0.40<kappa<0.60). Kramer versus |

| Reference | Algorithms compared | Sensitivity | Specificity | Positive (negative) predictive values | Concordance with allergy diagnosis | Concordance with other algorithms |
|---|---|---|---|---|---|---|
| | | | (0.18<Spec<0.63) | | | Naranjo (k=0.51). |
| Theophile et al. 2013[152] | Probabilistic method Liverpool Naranjo | Probabilistic method: 0.96 Naranjo and Liverpool were identical with 2 scores calculated depending on whether 'possible' was considered in favour or disfavour of drug causation: 1 or 0.42 | Probabilistic method: 0.56 Naranjo and Liverpool: 0.11 or 0.89 | Probabilistic method: 0.92 (0.71) Naranjo and Liverpool: 0.86 or 0.95 (1 or 0.22) | Logistic method gave results closer to expert opinion and the Liverpool and Naranjo algorithms depended on the interpretation of the 'possible' category of cases. | Naranjo and Liverpool performed similarly with more cases of 'definites' in the latter. |

1

### 5.3.4 Most commonly used algorithm criteria

For the current review we used the Agbabiaka et al. 2008[3] findings for 20 algorithms which included drug allergy as part of the evaluation of ADR, the 5 probabilistic or Bayesian studies in Agbabiaka et al. 2008,[3] and the 7 additional algorithms added into this review, to assess how frequently different causality criteria appeared across all of the algorithms (see **Table 12**). The assessment criteria were ranked as follows:

**Table 12:   Frequency causality criteria were used across 32 algorithms and probability scores (25 from the systematic review and 7 added in the current review)**

| Assessment criteria | Included in algorithms, n/total (%) |
| --- | --- |
| 1. Time to onset or temporal sequence | 24/32 (75%) |
| 2. Response pattern to drug (clinical response) | 24/32 (75%) |
| 3. Rechallenge | 22/32 (69%) |
| 4. Alternative aetiological candidates | 17/32 (53%) |
| 5. Confirmed by lab evidence | 16/32 (50%) |
| 6. Drug level or evidence of overdose | 15/32 (47%) |
| 7. Dechallenge | 14/32 (44%) |
| 8. Background epidemiological or clinical information | 12/32 (38%) |
| 9. Previous exposure or drug information | 12/32 (38%) |
| 10. Concomitant drugs | 12/32 (38%) |
| 11. Challenge | 10/32 (31%) |
| 12. ADR characteristics or mechanism | 8/32 (25%) |

The evidence shows that none of the criteria are used consistently in all of the algorithms. This includes 'time to onset or temporal sequence' and 'response pattern to drug (clinical response)' which were only used as assessment criteria in 24 (75%) of the 32 algorithms. Questions about drug challenge and ADR characteristics or mechanisms featured least frequently across algorithms, only occurring in 10 and 8 of 32 algorithms (31% and 25%), respectively.

 Agbabiaka et al. (2008)[3] also reviewed comparisons of algorithms which were updated here. These are studies in which people with suspected drug allergies are assessed with more than one algorithm and the level of agreement (that is, congruency) between the assessments is then calculated. Congruencies showed the whole range from 0% to 100% agreement with no agreement between the Begaud and Kramer or Jones in one study and a 100% agreement between Kramer and Jones in the same study. Even the same comparisons sometimes had very different levels of agreement across comparisons (for example, comparisons of Kramer and Jones showed perfect agreement in one study and only moderate agreement, 67%, in another).Economic evidence

**Published literature**

No relevant economic evaluations were identified.

See also the economic article selection flow chart in Appendix F.

# 5.4 Evidence statements

**Clinical**

- Assessment criteria: moderate quality evidence from 32 algorithms and probability scores (according to quality of the included systematic review and the quality of the additional algorithms) indicated no clear criteria that were used consistently to assess whether a person has a drug allergy. The most frequently used criteria were 'time to onset or temporal sequence' and 'response pattern to drug'.

- Assessment comparisons: there were highly variable levels of agreement between algorithms ranging from no agreement (0%) to a perfect level of agreement (100%) with some inconsistencies in results for the same comparisons in different studies. In all comparisons the Naranjo algorithm was used as one of the comparators or the only reference standard. The second most frequent comparator was the Kramer algorithm.

**Economic**

- No relevant economic evaluations were identified.

# 5.5 Recommendations and link to evidence

<table>
<tr>
<td rowspan="2"></td>
<td colspan="2">

1. **When assessing a person presenting with possible drug allergy, take a history and undertake a clinical examination. Use the following tables as a guide when deciding whether to suspect drug allergy.**

**Tables 1–3 Signs and allergic patterns of suspected drug allergy with timing of onset after exposure to drug[c]**

**1 Immediate, rapidly evolving reactions**

| | |
|---|---|
| **Anaphylaxis – a severe multi-system reaction usually with erythema, urticaria or angioedema in combination with hypotension and/or bronchospasm** | **Onset usually under 1 hour, previous exposure not always confirmed** |
| **13. Urticaria or angioedema without systemic features** | |
| **Exacerbation of asthma, for example with non-steroidal anti-inflammatory drugs (NSAIDs)** | |

**2 Non-immediate reactions without systemic involvement**

| | |
|---|---|
| **Widespread red macules or papules (exanthem-like)** | **Onset usually on day 6–10 of first drug exposure (reaction to first exposure may be more prolonged), or day 1–3 of second exposure** |
| **Fixed drug eruption (localised inflamed skin)** | |

</td>
</tr>
<tr>
<td>**Recommendation**</td>
<td>**3 Non-immediate reactions with systemic involvement**</td>
</tr>
</table>

---

[c] Note that these tables describe common and important presenting features of drug allergy but other presentations are also recognised

| | | |
|---|---|---|
| | Widespread red macules, papules or erythroderma with systemic involvement. For example, drug reaction with eosinophilia and systemic symptoms (DRESS) or drug hypersensitivity syndrome (DHS) – characterised by fever, lymphadenopathy, liver dysfunction and low platelets | Onset usually 2–6 weeks after first drug exposure, or 24–48 hours after second exposure |
| | Toxic epidermal necrolysis or Stevens–Johnson syndrome – characterised by mucosal or cutaneous erosions, vesicles, blistering or epidermal detachment, and red purpuric macules or erythema multiforme. Painful rash and fever are often early signs | Onset usually 7–14 days after first drug exposure, or 24–48 hours after second exposure |
| | Acute generalised exanthematous pustulosis – widespread pustules, usually with a fever and neutrophilia | Onset 3–5 days after first drug exposure |
| | Common disorders caused, rarely, by drug allergy:<br>eczema<br>hepatitis<br>photosensitivity<br>vasculitis | Time of onset variable |

2. Be aware that the reaction is more likely to be caused by drug allergy if it occurred during or after use of the drug and:

- the drug is known to cause that type of reaction or
- the person has had a similar reaction to that drug or class of drug in a previous exposure.

3. Be aware that the reaction is less likely to be caused by drug allergy if:

- there is a possible non-drug cause for the person's symptoms, for example, they have had similar symptoms when not taking the drug, or
- the person has gastrointestinal symptoms only.

| | |
|---|---|
| Relative values of different outcomes | The following outcomes were identified by the GDG as important for decision-making: mortality, number of repeat drug allergic reactions, length of hospital stay, acute admission or readmission into secondary care, number of contacts with healthcare professionals, inappropriate avoidance of drugs, health-related quality of life.<br>The group noted that no evidence was identified that directly addressed the effectiveness of algorithms in terms of the clinical outcomes specified, but the evidence instead focused on causality criteria with associated scores in developing an algorithm. |
| Trade-off between clinical benefits and harms | The group agreed that the benefit of an algorithm for the assessment of signs and symptoms is that it can help in identifying whether the reaction observed is likely to be caused by a drug. However, in the group's opinion, the key potential harm of recommending the use of an |

| | |
|---|---|
| | algorithm to people with a suspected drug allergy is the poor predictive value provided by algorithms. Specifically, the lack of absolute prediction of whether the person presenting with a suspected drug allergy is experiencing an allergic reaction or not and the risk of clinicians providing false reassurance was a key concern.<br><br>The GDG noted that signs and symptoms of drug allergy in children may differ from those in adults, and typical patterns suggesting an allergic reaction to a drug may not apply in a child's case. For example, non-specific rashes are more common in children and these are usually not due to drug allergy, whilst severe cutaneous reactions are less common in children. The GDG also recognised that people of certain ethnicities and those with certain comorbidities such as cystic fibrosis or HIV are at higher risk of allergic reaction to specific drugs or drug classes. |
| Economic considerations | No relevant economic evidence was identified. The GDG did not prioritise this question for original economic analysis.<br><br>The GDG agreed that the proposed assessment would most likely be carried out as part of an initial GP (or other non-drug allergy specialist) assessment, but could take longer than current practice (which generally involves noting an adverse reaction, rather than assessing the reaction and investigating the possibility of an allergy). Therefore, there may be a small increase in initial cost. However, the GDG felt that appropriate assessment would be of great clinical benefit to the person with a suspected drug allergy, as it would be likely to improve the accuracy of diagnosis. Accurate diagnosis will improve quality of life, and reduce the later costs associated with incorrect labelling of drug allergy (such as those incurred by patients who are unnecessarily given alternative second-line drugs, which are often more expensive and less effective than the first-line option). Appropriate assessment using the recommendations above will therefore assist selection of the appropriate treatment strategy for each person with a suspected drug allergy, and therefore promote economic efficiency of the clinical pathway. The GDG agreed that carrying out the assessment when the patient first presents with a potential allergic reaction would lead to the best clinical outcomes, as details of the reaction are likely to be documented more accurately than if left to a later stage.<br><br>Overall the GDG agreed that the benefits (improvements in quality of life and reduced future costs) of the signs and symptoms checklist would outweigh the small upfront cost of a longer initial consultation. |
| Quality of evidence | The aim of the review of algorithms was to identify common signs and symptoms that indicate whether a person may have a drug allergy. The evidence showed that a number of the algorithms did not specify such patterns but focused on the types of questions that physicians need to consider when trying to identify whether the drug caused the reaction. The NICE quality assessment tool for systematic reviews was applied to the published systematic review. A further tool was designed to assess the quality of algorithm studies added to this review. The studies included in the review were assessed as good to moderate quality. However, since the algorithms that were reviewed did not always address signs and symptoms directly, the evidence was given less value in drawing up the recommendations.<br><br>The GDG advised that not all the algorithms reviewed were applicable to primary care as they required too much time for a GP to use during standard consultations, required challenge testing, or did not result in a final clinical decision for managing a patient.<br><br>The GDG noted that the algorithms included in the review looked at adverse drug reactions and not at drug allergy specifically and were not |

| | |
|---|---|
| | assessed for effectiveness in clinical settings. |
| Other considerations | The GDG concurred with the conclusion of the Agbabiaka3 systematic review that clinical judgement is still required when using an algorithm as a decision-making tool, and that no single algorithm is accepted as a gold standard. The GDG noted that the Naranjo113 and Kramer83,84 studies were the most commonly referred to within the literature, and the study by Jones which compared the 2 favoured the Naranjo algorithm.113 The European Network for Drug Allergy questionnaire (Bousquet 200918) was a large study designed for use by GPs and was assessed as being of high quality. However, no study had addressed how effective these tools were within a clinical practice setting, and the GDG thought that none of the algorithms were practical for use in general practice or other non-specialist settings. |
| | Most of the studies did not assess the clinical effectiveness (that is, directly leading to improved patient outcomes) of algorithms against each other or against other methods of diagnosis. This evidence would have been included but no further studies were identified. The GDG noted the difficulty of capturing the wide range of drugs and reactions to drugs in a single decision-making tool, and that as drug allergy is a subset of adverse drug reaction, it was difficult to identify drug allergy using an adverse drug reaction questionnaire such as the tools produced by Kramer83,84 or the European Network for Drug Allergy (ENDA).18 The GDG suggested alternatives which may be more effective, such as checklists, pathways or flow charts. The GDG questioned the helpfulness of a probability score as used in the ENDA questionnaire18 because it does not lead to a decision for the clinician. However, the group did think a checklist of common symptoms may be helpful and further agreed that any decision tool should ideally be short, easy to use and include a score that would determine the action to be considered by the clinician. The group cited the use of the CHADS2 system112 (congestive heart failure, hypertension, age ≥75 years, type 2 diabetes and previous stroke or transient ischemic attack), which is used as a predication rule for atrial fibrillation. Although no suitable scoring system was identified from the review, the development of a validated algorithm or decision rule including a scoring system for use within non-specialist settings would be a helpful guide in assessing and managing people who have had a suspected allergic reaction to a drug. |
| | The GDG agreed the common signs and symptoms listed in the ENDA study18 could be adapted and used as a basis for the recommendations. The GDG acknowledged the questions used within the Naranjo paper are for use within a specialist setting,113 however they believed some of these were also relevant for use within a non-specialist setting and would be a helpful addition to the recommendations as a part of the initial assessment and decision-making process undertaken by the clinician. Providing timings of when signs and symptoms are likely to occur after exposure to a drug was thought to be helpful when making an assessment. The group arrived at the timings given in the recommendations through informal consensus based on their clinical experience and knowledge of the literature in this area. |
| | The group noted that currently, adverse reactions are listed in the information provided with most drugs and these reactions are categorised from common reactions, to less common reactions and rare reactions. |

1

# 6 Measuring serum tryptase after suspected anaphylaxis

## 6.1 Introduction

The measurement of serum tryptase after allergic reactions remains under-used, even after life-threatening episodes of anaphylaxis. Acute elevation of serum tryptase indicates degranulation of mast cells which occurs either due to an IgE-mediated mechanism, for example with penicillin allergy, or may result from direct degranulation of mast cells through non-IgE-mediated means, for example with NSAIDs or opiates. The rise in tryptase levels starts to be detected in serum within minutes of anaphylaxis but the level will gradually revert to normal over the next 6–24 hours depending on the height of the increase and often correlates with the severity of the anaphylaxis.

Anaphylaxis is a severe, life-threatening, generalised or systemic hypersensitivity reaction. It is characterised by rapidly developing life-threatening problems involving the airway (pharyngeal or laryngeal oedema), breathing (bronchospasm with tachypnoea), circulation (hypotension or tachycardia), or a combination of these. In most cases, there are associated skin and mucosal changes. However, some of the symptoms of anaphylaxis may be due to other causes, such as an acute cardiovascular or respiratory event. Therefore, measurement of serum tryptase taken in a timely manner can help to identify whether the cause is due to anaphylaxis and if the level is acutely elevated this should reduce the requirement for unnecessary investigations of other causes. An acute increase in serum tryptase also indicates that the reaction was potentially life-threatening and, therefore, indicates a need to identify the drug that caused the reaction and any potential cross-reacting agents in order to reduce further risk.

## 6.2 Review question: What is the clinical and cost effectiveness of serum tryptase testing compared with reference standard tests for the diagnosis of an anaphylactic reaction due to suspected drug allergy?

For full details see review protocol in Appendix C.

**Table 13: Characteristics of review question**

| | |
|---|---|
| **Population** | Patients presenting with signs and symptoms of anaphylaxis |
| **Intervention (index test)** | Serum tryptase test taken during an acute reaction |
| **Comparison (reference standard)** | • Other methods of confirming diagnosis of drug allergy such as skin tests, oral challenge test or a more complete diagnostic work up<br>• No serum tryptase done during acute reaction |
| **Outcomes** | 1. Pre-test probability<br>2. Sensitivity<br>3. Specificity<br>4. Positive predictive value (PPV)<br>5. Negative predictive value (NPV)<br>6. Number of cases missed (false negative) |
| **Study design** | Diagnostic cohort studies |

## 1  6.3  Clinical evidence

2  The utility of serum tryptase for the diagnosis of anaphylaxis has been published in the context of
3  NICE Clinical Guideline 134: Anaphylaxis (2011).[116] We conducted a full search on this topic and
4  identified 1[57,57] study that was not included in the anaphylaxis guideline and a further study[133]
5  published since the guideline which were both added to the this review. All studies included in the
6  Anaphylaxis guideline that were not specific to drug allergy were excluded. After this exclusion 2
7  studies[99,106] remained from the Anaphylaxis guideline as well as the additional studies.[57,133]

8  Evidence was divided by serum tryptase threshold:

9  • Two studies provided evidence for testing at a medium threshold at peak (11.4 and 12
10   microgram/litre) and

11  • Three studies provided evidence for testing at a high threshold at peak (24 and 25
12   microgram/litre)

13  Any information about the timing of testing was also summarised and is presented in the GRADE
14  evidence profile (Table 15).

15  Evidence from these studies are summarised in the clinical GRADE evidence profile below (Table 15).
16  See also the study selection flow chart in Appendix E, sensitivity and specificity forest plots in
17  Appendix J, study evidence tables in Appendix H and exclusion list in Appendix K.

18  **Table 14:  Summary of studies included in the review**

| Study | Objective, index test and reference standard | Population | Outcomes |
|---|---|---|---|
| Malinovsky et al. 2008[99] | Aim to evaluate incidence of hypersensitivity reactions during anaesthesia by using histamine and tryptase measurements and allergological investigations to investigate suspected or unexplained reactions.<br><br>Reference standard<br>Clinical diagnosis and immunological tests | Patients with suspected hypersensitivity reaction to anaesthetics (29 general, 2 regional) at University Hospital Nantes from May 2001 to April 2003 (hypersensitivity reaction determined if presented with cutaneous symptoms, that is urticaria or angioedema) isolated or in association with other clinical symptoms like bronchospasm, hypotension, or cardiovascular collapse or if circulatory inefficacy in close relation with anaesthetic drug injection in absence of other explanation.<br><br>Patients with IgE-mediated hypersensitivity reactions:<br>Median age:<br>43 years (range: 8–80)<br>45% (10/22) male, 55% (12/22) female<br>Patients without IgE- | With 12 micrograms/ litre threshold:<br>Sens: 63.6% (95% CI 40.7% to 82.8%)<br>Spec: 100%<br>(when calculated by analyst specificity was 88.9% with 95% CI 51.8% to 99.7%)<br><br>With 25 micrograms/ litre threshold:<br>Sens: 40.9% (95% CI 20.7% to 63.6%)<br>Spec: 100% (95% CI 66.4% to 100%)<br><br>With 12 micrograms/ litre threshold:<br>PPV: 100%<br>NPV: 53%<br>(when calculated by analyst these values were<br>PPV: 93.3% (95% CI 68.1% to 99.8%)<br>NPV: 50% (95% CI 24.7 to 75.3%))<br>With 25 micrograms/ |

| Study | Objective, index test and reference standard | Population | Outcomes |
|---|---|---|---|
| | | mediated hypersensitivity reactions: Median age: 45 years (range: 19–78) 56% (5/9) male, 44% (4/9) female | litre threshold: PPV: 100% (95% CI 66.4% to 100%) NPV: 41% (95% CI 20.7% to 63.6%) |
| Mertes et al. 2003[106] | Aim to survey allergic and non-immunologically mediated reactions during anaesthesia, description of clinical characteristics, and identification of possible factors and responsible drugs.<br><br>Reference standard<br>Clinical diagnosis and skin prick test or IgE | Patients with adverse reaction during anaesthesia in France between Jan 1999 and December 2000 | With 25 micrograms/ litre threshold: Sens: 64% (95% CI 56.4% to 71.1%) Spec: 89.3% (95% CI 80.6% to 95.0%) With 25 micrograms/ litre threshold: PPV: 92.6% (95% CI 86.3% to 96.5%) NPV: 54.3% (95% CI 45.7% to 62.8%) |
| Harboe et al. 2005[57] | Aims of this study were to describe a patient population that developed peri-anaesthetic anaphylaxis in the years 1996–2001 and to evaluate the standardised protocol used for allergy follow-up examination at 1 allergy outpatient clinic in Western Norway.<br>Index test<br>Serum tryptase was measured using the Pharmacia UniCAP FEIA system (Pharmacia Diagnostics). Researchers attempted to obtain serum samples at 3 time points: before, within 2 hours after and on the day after the reaction. Levels were considered increased if the 2-hour serum concentration was above 24 micrograms/litre or 3 times that of the background concentration.<br><br>Reference standard<br>Skin prick tests performed in duplicate. | Patients who had an anaphylactic reaction to general anaesthesia | A significant acute (within 2 hours) increase of serum tryptase accompanied 40 (48.2%) of the anaphylactic reactions. In 25 cases (30.1%), no increase was detected, but for 15 of these, the time interval between reaction and blood sampling was not specified. From 18 (21.7%) of the events, 2-hour serum samples were not obtained. |
| Sala-Cunill et al. 2013[133] | Aim was to determine sequential serum tryptase concentration in patients with anaphylaxis, both during the acute episode and at baseline, and to evaluate its usefulness in the diagnosis of anaphylaxis and as a marker related to the clinical severity of the reaction.<br><br>Index Test<br>Tryptase was measured using the UniCAP-Tryptase fluoroimmunoassay (Phadia, now Thermo Fisher Scientific). | Patients with a confirmed clinical diagnosis of anaphylaxis by allergist and serum tryptase drawn during anaphylaxis (mixed population). | Overall sensitivity of serum tryptase in drug allergy patients only: 33/51 (65%). |

| Study | Objective, index test and reference standard | Population | Outcomes |
|---|---|---|---|
| | A serum tryptase concentration ≥11.4 micrograms/litre was considered high.<br><br>Reference standard<br>Skin prick test | | |

3

**Table 15:   Clinical evidence profile: serum tryptase**

| Number of studies | Study designs | n | Risk of bias | Inconsistency | Indirectness | Imprecision | Sensitivity – median (95% CI) | Specificity – median (95% CI) | PPV – median (95% CI) | NPV – median (95% CI) | Timing | Quality |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Mast cell tryptase medium threshold at peak (11.4 and 12 microgram/litre)** | | | | | | | | | | | | |
| 2 | Cross-sectional | 82 | very serious risk of bias[a] | N/A[b] | no serious indirectness | very serious imprecision[c] | 64% (41–83%); 65% (50–78%) | 89% (52–100%) | 93% | 50% | In 1 study 30–60 minutes (positive readings were on average 5.25 times higher than after 24 hours). In the other study 65 people with samples taken at 2 hours and 40 (61%) had increased serum tryptase. | VERY LOW |
| **Mast cell tryptase high threshold at peak (24 and 25 microgram/litre)** | | | | | | | | | | | | |
| 3 | Cross-sectional | 355 | very serious risk of bias[a] | serious inconsistency[c] | no serious indirectness | very serious imprecision[c] | 41% (21–64%); 64% (56–71%); 62% (49–73%) | 100% (66–100%); 89% (81–95%) | 93%; 100% | 54%; 41% | One study is the same as above. In another study readings were taken at 2 hours. In the third study peak levels were reached between 1–2 hours, but average level remained elevated at 4–6 hours. 20/45 had high levels at 4–6 hours and 9/27 at 12–24 hours. | VERY LOW |

*Only 3 studies contributed to the test at each threshold and results were not pooled. All extractable values are given in the table rather than 1 median value.*

*(a)  Risk of bias was assessed using the QUADAS-2 checklist. The overall risk of bias for each outcome was assessed according to the risk of bias for the majority of the evidence.*

*(b)  There was insufficient data to derive a 2×2 table and assess level of inconsistency (sensitivity and specificity could only be calculated in 1 study).*

*(c)  Inconsistency and imprecision were assessed by inspection of the sensitivity/specificity paired forest plots and the confidence intervals of these accuracy measures. Inconsistency was assessed based on the point estimate (i.e. ranging from below chance level, 41% to moderate sensitivity, 64%), The judgement of precision was based on the confidence interval in sensitivity / specificity. A range of between 10% and 20% was considered to be seriously imprecise whereas more than 20% was considered to be very seriously imprecision. Judgements reflected the poorest quality rating.*

## 6.4 Economic evidence

**Published literature**

No relevant economic evaluations were identified.

See also the economic article selection flow chart in Appendix F.

**Unit costs**

Costs from the Protein Reference Unit in Sheffield[69] are used as example costs: the cost per test is £36.67, therefore the total cost estimate of tryptase testing is £73.34. Note that this estimate does not capture the full economic impact of tryptase testing, which would include the time of a healthcare professional to administer the tests, as well as downstream cost and quality of life implications of using the tests.

## 6.5 Evidence statements

**Clinical**

- Very low quality evidence from 4 observational studies (n=480) showed good level of specificity (89–100% where it was possible to derive this measure) regardless of threshold. Sensitivity was low (median 64% regardless of threshold). There was large uncertainty around the estimate and it is therefore unclear how to interpret this. Information on timing was not available in all studies, but when described peak levels were reached up to 2 hours.

**Economic**

- No relevant economic evaluations were identified.

## 6.6 Recommendations and link to evidence

| | |
|---|---|
| | **4. After a suspected drug-related anaphylactic reaction, take blood samples for mast cell tryptase in line with recommendations in Anaphylaxis (NICE clinical guideline 134).** |
| | **5. Record in the person's notes and on the pathology request form, the exact timing of both blood samples taken for mast cell tryptase after onset of suspected anaphylaxis.** |
| | **6. Ensure that tryptase sampling tubes are included in emergency anaphylaxis kits.** |
| **Recommendations** | |
| Relative values of different outcomes | The following outcomes were identified by the GDG as important for decision-making: pre-test probability, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), number of cases missed (false negatives), number of cases mislabelled (false positives).<br><br>A positive test result (acutely elevated serum tryptase) would be highly suggestive of drug allergy and should direct further investigation. Therefore the specificity of the test result is important, that is, false positive results should be low. For this condition it is also paramount not to miss cases and |

| | |
|---|---|
| | therefore if a person tests negative on tryptase the probability that he or she had an anaphylactic reaction should be lower. The sensitivity of the test result is therefore also important. However, the GDG agreed that a normal serum tryptase, taken acutely does not exclude drug allergy. Therefore the sensitivity measurement of the test may not be weighted as the most important outcome. |
| Trade-off between clinical benefits and harms | The evidence indicated that the proportion of people who have the condition when they tested positive (PPV) was high. Specificity values were also generally very high (between 89% and 100%). However since sensitivity was variable and modest, many people without elevated levels of tryptase did have anaphylactic reactions due to drug allergy. They would therefore be missed at this time point and might receive the drug again in the future before referral to specialists. Moreover, people with negative tryptase results might wrongly believe that the reaction was unrelated to the drug they had received. |
| Economic considerations | No relevant economic evidence was identified. The GDG identified diagnostic tests (serum tryptase and serum specific IgE) as the second highest priority area for original economic analysis. However, the GDG concluded that modelling would not be feasible for this review question due to the lack of necessary clinical data linking diagnostic test results with future clinical outcomes such as further allergic reactions, alternative drugs taken, hospitalisation and resource use. The GDG therefore considered the unit costs of these tests and discussed the likely impact on downstream resources and health related quality of life. |
| | Mast cell tryptase blood testing has an additional cost, including the analysis of 2 tests (£77) and additional healthcare professional time to collect the samples. Tryptase results are highly useful to GPs and specialists when they are later considering whether a person has a drug allergy and deciding what further tests are required. They are also helpful in informing the healthcare professional on what action should be taken in managing any drug allergy. |
| | The GDG believed that correctly administered and reported tryptase testing would be likely to reduce future resource use by reducing the extent of further investigations needed into possible drug allergy in an individual. |
| | Tryptase testing would also increase clinicians' abilities to correctly diagnose an individual as having or not having a drug allergy. This could reduce future hospitalisations due to further allergic reactions in those with drug allergy, thereby reducing costs and improving quality of life, and reducing excess spending on unnecessary alternative drugs in those without drug allergy. |
| | The GDG therefore agreed that mast cell tryptase testing is likely to be cost effective. |
| | For tryptase testing to take place on a routine basis the incorporation of blood sample tubes for tryptase testing into anaphylaxis kits would be an efficient method of ensuring these very low cost items are available to clinicians at the point at which they are needed. |
| Quality of evidence | The quality of the evidence was judged to be very low for all thresholds of serum tryptase. Some studies had poor definitions of the hypersensitivity reaction or recorded time intervals poorly. A variety of different tests was also used (for example, radioimmunoassays (RIA), Immunotech; UniCAP system, Pharmacia) which may also limit the generalisability of these results. The statistical measures did show wide confidence intervals and it is therefore difficult to estimate confidently how accurate the tests were as confidence intervals ranged sometimes from 41% to 83%. |
| Other considerations | Tryptase testing is currently usually carried out in secondary care. Serum tryptase tests will remain stable for 24 hours at room temperature and therefore the GDG considered that it was a suitable test to be carried out within a GP setting and would assist in the future management of the person if referred on to secondary care. The group agreed that the test is currently |

underutilised within primary care, but needs to be undertaken in a timely manner and records of timings kept in the person's notes.

No studies were identified that directly reported evidence for the use of serum tryptase testing in children. The GDG discussed whether any specific recommendations were needed for children and concluded that the recommendations would apply to all age groups.

The GDG agreed that sample tubes should be incorporated into anaphylaxis kits and resuscitation trolleys, as this would provide a practical prompt to take a blood sample at the time of the reaction and would make the process easier and quicker.

The GDG discussed the timing of tryptase testing with peak elevations usually reported around 1–2 hours after the reaction. The utility of testing beyond 4 hours was debated. One study (Sala-Cunhill et al. 2013[133]) reported patients with elevated tryptase at different time points beyond 2 hours, but this was in a mixed population of a small group of people with drug allergy reactions. In this study the number of people with tryptase levels recorded later than 2 hours was small (a mixed allergy group of 45 people at 4–6 hours and 27 at 12–24 hours). This indicates that serum tryptase may remain elevated beyond 4 hours, but this study was not large enough to be conclusive. The study reported elevated tryptase in the 1–2 hour timeframe as significantly higher than at any other time point. The other studies all investigated reactions to anaesthesia and did not report any timings other than a 2-hour time point.

The NICE Anaphylaxis guideline[116] recommends that the test should be carried out preferably within 2 hours and not beyond 4 hours in order to encourage people to carry out the test early. Although a raised tryptase may occur beyond the 4-hour period, this would usually only be in a small percentage of people. The decision around timing of the tests in the Anaphylaxis guideline was made by consensus, and so the GDG discussed whether the same view would be held by health professionals now. The GDG noted that the test was more likely to be done within a shorter time period in a hospital emergency setting, and that after 4 hours the patient may have been moved and so there may be an increased chance the test would not be undertaken at all and cases may be missed.

The recommendations for serum tryptase testing in the Anaphylaxis guideline are valid for those with a suspected drug reaction and have therefore been referred to within this guideline.

1

# 7 Measuring serum specific immunoglobulin E (IgE)

## 7.1 Introduction

In this section we have considered the clinical and cost effectiveness of serum specific IgE testing for the diagnosis of drug allergy. Serum specific IgE testing is only available for reactions to a limited number of drugs, including:  amoxicillin, ampicillin, cefaclor, chlorhexidine, morphine, penicillin and suxamethonium. The sensitivity and specificity of each of these tests in predicting whether a patient with a history of drug allergy is either allergic or non-allergic have been considered in order to evaluate whether this test could be used within a non-specialist setting such as a GP's surgery. This is the only non-acute test that can be undertaken in a non-specialist setting. For alternative tests such as skin prick testing or drug challenges the individual would need to be referred to specialist drug allergy services for investigation.

## 7.2 Review question: What is the clinical and cost effectiveness of serum specific IgE testing compared with reference standard tests in the diagnosis of drug allergy for the following drugs?

- amoxicillin
- ampicillin
- cefaclor
- chlorhexidine
- morphine
- penicillin G
- penicillin V
- suxamethonium

For full details see review protocol in Appendix C.

Table 16:   Characteristics of review question

| Population | Patients presenting with signs and symptoms of suspected drug allergy<br>Patients with a record of suspected drug allergy |
|---|---|
| Intervention (Index test) | Serum specific IgE test for the following agents:<br>• Ampicillin<br>• Amoxicillin<br>• Cefaclor<br>• Chlorhexidine<br>• Morphine<br>• Penicillin G<br>• Penicillin V<br>• Suxamethonium |
| Comparison (reference standard) | • Other methods of confirming diagnosis of drug allergy such as skin tests, oral challenge test or a more complete diagnostic work<br>• No serum specific IgE test (follow-up) |
| Outcomes | 1. Pre-test probability<br>2. Sensitivity<br>3. Specificity |

| | |
|---|---|
| | 4. Positive predictive value (PPV) |
| | 5. Negative predictive value (NPV) |
| | 6. Number of cases missed (false negative) |
| **Study design** | Diagnostic cohort studies |

## 7.3 Clinical evidence

We searched for diagnostic cohort and case–control studies as well as case series for the utility of serum specific IgE testing. Fourteen studies were identified for this review.[17,46,47,52,61,81,82,92,129,136,137,142,158,162] Evidence from these papers is summarised in the clinical GRADE evidence profile below (Table 18). See also the study selection flow chart in Appendix E, sensitivity and specificity forest plots in Appendix J, study evidence tables in Appendix H and exclusion list in Appendix K.

The evidence in this review is presented by class of drug as follows: beta-lactam antibiotics, neuromuscular blocking agents and chlorhexidine.

The IgE tests used and the study populations were variable and therefore a diagnostic meta-analysis was not carried out. The quality of studies was assessed using the Quality Assessment of Diagnostic Accuracy Studies tool (QUADAS-2) criteria.

**Table 17: Summary of studies included in the review: beta-lactam antibiotics**

| Study | Intervention, comparison | Population | Outcomes |
|---|---|---|---|
| Blanca et al. 2001[17] | Index test<br>Pharmacia CAP System FEIA serum specific IgE has a range of 0.35–100 kUA/litre with a cut-off value of ≥0.35 kUA/litre for a positive test and <0.35 kUA/litre for a negative test.<br><br>Reference standard<br>Skin prick tests; intradermal tests in all subjects. Controlled challenge in those who were skin test negative and in whom only 1 episode of clinical symptoms has occurred. | Patients attending the clinical outpatient department before the skin test procedure<br>n=74 drug allergy patients in 3 groups:<br>Group 1 comprised 19 subjects with an immediate reaction to benzyl penicillin (BP) or amoxicillin (AX) and were skin test positive to amoxicillin or benzylpenicilloyl (BPO) independently of positivity to ampicillin (AMP) and minor determinant mixture (MDM).<br>Group 2 comprised 29 subjects with an immediate reaction to an AX derivative, were skin test positive to AX determinants and negative to BPO and had good tolerance to BP;<br>Group 3 comprised 26 subjects with an immediate reaction to penicillin or AX who were skin test negative to all penicillin derivatives used in the study.<br>2 control groups of 55 patients were included:<br>Group 4 comprised 25 | Results for Groups 1–3 by hapten benzylpenicilloyl (BPO) and amoxicilloyl (AXO)<br>BPO:<br>TP: 24<br>FP: 1<br>FN: 50<br>TN: 54<br>Sensitivity: 32%<br>Specificity: 98%<br><br>AXO:<br>TP: 32<br>FP: 1<br>FN: 42<br>TN: 54<br>Sensitivity: 43%<br>Specificity: 98%<br><br>BPO+AXO<br>TP: 37<br>FP: 2<br>FN: 37<br>TN: 53 |

| Study | Intervention, comparison | Population | Outcomes |
|---|---|---|---|
| | | patients with a clinically documented non-IgE-mediated reaction to penicillin. Subjects who developed maculopapular or exanthemic reactions with an interval greater than 6 hours and usually within 24–48 hours after taking the drug were included in this group. Immediate skin tests to BPO, AX AMP and MDM had to be negative;<br><br>Group 5 comprised 30 subjects with no history of allergic reaction to beta-lactams, a negative skin test to BPO, MDM, AX and AMP and good tolerance to BP and AX. | |
| TaFontaine et al. 2007[47] | Index test<br>Pharmacia CAP System FEIA serum specific IgE has a range of 0.35–100 kUA/litre with a cut-off value of ≥0.35 kUA/litre for a positive test and <0.35 kUA/litre for a negative test. The beta-lactam $c_1$ (penicilloyl G), $c_6$ (amoxicillin), $c_5$ (ampicillin) and $c_7$ (cefaclor) covalently coupled to ImmunoCap interact with the specific IgE in the serum samples tested.<br><br>RAST testing by Research Unit for Allergic Diseases, Carlos Haya Hospital, Malaga, Spain.<br><br>Reference standard<br>Skin tests with different beta-lactams and drug provocation tests. | Patients who developed a reaction to a beta-lactam <6 hours after drug intake and exhibited either urticaria alone or anaphylaxis without shock (urticarial and another non-cutaneous symptom) or anaphylaxis with shock. | Whole population CAP FEIA:<br>Sensitivity: 16.7%<br>Specificity: 93.3%<br>PPV: 45.5%<br>NPV: 77.1%<br><br>RAST:<br>Sensitivity: 50.0%<br>Specificity: 73.3%<br>PPV: 38.5%<br>NPV: 81.5% |
| Holm & Mosbech 2011[61] | Index test<br>IgE ImmunoCAP FEIA system (Phadia, Uppsala, Sweden) with a cut off value of 0.35 kUA/litre.<br><br>Reference standard<br>Penicillin challenge test | Patients with clinical reaction to penicillin and negative IgE were offered a challenge with penicillin V, penicillin G or both | A patient with a history of a mild reaction to penicillin that occurred more than 15 years previously and with no detectable serum IgE antibodies to penicillin V, penicillin G, amoxicillin or ampicillin would have only a 0.4% risk for reacting when given penicillin V or G in a clinical setting.<br>NPV: 97.6% |

| Study | Intervention, comparison | Population | Outcomes |
|---|---|---|---|
| Kraft & Wide 197682 | **Index test**<br>RAST technique by Wide, Bennich & Johnsson. Results were considered as negative when the activity was less than mean plus 2 SD for negative controls.<br><br>**Reference standard**<br>Skin tests | Patients seen either in the 2nd Department of Dermatology, University of Vienna or during consultant visits to other University or City hospitals in Vienna divided into 3 groups:<br>Group A: Included 31 patients seen during the first 24 hours of acute reactions to penicillin and tested with available test systems including skin tests later on.<br>Group B: Included 33 patients with history of reactions to penicillin 18 days to 11 years previously and tested by the available test systems including skin tests.<br>Group C: Included 15 patients who were seen in the first 24 hours of acute reactions to penicillin, but tested by in vitro methods only. | The benzylpenicilloyl specific RAST showed an overall correlation of 95.1 % with PPL performed skin tests.<br><br>TP: 18<br>FP: 3<br>FN: 5<br>TN: 38<br>Sensitivity Group A and B combined: 78%<br>Specificity Group A and B combined: 93%<br>Positive predictive value Groups A and B combined: 86%<br>Negative predictive value Groups A and B combined: 88% |
| Kraft et al. 197781 | **Index test**<br>RAST by Pharmacia Diagnostics. Results were expressed in Phadebas RAST classes 0, 1, 2, 3 and 4 according to a reference system established by running four reference sera (A, B, C and D) with reference discs during each assay in parallel to the unknown samples. In this study class 0 was considered to be a negative RAST result.<br><br>**Reference standard**<br>Skin prick tests and intradermal tests. | Patients seen either in the 2nd Department of Dermatology, University of Vienna or during consultant visits to other University or City hospitals in Vienna divided into 4 groups:<br>Group A: Included 69 patients examined within 2 days of acute reaction to penicillin and who were tested for circulating specific IgE and by skin tests.<br>Group B: Included 49 patients with history of reactions to penicillin in the period 3 weeks–5 years before the study and who were tested for circulating specific IgE and by skin tests.<br>Group C: Included 76 patients who were examined during the first 2 days of acute reactions to penicillin but tested by in vitro tests only.<br>Group D:<br>Included 10 patients who exhibited penicillin allergy which was proved by skin tests in the period 2–5 years before the study and who | Group A:<br>TP: 16<br>FP: 0<br>FN: 3<br>TN: 50<br><br>Sensitivity: 84.2%<br>Specificity: 100%<br>Agreement between RAST and skin test: 95.7%<br><br>Group B:<br>TP: 9<br>FP: 0<br>FN: 7<br>TN: 33<br><br>Sensitivity: 56.3%<br>Specificity: 100%<br>Agreement: between RAST and skin test: 82.5%<br><br>In Group D 10 patients had proven penicillin allergy 2–5 years before the study. 4 of 10 had showed a positive reaction to RAST:<br>Sensitivity: 40% |

| Study | Intervention, comparison | Population | Outcomes |
|---|---|---|---|
| | | were tested by in vitro tests. | |
| Qiao et al. 2005129 | Index test<br>Radioallergosorbent test (RAST)<br><br>Reference standard<br>Intradermal tests in all subjects with benzylpenicillin G at a concentration of 500 U/ml. | Patients recruited from 2 Chinese hospitals divided into 3 groups:<br>Group A with historical positive skin test;<br>Group B with immediate positive skin test;<br>Group C with a negative skin test. | Group B:<br>TP: 75<br>FN: 47<br><br>The positive rate (sensitivity) of specific IgE antibodies in 259 patients was 62.2%. Of these, the positive rates of specific IgE antibodies in Group A, B, and C were 62.7%, 61.5% and 63%. In 122 patients with immediate positive skin test (Group B), the positive rate of specific IgE was increased with the degree of positive skin test. Where the degrees of skin test were + (5–8 mm), 2+ (8–10 mm), 3+ (10–12 mm) and 4+ (>12 mm), the positive rates of specific IgE were 45.7, 57.1, 85.2 and 100% respectively. |
| Sanz et al. 1996137 | Index test<br>Pharmacia CAP System FEIA serum specific IgE has a range of 0.35–100 kUA/litre with a cut-off value of 0.35 kUA/litre for a positive test and <0.35 kUA/litre for a negative test.<br><br>Reference standard<br>Skin test | Sera from patients who had been diagnosed with adverse reaction to beta-lactams and a history very suggestive of drug allergy. | 85% of cases were specific IgE negative against Penicillin G, Penicillin V and ampicillin and 44% against amoxicillin.<br>Skin test versus beta-lactam specific IgE Sensitivity 31.81% Specificity 88.57% |
| Sanz, Gamboa & De Weck, 2002136 | Index test<br>Pharmacia CAP System FEIA serum specific IgE has a range of 0.35–100 kUA/litre with a cut-off value of ≥0.35 kUA/litre for a positive test and <0.35 kUA/litre for a negative test was used against penicilloyl G, penicilloyl V, ampicillin and amoxicillin.<br><br>Reference standard<br>Skin prick tests; intradermal tests in all subjects. Challenge in some patients with negative skin tests. | Patients presenting with immediate symptoms after beta-lactam. | Group 1: Results for 5 subgroups: Groups 1a: Patients clinically reacting to benzylpenicillin (BP) or amoxicillin (AX) and with positive skin tests to BP-derived reagents and to AX: 33% positivity (sensitivity) for BP and 33% positivity for AX.<br>Group 1b: Patients with AX as the culprit drug but skin tests only positive to BP-derived reagents AND Group 1c: Patients with BP as the culprit drug and skin tests only positive to BP derived reagents AND Group 1d: 1 patient with BP as the culprit drug and the skin test |

| Study | Intervention, comparison | Population | Outcomes |
|---|---|---|---|
| | | 72 | paradoxically positive to AX: 35% positivity (sensitivity) for BP and 22% positivity for AX. Also, 1 subgroup 1e of 6 patients reacting specifically to CEs.<br><br>Total sensitivity in Group 1: 38% positive to BP and 17% positive to AX.<br><br>Group 2: Results for 2 subgroups<br>Group 2a: Skin test positive to AX/AMPI (ampicillin), BP not done<br>Group 2b: Skin test positive to AX/AMPI and negative to BP.<br>Total sensitivity in Group 2: 26% positive to BP and 32% positive to AXO.<br>Group 3: Results for 16 cases presenting with an immediate clinical reaction to AX but with negative skin tests.<br>Total sensitivity in Group 3: 19%<br>Finally, in the group of 30 control patients, 4 had a positive CAP test resulting in a specificity of 87%. |
| Silva et al. 2009143 | Index test<br>Pharmacia CAP System (Phadia)serum specific IgE has a range of 0.35–100 kUA/litre with a cut-off value of ≥0.35 kUA/litre for a positive test and <0.35 kUA/litre for a negative test.<br><br>Reference standard<br>Skin prick tests; intradermal tests if skin prick tests were negative. When skin tests and specific IgE were both negative, drug challenge with the suspected beta-lactam was performed. | Patients referred to Drug Allergy Division with history of beta-lactam hypersensitivity | Only 33 patients had full range of testing. Only patients with negative skin testing and negative IgE received oral challenge. As there were no IgE positive patients in this cohort, only NPV could be calculated.<br>NPV: 93.9% |
| Vega et al. 1994158 | Index test<br>RAST – radiolabeled substance uptake test using discs treated with PG and AX. | Patients with history of an immediate allergic reaction to amoxicillin (AX) and good tolerance of penicillin G (PG). | All 54 patients were either skin test or challenge test positive to AX.<br>TP: 22<br>FP: 0 |

| Study | Intervention, comparison | Population | Outcomes |
|---|---|---|---|
| | Reference standard<br>Skin prick test, intradermal or drug provocation tests. | 73 | FN: 33<br>TN: 0<br>Sensitivity of RAST for AX: 40%<br>Specificity of RAST for AX: unable to calculate |
| Vultaggio et al. 2009162 | Index test<br>CAP system FEIA (Phadia, Uppsala, Sweden) for specific IgE antibodies. Serum in this sample was analysed for IgE towards the hapten c1 (penicilloyl G), c2 (penicilloyl V), c5 (ampicilloyl) and c6 (amoxicilloyl). Serum samples were considered positive when one or more hapten positivities occurred. 2 available commercial tests were performed (old and new CAP) characterised by different cut-off values of positivity (0.35 and 0.10 kUA/litre, respectively).<br><br>Reference standard<br>Skin prick test, intradermal test or both. | Patients with history of suspected immediate ADR to beta-lactams in the past year and a positive skin test. | Diagnostic performance of new and old CAP system for beta-lactam allergy:<br>Sensitivity (95% CI):<br>New test 0.85 (0.69 to 0.95)<br>Old test 0.44 (0.27 to 0.62)<br><br>Specificity (95% CI):<br>New test: 0.54 (0.44 to 0.63)<br>Old test 0.80 (0.72 to 0.87) |

Summary of studies included in the review: neuromuscular blocking agents

| Study | Intervention, comparison | Population | Outcomes |
|---|---|---|---|
| Fisher & Baldo 200046 | Index test<br>Radio immune assay for morphine and radio immune assay for specific IgE<br><br>Reference standard<br>Intradermal skin testing | Patients defined as experiencing anaphylaxis on the basis of a positive serum mast cell tryptase and positive skin test to one or more NMBAs divided into 4 groups:<br>Group 1<br>Patients who had an elevated serum mast cell tryptase level and showed a positive skin test to at least 1 NMBA<br>Group 2<br>Patients who had an elevated serum mast cell tryptase level and showed a positive skin test to a drug other than a NMBA<br>Group 3<br>Patients who had suspected anaphylaxis but a serum mast cell tryptase level that was not elevated and skin tests to NMBDs were negative | Group 1 results only:<br>Positive skin test and positive specific IgE RIA: 47/69 (68%)<br>Positive skin test and positive morphine RIA: 67/69 (97%). |

| Study | Intervention, comparison | Population | Outcomes |
|---|---|---|---|
| | | Group 4 Patients who had suspected anaphylaxis, serum mast cell tryptase levels were not elevated and no skin testing was performed | |
| Laroche et al. 2011[92] | **Index test** Quaternary ammonium morphine [QAM] ImmunoCAP; Phadia AB, Uppsala, Sweden. The detection limit was 0.10 kUA/litre. The cut-off serum concentration was 0.35 kUA/litre.<br><br>**Reference standard** Skin prick tests and intradermal skin tests. | French patients who reacted during anaesthesia, 2001–2007: Group A: 57 reactors were selected on the basis of immediate reactions after NMBA injection, increased concentrations of histamine or tryptase, and a positive skin test to the administered NMBA Group B: 57 reactors with negative skin test to NMBAs during the same period. | Overall results: TP: 48 FP: 14 FN: 9 TN: 43 Overall sensitivity of 84.2% Overall specificity of 75.4%. PPV 77.4% NPV 82.7% |
| Summary of studies included in the review: chlorhexidine | | | |
| Study | Intervention, comparison | Population | Outcomes |
| Garvey et al. 2007[52] | **Index test** Chlorhexidine ImmunoCAP (Phadia AB) a cut-off value of ≥0.35 kUA/litre for a positive test and <0.35 kUA/litre for a negative test.<br><br>**Reference standard** Skin prick tests in all subjects. Intradermal tests if prick test was negative. | 22 patients with strong suspicion of allergy to chlorhexidine because of repeated or delayed reactions and results of initial skin testing. | Sensitivity: 91.7% Specificity: 100% PPV: 100% NPV: 91% |

1 *Abbreviations: AMP: ampicillin; AX: amoxicillin; AXO: amoxicilloyl group; BP: benzyl penicillin; BPO: benzylpenicilloyl group;*
2 *CAP: Pharmacia CAP system; FEIA: fluoroenzymoimmunoassay; FN: false negative; FP: false positive; MDM: minor*
3 *determinant mixture; NMBA: neuromuscular blocking agent; NPV: negative predictive value; PPV: positive predictive value;*
4 *RAST: radioallergosorbent test; RIA: radioimmunoassay; SD: standard deviation; TN: true negative; TP: true positive*

5

**Table 18: Clinical evidence profile: serum specific IgE – beta-lactam antibiotics, neuromuscular blocking agents, chlorhexidine**

| Number of studies | Study designs | N | Risk of bias | Inconsistency | Indirectness | Imprecision | Sensitivity – range, median (95% CI) | Specificity – range, median (95% CI) | PPV – range, median (95% CI) | NPV – range, median (95% CI) | Quality |
|---|---|---|---|---|---|---|---|---|---|---|---|
| **Serum IgE (for beta-lactams)** | | | | | | | | | | | |
| 11 | Cohort, case–control and case series | 1624 | serious risk of bias[a] | serious inconsistency[b] | no serious indirectness | very serious imprecision[c] | Range 30–85%, median 54% (33–73%) | Range 54–100%, paired median 76% (67–83%) | Range 32–95%, paired median 32% | Range 42–98%, paired median 89% | VERY LOW |
| **Serum IgE (for neuromuscular blocking agents)** | | | | | | | | | | | |
| 2 | Cohort | 461 | very serious risk of bias[a] | N/A[d] | N/A[d] | very serious imprecision[c] | 84% (72–93%) | 75% (62–86%) | 77% | 83% | VERY LOW |
| **Serum IgE (for chlorhexidine)** | | | | | | | | | | | |
| 1 | Case series | 22 | very serious risk of bias[a] | N/A[d] | N/A[d] | N/A[e] | 92% | 100% | 100% | 91% | VERY LOW |

*GRADE was conducted with emphasis on test sensitivity and NPV (proportion of people with a positive test who have drug allergy and proportion of people with a negative test result who do not have drug allergy, respectively) as this was the primary measure discussed in decision-making. The median sensitivity was identified and then the paired specificity, PPV and NPV were reported respectively.*

*(a) Risk of bias was assessed using the QUADAS-2 checklist. The overall risk of bias for each outcome was assessed according to the risk of bias for the majority of the evidence.*

*(b) Inconsistency was assessed by inspection of the paired sensitivity and specificity forest plots. Reasons for heterogeneity between studies include type of IgE test or study population (for example, type of beta-lactam allergy).*

*(c) The judgement of precision was based on visual inspection of the confidence region in the sensitivity and specificity plots. A range of 10% was considered to be seriously imprecise whereas 20% or more was considered to be very seriously imprecise.*

*(d) There was insufficient data to assess level of inconsistency (sensitivity and specificity could only be calculated in 1 study).*

*(e) Imprecision could not be assessed because confidence intervals were not provided in the study.*

## 7.4 Economic evidence

**Published literature**

No relevant economic evaluations were identified.

See also the economic article selection flow chart in Appendix F.

**Unit costs**

Costs from the Protein Reference Unit in Sheffield[69] are used as example costs: the cost per allergen-specific IgE test is £14.30. Note that this estimate does not capture the full economic impact of IgE testing, which would include the time of a healthcare professional to administer the test, as well as the downstream cost and quality of life implications of using the test.

## 7.5 Evidence statements

**Clinical**

*Serum specific IgE – beta-lactam antibiotics*

- Very low quality evidence from 11 observational studies (n=1624) indicated very variable results in terms of sensitivity and specificity. Specificity was generally higher than sensitivity indicating that the test is better at 'ruling in' than 'ruling out' beta-lactam allergy. However, imprecision was too high to draw clear conclusions about the test accuracy of this test.

*Serum specific IgE – neuromuscular blocking agents*

- Very low quality evidence from 2 observational studies (n=461) indicated relatively high levels of misclassification with sensitivity 84% and specificity 75%. The confidence region was large and only 1 result could be clearly extracted. It is therefore difficult to draw clear conclusions about this test in clinical practice.

*Serum specific IgE – chlorhexidine*

- Very low quality evidence from 1 observational study (n=22) indicated high levels of test accuracy. However, the number of participants in this study was small and it is therefore unclear whether this result is representative until further research is conducted.

**Economic**

- No relevant economic evaluations were identified.

## 7.6 Recommendations and link to evidence

| Recommendations | 7. Do not use blood testing for specific IgE for diagnosing drug allergy in a non-specialist setting. |
|---|---|
| Relative values of different outcomes | The following outcomes were identified by the GDG as important for decision-making: pre-test probability, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), number of cases missed (false negatives), number of cases mislabelled (false positives). |
| | The rate of false negatives represents the proportion of people with a drug allergy in whom allergic reactions will be missed by serum specific IgE testing; the GDG considered this outcome to be significant. Test sensitivity (the proportion of people with drug allergy who have a positive test) is therefore also an important outcome. However, the group also agreed that specificity is important in order that people who do not have an allergy do not falsely receive a positive test result and as a consequence no longer receive the drugs they require or are switched to less effective medication. |
| Trade-off between clinical benefits and harms | The GDG agreed that many people with penicillin allergies will receive false negative IgE test results. The evidence was consistent with low levels of diagnostic test sensitivity shown. |
| | The group acknowledged that for beta-lactam antibiotics IgE testing has poor negative predictive values, and there was concern that people with suspected drug allergies may be falsely reassured. However, specificity and positive predictive values were on the whole higher indicating that people who do not have drug allergies would have a high probability of having a negative test, and conversely a high percentage of people with a positive test result go on to be diagnosed with drug allergy. |
| | There was less evidence on testing for neuromuscular blocking agents or chlorhexidine. However, studies reported better sensitivity and negative predictive value results compared to IgE testing for beta-lactams. This seems to suggest that fewer people are missed by using serum specific IgE in these cases. |
| Economic considerations | No relevant economic evidence was identified. The GDG identified diagnostic tests (serum tryptase and serum specific IgE) as the second highest priority area for original economic analysis. However, the poor diagnostic accuracy shown by IgE testing in the clinical evidence for this review meant that economic modelling, even if feasible, was not necessary for the GDG's decision-making and so original analysis was not conducted. |
| | Carrying out this test incurs costs associated with the time of a GP or nurse, the laboratory test itself, and follow-up appointments. The clinical evidence reveals low sensitivity and specificity values of serum specific IgE tests, and therefore the results of these tests are not deemed a sufficient result on which to base a diagnosis of drug allergy. |
| | The GDG were particularly concerned with the high levels of false negative results revealed by the clinical evidence. False negatives could lead to repeat reactions, which in turn have a high cost (emergency admission) and a significant impact on quality of life. False positive results could also have an economic impact, as a person may unnecessarily receive an alternative drug when a drug is needed in future. Alternative treatments are generally less effective and sometimes more expensive than first-line treatments. |
| | These economic considerations need to be balanced against the potential benefit from obtaining a true result. If the results of the test could be relied upon, people receiving a true positive result could take up an appropriate management strategy and the cost of referral would be saved. Likewise, true |

| | negatives would not need to avoid the drug in question any longer. However, the clinical evidence has revealed such inaccuracy in the test results that the results of serum specific IgE tests cannot be considered conclusive. Diagnoses cannot be based on this test alone regardless of the outcome, and therefore the additional cost of these tests is an inefficient use of resource. |
| --- | --- |
| | The GDG therefore agreed that serum specific IgE tests are unlikely to be cost effective when used on their own in a non-specialist drug allergy setting. |
| Quality of evidence | Quality was assessed as very low for all evidence (serum IgE testing for beta-lactams, neuromuscular blocking agents or chlorhexidine). This was mainly due to the heterogeneity of study populations, type of test used, type of allergy and imprecision of the accuracy measures. Many studies also did not use a gold standard (drug provocation test) as a reference point. As the evidence came from highly selective populations the GDG agreed that it was difficult to extrapolate results to the whole population of people with drug allergies and were therefore cautious about making specific recommendations. |
| Other considerations | The GDG agreed that these tests do not have proven utility in primary care as results could be open to misinterpretation due to poor sensitivity. Additionally the tests do not add much to diagnosis made from a clinical history. The group recognised that in a specialist setting this test would not be used in isolation but may be used in addition to a skin prick test and the clinical presentation. The group noted that many allergic drug reactions are not IgE-mediated and the tests do not include all immunoreactive epitopes. The GDG noted that RAST (radioallergosorbent test) is an old technology and no longer used. |
| | None of the studies addressed testing in children and none were conducted in primary care settings. The GDG noted that serum specific IgE for diagnosing drug allergy may be useful in the specialist setting in conjunction with clinical history and other allergy investigations. |

1

# 8 Documenting and sharing information with other healthcare professionals

## 8.1 Introduction

Analysis of patient safety incidents reported to the National Reporting and Learning System (NRLS) over 8 years (2005–2013) identified 18,079 incidents involving drug allergy. There were 6 deaths, 19 severe harms, 4,980 other harms and 13,071 near misses reported.[122] The majority of these incidents involved a drug that was prescribed, dispensed or administered for a patient with a previously known allergy to the drug or drug class. The drug allergy information was usually documented in the clinical notes, medication card or allergy (red band) bracelet. Despite this a drug was administered to a patient known to be allergic resulting in moderate to severe harm in more than 1000 cases. This shows that documentation is often ineffective or is ignored and avoidable incidents due to drug error are common.

Patients who have experienced drug allergy are not routinely provided with written information. Therefore, with the passage of time, details of the drug, possible cross-reacting agents and an indication of the severity of the reaction become increasingly difficult to recall. In some clinical situations, it may be necessary to re-expose the patient, for example where an alternative drug is less effective or the patient has multiple drug allergies. However, with incomplete clinical details of the original reaction it may not be possible to make a judgement on whether a reaction was immunologically mediated, and hence assess the risk of an allergic reaction on re-exposure.

Detailed clinical information is also needed for patients referred for specialist investigation of drug allergy and that process may be prolonged, requiring additional consultations, if documentation is incomplete.

## 8.2 Review question: What are the most clinically and cost effective documentation strategies for communicating drug allergy information across all NHS services to prevent patients from receiving drugs to which they are allergic?

For full details see review protocol in Appendix C.

**Table 19:   PICO characteristics of review question**

| Population | Patients with drug allergies and healthcare professional involved in the care of patients with drug allergies |
| --- | --- |
| Interventions | • Patient-held records or information worn by patients<br>• Hospital-based notices worn by patients (such as coloured arm bands)<br>• Automated messages (for example, screensavers)<br>• Mandatory reporting of drug allergy status in paper or electronic medication records<br>• Mandatory documentation of details related to adverse drug reactions<br>• Mandatory documentation of details of any investigations for suspected drug allergy<br>• Position of the information or alerts relating to drug allergy status in medical or electronic records<br>• Design of drug charts<br>• Use of Summary of Care Records<br>• Computerised physician or prescriber order entry systems (CPOE) |

| Comparisons | No intervention or another intervention alone or in combination |
|---|---|
| Outcomes | • Medication errors (inappropriate prescription or administration of drugs)<br>• Number of repeat drug allergic reactions (including patient-reported episodes)<br>• Inappropriate avoidance of drugs<br>• Health-related quality of life |
| Study design | Any study design other than case studies, comments and letters to the editor |

Following discussion with the GDG, it was recognised that documentation completion rate would be an informative surrogate outcome for medication errors. Absence of information on drug allergy from documentation could be erroneously interpreted as absence of drug allergy and this can potentially lead to prescriber errors. Therefore, we have included studies that did not necessarily report rates of medication errors but reported how complete or accurate the recorded data were in documentation.

Due to the large number of interventions (some further interventions are described in the full protocol in Appendix C) it was decided to prioritise higher quality evidence if necessary. Pharmacy reviews and reconciliation were not classified as documentation strategies and studies describing these interventions were excluded.

## 8.3 Clinical evidence

In this review we aimed to identify documentation strategies that ensure that drug allergy status is clearly indicated and effective in minimising medication errors. Documentation includes the way physicians record the drug allergy status as well as how the person with the allergy might indicate that he or she has a drug allergy (such as bracelets, for example). Thirty-three observational studies[1,8,9,15,19,27,29,41-44,56,60,64,67,86,93,98,100,104,105,110,121,124,127,138,139,144,145,147,148,157,167] and 2 randomised trials[58,151] were included in this review.

Studies can be broadly divided into 2 main categories:

- Twenty-one studies[1,8,9,15,19,27,42-44,64,67,86,93,98,105,121,124,147,148,151,157,165] investigated the effectiveness of computerised physician or prescriber order entry systems (CPOE) and other computer systems that aim to limit errors in medication prescriptions for people with drug allergies.
  - o A subset of these studies[64,67,86,151] describes the frequency at which allergy alerts are ignored or overridden and the reasons for this.
  - o The computerised order systems included medication lists which sometimes suggested dosage and route as well as various levels of checking systems to alert physicians to a variety of issues including drug allergies (usually also including drug–drug interactions, drug–laboratory problems and redundant medication checks).
- Nine studies[29,41,58,60,100,104,124,144,167] assessed the design of pro formas and charts to indicate drug allergy status and their effectiveness in minimising drug errors.
  - o Examples of such charts were provided in 4 studies.[29,60,100,144] Three of those included a box with an 'allergy' heading and 1 of them provided additional prompts for type of reactions (however this study used the form both for assessment and documentation). The other studies referred to design, structure or designated areas without additional detail.

Evidence from the 2 randomised controlled trials[58,151] was combined with evidence from observational studies. This was due to major problems with study design and directness of outcomes in the trials. The trial by Tamblyn et al. (2008), investigating 'on demand' versus 'automatic' alerts, refers to error rates and overrides without a specific group of drug allergy errors and in the trial by Harris et al. (2002) the structured pro forma intervention was only used by a small minority of participants.

Evidence for the main 2 categories (computerised, structured charts) are summarised in the clinical evidence summary tables (Table 23 and Table 24). Other individual types of documentation are described in 5 studies.[56,127,138,139,145] These are summarised in narrative form in section 8.3.4. See also the study selection flow chart in Appendix E, forest plots in Appendix J, study evidence tables in Appendix H and exclusion list in Appendix K.

### 8.3.1 Summary of included studies

Table 20 summarises the main study characteristics of studies investigating the effectiveness of computer systems. Table 21 summarises the main study characteristics of studies investigating the effectiveness of pro formas and chart designs. Studies investigating other communication strategies are summarised in Abbreviation: ADR: adverse drug reaction

**Table 22**.

**Table 20: Summary of studies addressing computerised documentation systems**

| Study | Study design | Documentation type | Outcomes | Comments |
|---|---|---|---|---|
| Abramson et al. 2011[1] | Prospective non-randomised before–after design | 6 providers who adopted e-prescribing within a commercially available electronic health record system and 15 providers who remained paper based | Electronic system users compared to providers not adopting the new system after 1 year: Overall error rates decreased when the new system was brought (from 26% to 16%). Error rates were lower for those providers who adopted new system compared to non-adopters (16% and 38.4%) after 1 year. The main decrease was in 'rule violations' which were departures from the standard prescribing unlikely to cause harm (5.8 in adopters versus 56.5 in non-adopters). Errors labelled 'Near misses' (including allergies) remained stable and did not differ between adopters and non-adopters (1.9% and 2.7%). | The strength of this study was that it provided a comparison group with detailed baseline characteristics. |
| Bates et al. 1999[9] | Prospective time series analysis with 4 periods | CPOE | Over the 4 time periods medication errors decreased (baseline before adoption of CPOE): 14.2 (before); 5.1 (period 1); 7.4 (period 2); 2.7 (period 3). Included in these errors were documented allergy errors which fell from 10 to 0 over the time period | A large number of medication orders were investigated, for example 14,352 orders alone in Period 3. |
| Bates et al. 1998[8] | Before-and-after study | CPOE | Mean rate of non-intercepted serious medication errors: Before CPOE: 10.7 events per 1000 patient-days After CPOE: 4.86 events per | This documentation review has only extracted data from Phase I, and between Phase I and Phase II. The data from |

| Study | Study design | Documentation type | Outcomes | Comments |
|---|---|---|---|---|
| | | | 1000 patient-days<br>Number of allergy errors:<br>Before CPOE: 0.65 events per 1000 patient-days<br>After CPOE: 0.29 events per 1000 patient-days | post-Phase II were not extracted as there are a number of potential confounders. |
| Benkhaial et al. 2009[15] | Retrospective data review | ICD-10 codes to be used as part of an electronic drug prescribing system | Proportion of patients with ICD-10 having medication error: 20%<br>Proportion of patients with manual documentation having medication error: 21.6%<br>No difference in the risk of being prescribed a drug potentially inducing an allergy whether the allergy was only documented as an ICD-10 code or documented in the paper record (p=1.0) | The study intended to allocate different drugs and drug groups to ICD-10 codes as guidance for allergy alerts to systemically administered drugs. It assessed the value of the ICD-10 codes as triggers for decision support in an electronic prescription system. |
| Brown et al. 2000[19] | Indirect comparative study | CPOE / ADE alert system | The screening component of the ADE alert system had a true positive rate of 11% of evaluated alerts, of which 5% were ADEs and 6% were potential ADEs.<br><br>Total entries into the system: 1643<br>Entries evaluated by a pharmacist: 759<br>ADEs documented: 57<br>ADEs found by traditional methods: 23<br>ADEs found by the new system: 34<br>Potential ADEs found by the new system: 48<br>False positive alerts: 655 | The study did not compare the effectiveness of the new ADE alert system with traditional approach using the same set of data.<br>It is not explained in the article how the study obtained the figure of 11% true positive rate.<br>The different categories of counts as shown on the left are not defined clearly in the article. |
| Colpaert et al. 2006[27] | Non-randomised comparative study | CPOE / Intensive care information system (ICIS) | Total medication prescribing errors (MPEs)*:<br>Computerised unit: 44/1286 (3.4%)<br>Paper-based units: 331/1224 (27.0%)<br>p<0.001<br><br>of which:<br>Serious MPEs**:<br>Computerised unit: 23/1286 (1.8%)<br>Paper-based units: 60/1224 | Rates of MPEs in 1 computerised unit and 2 paper-based units were compared 10 months after implementation of ICIS in the computerised unit.<br>All medication and fluid prescriptions were checked for errors in a number of recorded elements such as drug name, dosage, route of administration and known allergy to the prescribed |

| Study | Study design | Documentation type | Outcomes | Comments |
|-------|--------------|--------------------|----------|----------|
| | | | (4.9%)<br>p<0.01<br><br>Total ADEs***:<br>Computerised unit: 2/1286 (0.2%)<br>Paper-based units: 12/1224 (1.0%)<br>p<0.001<br><br>In the charts, allergy notation was filled for:<br>69% of the patients in the computerised unit<br>2% of the patients in the paper-based units<br><br>Definitions:<br>*MPE: an error in the prescribing or monitoring of a drug.<br>**Serious MPE: non-intercepted potential adverse drug event (ADE) or ADE.<br>***ADE: MPE with potential to cause or actually causing patient harm. | drug.<br>The allergy status of the patient was shown by means of a differentially coloured highlighted icon in the toolbar as well as in the general prescription window.<br>The main limitations of the study are that the study took place in 1 tertiary care teaching hospital and the type of CPOE implemented is specifically designed for intensive care units, therefore, the findings from the study may not be generalisable. |
| Evans et al. 199444 | Prospective before–after study (Year 1 before introduction of new system, Year 2 and Year 3) | Computer based medical records | Overall Type B adverse drug events (known drug allergies, inappropriate administration and first-time use of drugs) decreased after introduction of the new system. Particularly 'known drug allergies' and 'inappropriate administration' was reduced from 13 to 0 and from 20 to 2 events respectively. | Number of events was very small to start with: 56 in 120,213 patient days at baseline and 18 in 107,868 patient days in Year 3 |
| Evans et al. 199542 | Before-and-after study | CPOE: LDS HELP system (LDS Hospital [Salt Lake City, Utah, USA] Health Evaluation through Logical Programming) | Incidence of ADEs due to antibiotics (out of the number of patients receiving antibiotics)<br><br>Pre-implementation: 15/403 (3.7%)<br>Post-implementation: 3/233 (1.3%)<br>This is a decrease of 2.4% | Computerised logic is used to suggest an antibiotic regimen that would cover the identified and potential pathogens. In addition to infection information, the logic uses patient allergies, drug-drug interactions, toxicity and cost in the selection of suggested antibiotics. |
| Evans et al. 199843 | Prospective cohort study | Computerised management programmes for | Number of drug allergy alerts<br>Pre-intervention: 146<br>Post-intervention: 35 | In addition to comparing pre- and post-intervention periods, the authors have |

| Study | Study design | Documentation type | Outcomes | Comments |
|-------|-------------|-------------------|----------|----------|
| | | antibiotic and anti-infective agents | Number of adverse events caused by anti-infective agents<br>Pre-intervention: 28<br>Post-intervention: 4<br>Mortality (mean±SD)<br>Pre-intervention: 172±22<br>Post-intervention (A): 36±18<br>Post-intervention (B): 52±27 | also compared between those who had their computer regimen overridden and those who did not, but for some outcomes and not all. |
| Hsieh et al. 2004[64] | Retrospective data review | Computerised system for drug allergy checking | In total, 80% of the alerts were overridden<br>Only 10% of the overridden allergy alerts were triggered by an exact match between the ordered drug and the listed drugs<br>Reasons given by physicians for overrides were: aware / will monitor (55%); patient does not have this allergy / tolerates (33%); patient taking drug already (10%); other (3%)<br>Rates of different degrees of adverse drug events owing to overridden allergy alerts: fatal (0%); life-threatening (0%); serious (47%); significant (53%) | This chart review was performed on a stratified random subset of all allergy alerts at a large hospital. |
| Hunteman et al. 2009[67] | Retrospective data review | CPOE | Allergy alerts were triggered at a mean of 2 alerts per patient.<br>Of all the patients whose records were analysed, 47% had a complete allergy profile with information on drug reaction details<br>Of all the drug alerts, 97% were overridden by practitioners.<br>The practitioners' rationales for overriding the alerts were: patient previously tolerated the medication (49%); the benefit outweighed the risk (29%); the medication was therapeutically appropriate (24%); a free-text explanation (8%). | The analysis was carried out only on data from 1 calendar month. |
| Kuperman et al. 2003[86] | Analysis of design features of 3 different computer systems (descriptive study) of | CPOE system for drug-allergy checking. | One week's worth of data from 1 of 3 systems was analysed. During this time 1043 drug allergy alerts were overridden 854 could be categorised into the following:<br>Has tolerated in past: 349 (33%)<br>Is aware of allergy: 278 (27%) | It is unclear what the overall override rate was in 1 week since the total number of orders was not given. Results are only provided as a snapshot rather than real 'study data'. |

| Study | Study design | Documentation type | Outcomes | Comments |
|---|---|---|---|---|
| | healthcare providers from 1 organisation in Boston (Partners HealthCare) | | Will monitor/follow: 159 (15%)<br>Not really allergic: 68 (7%)<br>Other: 189 (18%) | |
| Leung et al. 2013[93] | Before-and-after study | CPOE with CDS | Rate of ADEs (per 100 admissions):<br>All ADEs<br>Pre-implementation: 8.9<br>Post-implementation: 8.3<br>Preventable<br>Pre-implementation: 8.0<br>Post-implementation: 4.4<br>Non-preventable<br>Pre-implementation: 0.9<br>Post-implementation: 3.9<br><br>Rate of potential ADEs (per 100 admissions):<br>All potential ADEs<br>Pre-implementation: 8.9<br>Post-implementation: 8.3<br>Intercepted<br>Pre-implementation: 2.1<br>Post-implementation: 2.9<br>Non-intercepted<br>Pre-implementation: 53.4<br>Post-implementation: 133.9 | The participants eligible for inclusion were adults with renal failure, exposed to potentially nephrotoxic or renally cleared medications, and admitted to any of the 5 participating hospitals during the study period.<br><br>The 5 study sites had CPOE systems with variable CDS capabilities:<br>1) Basic CPOE with no CDS for renal disease (n=2)<br>2) Rudimentary CDS with laboratory display whenever common renally related drugs were ordered (n=2)<br>3) The most advanced support where, in addition to basic order entry and lab checks, physicians were provided with suggested doses for renally cleared or nephrotoxic medications, as well as appropriate drug monitoring for medications with narrow therapeutic indices (n=1) |
| Mahoney et al. 2007[98] | Before-and-after study | CPOE | The number of prescribing errors decreased from 833 before implementation of a Clinical Decision Support System (CDSS) to 109 post-implementation. | The study applied long assessment periods: 1 year before intervention and 1 year after intervention. |
| Menendez et al. 2012[105] | Before-and-after study | CPOE | Pre-implementation (2004 – 2006): Hand-writing system<br>Post-implementation (2007–2009): Clinical electronic record<br><br>Rate of errors:<br>Pre-implementation: 356 errors per 7001 discharges (5.1%) | The study was intended to describe the epidemiology and severity of medication errors detected in an acute geriatric hospital and the impact of the electronic clinical record on reducing these errors. |

| Study | Study design | Documentation type | Outcomes | Comments |
|---|---|---|---|---|
| | | | Post-implementation: 1197 errors per 11,347 discharges (10.5%)<br>RR=2.07 (99% CI 1.79 to 2.40)<br><br>Rate of moderate to serious errors (E–I)*<br>Pre-implementation: 33 out of 356 all errors (9.3%)<br>Post-implementation: 11 out of 1197 all errors (1%)<br>RR=0.10 (99% CI 0.20 to 0.05)<br><br>*These categories are from the National Co-ordinating Council for Medication Errors Reporting and Prevention Index for Categorizing Errors (from A to I, in the order of increasing severity). | |
| Mullett et al. 2001110 | Before-and-after study | CPOE: anti-infective decision support tool (DST) for a paediatric unit | Impact of introducing the DST was compared between a paediatric intensive care unit and adult shock-trauma intensive care unit (STICU) from a previous study:<br><br>Impact on drug allergy alerts:<br>Paediatric unit: No change<br>Adult unit: Large reduction<br><br>Impact on ADEs attributable to anti-infectives:<br>Paediatric unit: No change<br>Adult unit: Large reduction | This paediatric DST was based on a previously studied adult DST. It was designed to account for the therapeutic indication, the age and weight of the patient, the renal function, and the level of prematurity.<br>The frequency of drug allergy was found to be much lower in paediatric patients than in adults. |
| Neubert et al. 2013121 | Before-and-after study | CPOE: ADR knowledge base (KB) combined with hospital information systems (HIS) | Pre-implementation: Computerised monitoring system purely on laboratory data with no link to the prescribed medicines or other individual patient data<br>Post-implementation: Use of ADR-KB with HIS combined<br><br>As a result of the implementation of the new CPOE system, the sensitivity of ADR detection decreased (fewer irrelevant alerts) whilst the specificity increased (more targeted alerts) in 2 departments (internal medicine | This study did not analyse drug allergies separately from ADEs, however, it was included for the following 2 reasons:<br>1) It compares a CPOE with intensive chart review, which is a form of ADE detection strategies that is supposed to be the gold standard.<br>2) The new CPOE incorporated individual patient data stored in the hospital information system. The researchers wanted to crosslink a |

| Study | Study design | Documentation type | Outcomes | Comments |
|---|---|---|---|---|
| | | | and paediatrics) in a hospital.<br><br>Sensitivity: The number of ADR positive patients alerted by at least 1 signal in relation to the total number of ADR positive patients<br>Specificity: The number of all non-ADR patients not alerted by any signal in relation to the total number of non-ADR patients. | standard CPOE with individual patient data so that the signals generated are highly specific to that patient. |
| Soto et al. 2002147 | Retrospective review of electronic records from 834 patients receiving care from 167 physicians | Electronic medical records | Completion of drug allergy medical record documentation was low:<br>61.6% completion rate for internists and 50.4% for paediatricians | The main aim was to assess whether the documentation rate depended on physician specialty rather than documentation strategy. |
| Spina et al. 2011148 | Cross-sectional national survey (total respondents n=1543) | Experience with electronic prescribing system | 42% of respondents rely on the computer system to alert them about patient medication allergies. 81% reported that they enter a serious reaction into the appropriate data field and 15% that they would inform a pharmacist. | This study relied on self-reported survey answers rather than direct checks. |
| Tamblyn et al. 2008151 | Randomised controlled trial | Computer-triggered alert system (automatic) compared to on-demand (can be accessed during the prescribing process) drug management systems | 1% (41/4445) of prescribing problems were seen by physicians using on-demand compared to 10% (668/6505) of computer triggered. However of those seen 76% (31/41) were acted on by on-demand group and 12% (81/668) in the computer triggered group. Main reasons for overrides were 'benefit greater than risk' and 'interaction already known' or 'not clinically important'. | Even though the study quality is higher than those of other studies, it is unclear how many of the prescribing problems directly refer to drug allergies. |
| Varkey et al. 2008157 | Retrospective survey | CPOE | Frequency of intercepted prescription errors:<br>Handwritten prescriptions: 7.4%<br>Computerised prescriptions: 4.9%<br>Pre-printed prescriptions: 1.7% | The authors applied systematic random sampling, and reviewed prescriptions ordered each March of 1996, 1998, 2000 and 2002. |

1 *Abbreviations: ADE: adverse drug event; ADR: adverse drug reaction; CDS: clinical decision support; CPOE: computerised*
2 *physician order entry system; DST: decision support tool; ICD: International Classification of Diseases; MPE: medication*
3 *prescribing error; SD: standard deviation*

1

**Table 21: Summary of studies addressing design of pro formas and charts**

| Study | Study design | Documentation type | Outcomes | Comments |
|-------|-------------|-------------------|----------|----------|
| Coombes et al. 2009[29] | Prospective before-and-after observational audit | Standardised revised medication chart | All prescribing errors:<br>Pre-implementation: 23.5%<br>Post-implementation: 18.7%<br>Number of patients with ADRs and the incidence of ADRs:<br>Pre-implementation: 25.3% (302 ADRs)<br>Post-implementation: 26.2% (311 ADRs) | The focus of this study is on ADR documentation alerts and warfarin management, not on allergies. |
| Eneh & Fahy 2011[41] | Before–after audit in 6 psychiatric wards (2 acute and 4 long stay) | Formal assessment pro forma with clearly designed allergy section based on results from the first audit | After introduction of the new pro forma compliance with documentation of allergy status increased particularly in medication charts and admission notes, but less so in on the front of case notes. | It was stated that 'renewed awareness of the importance of documentation of allergy status was created', that is, results cannot be only attributed to the design of the pro forma. |
| Harris et al. 2002[58] | Randomised controlled trial | Structured pro forma for GP–emergency department communication | Number of referral letters that GPs sent out:<br>Intervention: 307<br>Control: 225<br>Number of times 'allergies' was included in the referral letters:<br>Intervention: 55 (18%)<br>Control: 4 (2%) | This is an RCT. The form is specifically for communication between GPs and emergency departments. |
| Hippen et al. 2000[60] | Prospective patient interview and retrospective review of existing records | Structured penicillin allergy assessment form | A pharmacist interviewed patients with suspected allergy to penicillin using the intervention (structured penicillin allergy assessment form) and found that:<br>18/60 (30%) had a probable true allergy<br>32/60 (53% had a possible true allergy<br>8/60 (13%) had a side effect or intolerance<br>2/60 (3%) were unlikely to have allergy | It assessed the validity of the allergy data in the existing unstructured method of recording penicillin allergy using an interviewer-led structured assessment form. |
| Marco et al. 2003[100] | Retrospective data review | Revised form of a new anaesthesiology preoperative evaluation form | Number of times allergy component was present in the forms:<br>Older form: 111/112 (99%)<br>Newer form: 102/105 (97%) | It is indicated that this retrospective review was 'randomised' but this concept has not been explained in the main text. |
| Mead et al. 1999[104] | Prospective review of referral letters | Pro formas compared to unstructured letters | Quality of 300 referrals was assessed according to presence of the following categories (demographic details; current-, | People who rated the letters did not show strong agreement in their assessment of quality |

| Study | Study design | Documentation type | Outcomes | Comments |
|---|---|---|---|---|
| | | | past- and social history, drugs and allergies):<br>No overall difference in quality between pro forma or unstructured referrals<br>Only 16% of referrals included information on allergies | (Kappa values ranged from 0.26 to 0.44) |
| Simmonds et al. 2000144 | Retrospective data review followed by a before-and-after study | New preoperative assessment sheet | Frequency of recording of allergy by anaesthetists:<br>Pre-intervention: 79/195 (40.5%)<br>Post-intervention: 75/227 (33.0%) | Allergy was only 1 of 12 elements that the study assessed. |
| Ortega et al. 2008124 | Retrospective data review followed by a before-and-after study | ADR computerised reporting tool integrated into the hospital information system for national drug surveillance system | As a result of the 5 improvement measures implemented, there was a reduction in all of the following:<br>Suspected allergy<br>Studied allergy<br>Yellow Cards sent<br>Yellow Cards necessary | The duration of Phase I was 29 months and that of Phase II was 8 months. In terms of the length of period and the quantity of data obtained, it is not a fair comparison. |
| Zenk et al. 1984 167 | Before-and-after study | Chart card with designated boxes to enter allergies and weight | Completion rate of allergy information at baseline were 33.3%, during the intervention 74% and post-intervention (without the intervention) it was 47.3% | Even though special training was provided, completion rate went down again once the structured form was withdrawn suggesting that the effect originated from the form rather than the training. |

*Abbreviation: ADR: adverse drug reaction*

**Table 22: Summary of studies reporting other documentation strategies**

| Study | Study design | Documentation type | Outcomes | Comments |
|---|---|---|---|---|
| Hackl et al. 201356 | Controlled interrupted time series analysis, qualitative interviews and standardised survey | ADE scorecards | Rate of detected ADE* cases (per 1000 inpatient stays)<br>15 months pre-implementation<br>15 months post-implementation<br><br>Departments that received the intervention:<br>(Intervention groups, n=3)<br>Pre-implementation: 812<br>Post-implementation: 706<br>Decrease of 106 cases per 1000 inpatient stays | The regression analysis comparing the pre-implementation and post-implementation periods in each department and comparing intervention departments and control departments, taking into account baseline ADE trends in all departments, showed no significant changes in ADE rates after the introduction of the ADE scorecards.<br>All 13 of the interviewed healthcare professionals |

| Study | Study design | Documentation type | Outcomes | Comments |
|---|---|---|---|---|
| | | | Departments that did not receive the intervention: (Control groups, n=2) Pre-implementation: 99 Post-implementation: 109 Increase of 10 cases per 1000 inpatient stays

*Definition of ADE used: "Any injury occurring during the patient's drug therapy and resulting either from appropriate care, or from unsuitable or suboptimal care." | considered the ADE scorecards to be useful to support decision-making and they expressed their intention to use the ADE scorecards as part of an ADE prevention approach. In the survey conducted after 1 year of use, all respondents stated that they would recommend using the ADE scorecards to their colleagues. Except for 1 physician, all healthcare professionals were convinced that ADE scorecards could contribute to increased medication safety. |
| Porter et al. 2006127 | Observational study at triage in paediatric ED setting | Review of medication orders and presence of allergy bracelet on the child | Of 28 children assessed to have an allergy 16 (57%) wore a bracelet. 5 of the children who had a bracelet, details did not agree with the assessed allergy (2 with false positive information and 3 blank). 111 children had at least 1 medication ordered and for 5 children with allergies the medication order was documented as negative. No cases of medication error were noted. | The main focus of the study was on accuracy of documentation rather than documentation as an intervention strategy. |
| Sard et al. 2008138 | Retrospective before and after comparison | 'Quicklist' (a list of commonly prescribed medication in the paediatric hospital) added to the CPOE | Errors per 100 orders decreased from 31 to 14. With respect to drug allergies errors per 100 orders decreased from 2 to 0. | The aim of the study was to reduce overall error rate. Therefore little detail is provided about the computer system's ability to alert to allergies. |
| Schadow et al. 2009139 | Non-randomised comparative study | Structured Product Labelling (SPL) drug knowledge representation added to CPOE | The study concluded that although less than 70% of the terms were mapped to SPL, it detected 4 times as many drug intolerance issues on twice as many patients. However, on closer inspection, the figures for allergies indicate that there was no difference between the intervention (SPL+CPOE) and the control (existing CPOE system) in terms of detection of allergens. | The comparator of this study was an in-house CPOE decision support system and thus it may not be applicable to other widely used CPOE systems. |
| Soller | Non- | Revised over- | Overall preference of allergy- | There was a financial |

| Study | Study design | Documentation type | Outcomes | Comments |
|---|---|---|---|---|
| et al. 2012145 | randomised comparative study | the-counter ibuprofen allergy alert | naïve consumers:<br>Existing alert: 22%<br>Revised alert: 78%<br>Overall preference of drug-induced allergy survivors:<br>Existing alert: 0%<br>Revised alert: 100% | incentive for the 'naïve consumers' to participate in this study. |

1   *Abbreviations: ADE: adverse drug event; CPOE: computerised physician order entry system; SPL: structured product labelling*

2

1   ### 8.3.2   Computerised prescribing systems

2   **Table 23:   Clinical evidence summary table: computerised prescribing systems**

| Number of studies | Study designs | Type of electronic system | Rate of errors at baseline | Effectiveness of systems – error rates | Effectiveness of systems – prevention of allergic reactions | Overrides | Reasons for overrides | Quality(a) |
|---|---|---|---|---|---|---|---|---|
| 21 | 1 RCT<br><br>1 prospective cohort study<br><br>1 indirect comparative study<br><br>10 before-and-after design studies<br><br>4 retrospective reviews<br><br>2 surveys<br><br>1 descriptive analysis study | Computerised physician order entry systems<br>Electronic medical record systems<br>Adverse drug event alert systems<br>Systems using ICD-10 codes<br>Drug checking systems<br>ADR reporting tools | Error rates were given in different units.<br>Per overall order errors (converted to 100 orders) range: 14–24%<br>By patient days: 0.04–1.1<br>Proportion of patients: 20–25% | Before–after studies showed a decrease in error rates:<br>Per order: ~10%<br>Per patient days: 0.03–0.5<br>One described total number reduction only: from 833 to 109<br>2 direct comparisons showed e-prescribing no more effective than hand written orders | The rate of 'near misses' did not differ significantly between a CPOE and paper system (1.9 versus 2.7 per 100 orders)<br>Number of non-intercepted potential adverse drug events (ADEs) as well as preventable ADEs decreased from 5.89 to 1.16 and 4.50 to 3.65 respectively<br>Preventable and non-intercepted serious medication errors were described to decrease after implementation from 2.9 per 100 patient days to 1.1 and 7.6 to 1.1 respectively<br>Adverse events caused by anti-infective agents decreased from 28 to 4 after implementation<br>Rates of adverse drug events owing to overridden allergy alerts was 5.9 per 100 patients (3.1 significant and 2.8 serious)<br>After implementation the number of suspected and detected ('studied') allergies went down from 90 to 24 and 15 to 5 respectively | 69–97% | Patient tolerated in the past<br>Patient is already taking the drug<br>Benefits outweigh harms<br>Patient aware and will be monitored<br>Not really allergic | VERY LOW |

3   *(a) The majority of evidence stems from study designs with major risks of bias, such as retrospective and before–after designs. The method of analysis was also often not adequately*
4   *described and did not adjust for any differences in group characteristics.*

**Narrative summary of other findings relating to computerised prescribing systems:**

- In 1 study,[124] a national survey, 42% of responding physicians reported that they relied on the computer system to alert them to the drug allergy.

- Another study[147] reported overall low completion rates of drug allergy records (61.6 for internists and 50.4 for paediatricians).

- In the randomised controlled trial[151] physicians using an on-demand system noticed fewer errors, but acted on the majority of those that they looked at (saw 1% and acted on 76% of those seen). Physicians using an automatic system saw more of the prescribing problems but only acted on a minority of those seen (saw 10% and acted on 12% of those seen).

- One study[93] found that change in ADE rate depended on the level of CDS. CPOE with the more advanced CDS features resulted in more significant reduction of ADE.

- Introduction of CPOE in 1 study[105] led to increase in the overall number of medication errors but decrease in the number of serious errors.

- Incorporation of individual patient data in to an existing computable ADR knowledge base in 1 study[121] led to decrease in sensitivity but increase in specificity of the ADR detection system.

- In general, CPOEs evaluated in more recent years tended to be adapted to suit the purpose of the study site.

### 8.3.3 Pro formas or structured charts

**Table 24: Clinical evidence summary table: pro formas or structured charts**

| Number of studies | Study designs | Pro forma types | Features of new pro forma | Effectiveness of new pro forma | Effectiveness-prevention of allergic reactions | Quality(a) |
|---|---|---|---|---|---|---|
| 9 | 1 RCT<br>5 studies with before-and-after study components<br>1 retrospective data review with prospective patient interview<br>2 prospective | 2 studies assessed a preoperative assessment form for patients undergoing surgical procedures<br>1 study assessed a standardised medication chart for inpatients<br>2 studies assessed a formal assessment pro forma with a clearly designated allergy section for i) use in paediatric inpatient unit and ii) within a department of psychiatry.<br>1 study assessed a structured | Making patient info more visible<br>Giving prompts for clinicians to provide certain info, including allergy<br>Allowing clinicians to provide detailed history of previous reactions<br>Clearly designating an allergy-only section<br>For communication | Positive outcomes observed<br>Reduction in prescribing errors<br>Increase in compliance with documentation of allergy status in some charts but not others<br>Increase in referral letters that include allergy information<br>Increase in accuracy of allergy identification<br>Increase in the number of times allergy components were included/completed | One study reported the changes in rates of reactions:<br>It was described that drug selection (previous ADR) was reduced from 21/9772 (0.21%) to 9/10352 (0.08%) | VERY LOW |

| Number of studies | Study designs | Pro forma types | Features of new pro forma | Effectiveness of new pro forma | Effectiveness-prevention of allergic reactions | Quality(a) |
|---|---|---|---|---|---|---|
| | review of referral letters and admission records | penicillin allergy assessment form for patients attending a day surgery unit at a hospital<br><br>1 study assessed a structured pro forma for communication between GP practices and emergency departments | between GPs and EDs: the front side was for GPs and the reverse side was for EDs to provide outcomes of the referred case<br><br>Standardised to be consistent with other forms used in local area | Negative outcomes observed<br><br>Increase in adverse drug reactions<br><br>No overall difference in quality of information between new pro forma or previous version<br><br>Decrease in frequency of recording of allergy by anaesthetists | | |

(a) *The majority of evidence stems from study designs with major risks of bias, such as retrospective and before–after designs. The method of analysis was also often not adequately described and did not adjust for any differences in group characteristics.*

### 8.3.4 Other documentation strategies

- One study[138] integrated a 'quicklist' containing the 75 most commonly prescribed medications in a paediatric department to the computerised order system and compared this to a computerised system without this list (that is, before implementation). Errors per 100 orders decreased from 31 to 14. With respect to drug allergies, errors per 100 orders decreased from 2 to 0. (Very Low quality evidence)

- One study[127] in an US paediatric emergency department reported that out of the 28 children with confirmed drug allergy, 16 (57%) were given a bracelet. 5/16 (31%) were incorrect or blank. (Very Low quality evidence)

- The addition of structured product labelling to a computer system was investigated in another study.[139] Even though the authors concluded that the structured system detected 4 times as many drug intolerance issues in twice as many patients, closer inspection of the results do not show differences in the detection of allergens between the intervention system and the existing system. (Very Low quality evidence)

- Results from a study of a revised version of an over-the-counter ibuprofen allergy alert, which included more information on symptoms of drug allergies, indicated that 78% of consumers and 100% of people with previous drug allergies preferred the revised version. (Very Low quality evidence)

- In 1 study[56], introduction of ADE scorecards, a tool aimed to increase team ADE awareness by allowing information on ADE available to the entire care team, did not lead to any significant change in the rate of ADE. (Very Low quality evidence)

## 8.4 Economic evidence

**Published literature**

No relevant economic evaluations were included.

See also the economic article selection flow chart in Appendix F.

## 8.5 Evidence statements

**Clinical**

*Computerised medical records and prescriptions:*

- Very low quality evidence from 20 observational studies and 1 RCT showed that error rates tended to decrease after computer systems were introduced. Some studies did not show an overall improvement when direct comparisons were made between paper-based and computer-based prescriptions. In the studies reporting on overrides the majority of computer alerts (69–97%) were ignored. One observational study demonstrated that the resulting changes in adverse drug event (ADE) rates depended on the complexity of clinical decision support (CDS) incorporated in the host CPOE: the more advanced the CDS was the lower the ADE rates following introduction of the CPOE.

*Pro formas or structured charts:*

- Very low quality evidence from 6 observational studies and 1 RCT evaluated new or revised versions of structured forms which allow the clinicians to record patient history and other clinical factors, and to assess patients' allergy status. Some of the positive outcomes included: increase in compliance with documentation of allergy status, presence of allergy information in referral letters, accuracy of allergy identification, the number of times allergy components were included or completed, and reduction in prescribing errors. Some of the negative outcomes were: increase in adverse drug reactions (in 1 study), decrease in frequency of recording of allergy by anaesthetists and no overall difference in quality of information provided by clinicians following intervention.

*Other strategies:*

- Very low quality evidence from 5 observational studies showed that i) the medication error rate decreased following an integration of a 'quicklist' to an existing computerised system; ii) drug allergy information on a significant proportion of children's bracelet were incorrect; iii) structured product labelling did not have a significant impact on allergen detection; iv) a revised, more comprehensive version of an over-the-counter ibuprofen allergy alert was preferred;  and v) introduction of ADE scorecards did not lead to change in ADE rate.

**Economic**

- No relevant economic evaluations were identified.

## 8.6 Recommendations and link to evidence

| Recommendations | **Recording drug allergy status**<br><br>8.  Healthcare professionals should document people's drug allergy status in their healthcare records using 1 of the following: |
| --- | --- |

- 'drug allergy'
- 'none known'
- 'unable to ascertain' (document it as soon as the information is available).

9. When documenting suspected or confirmed drug allergy status in routine care, record all of the following at a minimum:
   - drug name
   - nature of reaction
   - the date when the reaction occurred.

**Documenting new suspected drug allergic reactions**

10. When a person presents with suspected drug allergy, document their reaction in a structured approach that includes:
    - the generic and proprietary name of the drug taken
    - a description of the reaction (see recommendation 1)
    - the indication for the drug being taken (if there is no clinical diagnosis, describe the illness)
    - date and time of the reaction
    - the number of doses taken or number of days on the drug before onset of the reaction
    - the route of administration
    - which drug or drug classes to avoid in future.

**Maintaining and sharing drug allergy information**

11. Ensure that drug allergy status is documented separately from adverse drug reactions and that it is clearly visible to all healthcare professionals who are prescribing, administering and dispensing drugs.

12. Check drug allergy status and update, if needed, at every contact with the patient.

13. Check and update a person's documented drug allergy status and confirm it with the person (or their parents or carers if appropriate) before prescribing, dispensing or administering any drug.

14. Carry out medicines reconciliation for people admitted to hospital in line with recommendations in Technical patient safety solutions for medicines reconciliation on admission of adults to hospital (NICE patient safety solutions 1).

15. Ensure that information about drug allergy status is included in all:
    - GP referral letters
    - hospital discharge letters
    - prescriptions issued in any healthcare setting.

| | |
|---|---|
| | **After specialist drug allergy investigations**<br><br>**For recommendations on referral to specialist services see section 11.**<br><br>16. **After specialist drug allergy investigations, allergy specialists should document:**<br><br>• **the diagnosis – whether the person had an allergic or non-allergic reaction**<br>• **the investigations used to confirm or exclude the diagnosis**<br>• **drug or drug classes to avoid in future.** |
| Relative values of different outcomes | The following outcomes were identified by the GDG as important for decision-making: medication errors (inappropriate prescription or administration of drugs), number of repeat drug allergic reactions, inappropriate avoidance of drugs and quality of life. The first 2 were considered by the GDG to be the most important outcomes.<br><br>Not all of the stated outcomes were found in the studies included. In general, most of the studies reported outcomes related to medication prescribing errors or adverse drug reactions, and not specifically to drug allergy. |
| Trade-off between clinical benefits and harms | The GDG noted a recent report by NHS England[122] which highlighted the high incidence of medication errors and agreed that errors in prescribing and administering drugs are a serious concern.<br><br>The GDG observed that, at present, the labelling and coding used in electronic documentation systems do not enable such systems to differentiate between a side effect and an allergic reaction. It was agreed that if the information entered into such systems was of poor quality in the first instance then the output would also be of poor quality. The GDG considered that any system which allows accurate recording of information and prevention of erroneous prescription or administration of medications would be highly beneficial in improving patient safety.<br><br>Studies related to computerised prescriber order entry (CPOE) systems showed very high rates of overriding of automated alerts (between 69% and 97%). The GDG indicated that once a patient has been diagnosed as having a drug allergy, this status would remain on the patient's record. Therefore, if a patient had previously been incorrectly diagnosed as having a drug allergy, the trigger alerts at subsequent visits to their physician would be overridden.<br><br>Those studies that implemented structured approaches to documentation saw a reduction in medication prescribing errors and adverse drug reactions, and also increase in healthcare professionals' compliance to completing patients' medical charts. The GDG therefore endorsed the application of structured documentation to record details of suspected drug allergies. |
| Economic considerations | No relevant economic evidence was identified. The GDG did not prioritise this question for original economic analysis.<br><br>The GDG agreed that accurately documenting a person's current drug allergy status is vital in order to prevent inadvertent exposure to an allergen, and so to ensure patient safety. Whilst this may require an initial increase in healthcare professionals' time whilst current records are improved, in many case this is likely only to bring forward a discussion that a GP will have with the person at some later point in time, and the GDG were confident that any cost from increased numbers of GP consultations would be outweighed by increases in quality of life and costs saved due to future additional drug allergic reactions avoided.<br><br>Similarly, accurate documentation of all new suspected allergic reactions to drugs will help identify appropriate future treatment, leading to better clinical outcomes and improved quality of life, at low cost. Documentation of reactions which are found not to be allergic reactions will reduce the unnecessary future avoidance of |

| | drugs and so reduce the usage of more expensive and potentially less effective alternatives. Accurate and sufficiently detailed recording of information regarding reactions at the time they are first reported will also reduce time spent later attempting to understand records relating to drug allergy which are unclear or unstructured. |
|---|---|
| | As noted above, there is a significant incidence of medication errors at the point of drug prescription and administration.122 Avoidable repeat reactions can have significant impact on the health and quality of life of people who experience them and will give rise to significant treatment costs; low cost methods of reducing these errors are therefore likely to be cost effective. |
| | Checking the drug allergy status of a person before prescribing them a drug would take a matter of seconds within the course of a normal GP consultation for a person whose status has already been systematically documented according to these recommendations and whose status is unchanged. In the same way it will take healthcare professionals who dispense and administer medication a few seconds more to read prescriptions including slightly more information and to confirm this with the patient. |
| | Although a short amount of additional time added to many thousands of GP consultations and occasions when drugs are administered could add up to a significant total, the GDG emphasised the importance of accurate documentation and information sharing between health services in reducing both avoidable repeat allergic reactions and the costs involved in treating those reactions. There is also a possibility that time would be saved in some cases where a patient may currently be asked to explain their full allergy history on multiple occasions to those prescribing, dispensing or administering drugs to them who are not currently provided with sufficient, or any, allergy information, and so need to elicit the information afresh on each occasion. |
| | The GDG agreed that these strategies were therefore likely to be highly cost effective compared to current practice. |
| Quality of evidence | The studies included were predominantly observational studies from the USA and the electronic systems that they evaluated were designed and developed to suit the purpose of the study site. None of these systems can be directly compared with current or prospective systems in the UK. Importantly, most of the studies focused on rates of medication prescribing errors or adverse drug reactions in general, and data specific to drug allergy were minimal. |
| | The outcomes of the included studies varied considerably, with some documentation strategies leading to positive results whilst others led to less favourable effects. Positive findings from the implementation of computerised systems cannot necessarily be attributed to the system alone. It is possible that introduction of a new system itself raises awareness amongst the personnel working at the site, or that training that accompanies the system's introduction improves practice amongst healthcare professionals. The studies did not provide sufficient data on what training was provided with the computerised systems. |
| | Overall, although the studies observed a reduction in medication prescribing errors and adverse drug reactions, the evidence from these studies was varied and of very low quality. Therefore, the evidence did not enable the GDG to make recommendations on specific systems, and highlighted the need for further research. |
| Other considerations | The GDG noted that there is an increase in the use of computerised systems and a push towards paperless systems being introduced in NHS bodies. However, in the absence of evidence, it is not possible to make recommendations pertinent to such systems. Nevertheless, the GDG recognised that the quality of the information recorded within any documentation system is paramount and concluded that having a well organised, structured system in any format would be very helpful in reducing the number of prescribing errors and preventing allergic reactions. Specifying the information that needs to be recorded and allocating specific locations for details of |

drug allergy to be recorded will serve to enhance the skills of healthcare professionals in taking medical histories and increase their compliance in completing patients' medication charts. Details on the type of information or the level of detail being documented in the patient records were not described within the studies The GDG drafted consensus recommendations on when drug allergy status should be recorded, the level of detail required and who this information should be shared with based on their own clinical experience, and recent publications that have highlighted areas of good practice.2

The GDG was aware that some hospitals already have prescription forms including drug allergy status, but that this was not currently part of GP or dentist standard prescription forms (FP10, HS21B). Given the GDG's observation on the lack of communication between healthcare professionals in primary and secondary care and across different departments within hospitals, it is important to ensure that structured documentation is in place at all levels of patient care.

To prevent the loss of information about a patient's drug allergy between contacts with healthcare providers, it is important that patients are given the necessary information and details of their own drug allergy status, and that such information is held by the patient and shared with their clinicians. Evidence and recommendations related to this issue can be found in Chapter 9 (Information and support).

Guidance on medicines reconciliation on hospital admissions is available in NICE Patient safety guidance 1 (PSG1). The guidance aims to lay out patient safety solutions to ensure that medicines prescribed on admission correspond to those that the patient was taking before admission.

The GDG also noted the recent i-care report2 of the Academy of Medical Royal Colleges that highlighted the need for patient records to follow a standardised structure and content and to be available across organisational boundaries. The report's recommendation for a recognised nomenclature of clinical terms such as SNOMED to be used within the NHS was endorsed by the GDG. Computerised systems for patient records currently use a variety of different codes for drug allergy, and the GDG agreed implementation of a standard code and terminology would improve patient safety and management.

# 9 Providing information and support to patients

## 9.1 Introduction

Patients are often left bewildered following a suspected allergic reaction to a drug. Many questions are asked and too often few are answered: Was the reaction predictable? Should I have been prescribed the drug? Will I have a more severe reaction next time? Which drugs do I need to avoid? Am I at risk when taking a new drug in future? How will this impact on my future treatment?

Fear of experiencing a further reaction can be heightened by a lack of information and worsened if the original reaction was severe. If the patient's record of the details of the allergic reaction is incomplete or the patient is not provided with written information, then the patient may either remain at risk of inappropriately receiving the same or a cross-reacting drug again, sometimes with catastrophic consequences, or a different drug may be incorrectly and unnecessarily avoided in the future, compromising the quality of future medical treatment. A drug allergy may not have been responsible for the original reaction, and so if drug allergy is excluded it is equally important that this information is conveyed to the individual in order to provide reassurance and enable optimal treatment to be prescribed in future.

Written information given to the patient at the time of the reaction, with details of drug, number of doses and the nature and severity of the reaction will avoid uncertainty and in many cases allow prescription of an alternative drug not known to cross-react with the original compound. Details of the drug and reaction are invaluable if the same drug is needed again and will also increase the accuracy of diagnosis if the patient requires referral for specialist drug allergy investigation.

## 9.2 Review question 1: What information and support should individuals with suspected drug allergy or their parents and carers receive?

## 9.3 Review question 2: What information and support should individuals who have had specialist investigations or their parents and carers receive?

**Table 25: Summary of protocol characteristics of review question**

| | |
|---|---|
| **Population** | Patients (or their family and carers) with history or experience of suspected or diagnosed drug allergy |
| **Intervention** | Information about diagnosis and management of drug allergy |
| **Comparison** | Information strategies compared with each other |
| **Evaluation themes** | Patient experiences; preferences; perceptions, including factors which improve or act as a barrier to optimal care. Clinical and quality of life outcomes related to diagnosis and management of drug allergy. |
| **Study design** | Qualitative studies and surveys |

A single search was conducted for the review questions relating to patient information. The studies identified are presented in a single review, as the information was applicable to both questions.

Qualitative studies were identified as the main source of evidence for this review. The analysis of qualitative studies involves a search for common themes in participants' discourse. The themes from

each study were extracted and it was then investigated how many studies identified the same theme or different themes. This evidence is summarised in Table 27.

For full details see the review protocol in Appendix C and study selection flow chart in Appendix E.

## 9.4 Clinical evidence

Eight qualitative studies were identified.[6,21,22,48,66,85,87,97] Studies which addressed adverse drug reactions were included if they discussed patients with drug allergies as a subgroup of the study population. Of the 8 studies 1[6] directly applies to the paediatric population; all other studies refer to adults with drug allergies only. Summaries of study characteristics are presented in Table 26. In Table 27 common and individual themes are identified and summarised. Study quality is assessed according to criteria specific to qualitative research methods. These include clearly specified aims, study design, data collection and rigour of analysis. The complete list of quality characteristics is provided in the footnote to Table 26.

### 9.4.1 Study summary and quality

In Table 26 the included studies are briefly described. See Appendix H for full details of the studies. The numbers in the quality characteristics column refer to those characteristics, from a list of 14 items, which were assessed to be adequate or good.

**Table 26: Summary of studies included in the review: study quality**

| Reference | Population and setting | Aims of study | Data collection | Quality characteristics (a) | Confidence in study |
|---|---|---|---|---|---|
| Arnott et al. 2012[6] | Parents of 44 children with suspected adverse drug reactions; Edinburgh | To inform the management of communication about ADRs in children and to identify any unmet psychological, information and communication needs described by parents. | Semi-structured interviews | 1, 2, 3, 4, 5, 8, 9, 11, 12, 13, 14 | Moderate |
| Butt et al. 2011[21] | 14 adult survivors of SJS and TEN; 2 hospitals in UK | To explore the experiences, beliefs and attitudes of survivors of serious ADRs, using drug-induced Stevens–Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) as a paradigm. | Retrospective qualitative study using detailed semi structured interviews | 1, 2, 3, 4, 5, 9, 12, 13, 14 | Moderate |
| Butt et al. 2012[22] | Adult survivors of SJS and TEN; 208 internet | To interpret the reasons for | First person written | 1, 2, 3, 4, 5, 8, 9, 12, 13, 14 | Moderate |

| Reference | Population and setting | Aims of study | Data collection | Quality characteristics (a) | Confidence in study |
|---|---|---|---|---|---|
| | descriptions | individuals with serious ADRs posting information about their experiences on the internet and to determine whether issues discussed by patients and their relatives in their internet descriptions differ from those found through interviewing survivors of the condition face-to-face. | narratives by patients, relatives or friends. 139 descriptions were posted by patients, 69 by relatives and 1 was jointly submitted by patient and relative. Of those posted by relatives, 30 were posted by mothers. | | |
| Franic &, Pathak 200048 | Random sample of 400 female patients of child bearing age from the Women's Clinic at the Ohio State University Medical Center in Columbus, Ohio, USA.

74 of the returned surveys were useable. | There were 6 objectives over all, 1 of which was relevant to this review:
Do study participants prefer numerical as opposed to verbal descriptors in the communication of ADRs as drug therapy? (that is, not only what information should be communicated but how should it be presented) | Cross-sectional field study using survey instruments | 1, 2, 3, 4, 5, 7, 8, 10, 12, 13, 14 | Moderate |
| Hughes et al. 200266 | 10 adult patients purchasing a selected medicine (antihistamine, decongestant or ibuprofen) at a community pharmacy were interviewed. 4 focus groups of 22 patients total recruited | To investigate the knowledge of patients with regard to the side effects of over-the-counter medicines and the source of this | Ethnographic interviews and focus groups in Welsh School of Pharmacy, Cardiff University, UK. | 1, 2, 3, 4, 5, 13, 14 | Low |

| Reference | Population and setting | Aims of study | Data collection | Quality characteristics (a) | Confidence in study |
|---|---|---|---|---|---|
| | through 2 local schools. | information. | | | |
| Krska et al. 2011[85] | 1362 questionnaires, 27 telephone interviews and data from 230 Yellow Card reports all collected in the UK. | The aim was to determine how reporters to the Yellow Card Scheme identify adverse drug reactions. | A qualitative analysis from 3 sources was carried out: responses to open questions in postal questionnaires sent to all reporters during March 2008–January 2009 were categorised by 2 researchers independently; telephone interviews with a purposive sample of these reporters and the free-text field from completed Yellow Card reporting forms submitted during October 2005–September 2007. | 1, 2, 3, 4, 5, 8, 11, 13, 14 | Moderate |
| Laaksonen et al. 2002[87] | 82 patients were recruited using convenience sampling at a London teaching hospital during autumn 2000. 15% were assessed as having 'definite' or 'probable' adverse drug effects based on the Naranjo algorithm. The extent of information the patients desired was assessed through the 'extent of information desired (EID) scale, a | The aim was to explore the characteristics of medical patients, their information requirements, relationships with their perceptions about prescribed medicines and coexistent adverse drug effects. | Semi-structured questions explored patients' perceptions of the adverse effects of prescribed drugs. | 1, 2, 3, 4, 5, 6,8, 9, 11, 13, 14 | Moderate |

| Reference | Population and setting | Aims of study | Data collection | Quality characteristics (a) | Confidence in study |
|---|---|---|---|---|---|
| | subscale of a larger 12 item scale that assesses the Intrinsic Desire for Information (IDI scale). | | | | |
| Lorimer et al. 201297 | Patients with severe ADR admitted to a hospital for severe drug reactions<br><br>7 out of 15 had allergic reactions, including angioedema (enalapril (1), enoxaparin (1), clarithromycin (1)), Stevens–Johnsons syndrome (sulfasalazine (1)), severe rash (penicillin (1)), severe urticaria (amoxicillin (1)), allergic reaction to contrast media (1).<br><br>Other reactions were gastrointestinal bleeds (NSAIDS (3)), extrapyramidal effects (metoclopramide (1)), jaundice (cimetidine (1))<br>urinary retention (antipsychotics (1))<br>bruising due to interaction with warfarin (clarithromycin (1)),<br>muscle weakness, headache and confusion (statins (1)). | To explore patients' experiences of severe ADR and their views on reporting their ADRs to the Yellow Card scheme. | Semi-structured interview template was used. Open questions were used to explore the patients' views of their suspected ADR, information they have received about their medication, the potential effect on their future medication use and their views and knowledge of the Yellow Card scheme. | 1, 2, 3, 4, 5, 8, 9, 11, 12, 13, 14 | Moderate |

*(a) Quality characteristics assessed: 1. Clear aims; 2. Adequate background; 3. Appropriate methodology; 4. Appropriate design; 5. Appropriate recruitment strategy (sample and sampling) and appropriate data collection; 6. Reliability of data collection tool; 7. Validity of data collection tool; 8. Data collection methods described adequately; 9. Data analysis methods described adequately; 10. Reflexivity; 11. Ethical issues; 12. Rigorous data analysis; 13. Clear findings; 14. Value of research*

### 9.4.2 Summary of themes

All themes identified by the authors of the included studies were extracted. Adverse drug reactions were not always separated from the subset 'drug allergy' but were included if the theme could be extrapolated to allergy. Nine themes are summarised in Table 27 below.

1

**Table 27:   Summary of themes and related studies**

| Qualitative theme | Points highlighted in the theme | Studies identifying this theme |
|---|---|---|
| Poor explanations of possible adverse events or side effects of medications | Clinicians focused on other issues<br><br>Written information not given or difficult to understand | Arnott 2012; Butt 2012 |
| Non-medical sources of information | Personal experience with medicines<br><br>Media coverage<br><br>Information from family and friends<br><br>Seeking advice of others with similar experience about cause, symptoms and treatment<br><br>Internet (possible source of anxiety)<br><br>Books<br><br>Patient information literature not universally read. Reasons for reading: if medicine was new or not a regular medicine; side effect was experienced; medicine was for a child | Arnott 2012; Butt 2012; Hughes 2002; Krska 2011 |
| Management and communication with regards to ADR | Information poorly matched to parents' need at a time of fear and anxiety<br><br>Contradictory information<br><br>Concerns ignored or dismissed | Arnott 2012 |
| Implications of poor communication for patients and carers | Lack of information limits parental involvement about decisions for their child<br><br>Fear of repetition of ADR<br><br>Withholding of medications; avoidance of medicine in general<br><br>Fear of effect on reproduction (fertility, heredity)<br><br>Fear that other medical conditions may be related<br><br>Less trust in healthcare professionals | Arnott 2012; Butt 2011; Butt 2012; |
| Feelings about the experience of having an ADR | Disbelief<br><br>Anger<br><br>Fear of future reaction; fear of losing a useful therapeutic option<br><br>Frustration<br><br>Isolation | Lorimer 2012 |
| Information needs | Discussion with clinician of what happened<br><br>Implications for future health<br><br>How to avoid future reaction<br><br>Patients who have had an adverse drug reaction are more interested in receiving information than those who have not had a reaction | Arnott 2012; Laaksonen 2002 |
| Communication skills | Dialogue with clinician; information seen as responsibility of medical staff<br><br>Internet web sites and chat groups<br><br>Accessible and reliable information from pharmacist (rather than the Internet) | Arnott 2012; Butt 2011; Butt 2012; Franic 2000 |

| Qualitative theme | Points highlighted in the theme | Studies identifying this theme |
|---|---|---|
| | Support from the stories of others<br>Support from patient groups<br>Information about side effects or risks most helpful if provided numerically | |
| Linking signs and symptoms to possible ADR | Timing of reaction<br>Reaction listed in the patient information literature received<br>Symptom was unusual or never had it before<br>Changes with dose and rechallenge | Hughes 2002; Krska 2011 |
| Problems with patient information literature | Writing too small<br>Information related to children's medication dosage confusing and should be related to height and weight<br>Long lists of side effects would cause patients to wrongly attribute symptoms to their medication<br>Underused: Hughes et al. 2002, only 3/32 patients had read the patient information literature; Lorimer et al. 2012 not patients' job to inform themselves but the doctor's job. | Hughes 2002; Lorimer 2012 |

1   Table 27 indicates that the most frequently reported themes were 'non-medical sources of
2   information', 'implications of poor communication', and 'how to communicate'.

3   ## 9.5 Economic evidence

4   **Published literature**

5   No relevant economic evaluations were identified.

6   See also the economic article selection flow chart in Appendix F.

7   ## 9.6 Evidence statements

8   **Clinical**

9   • Moderate quality evidence from 8 qualitative studies (n=1927) using semi-structured interviews,
10  web posts, surveys and focus groups, identified 9 themes relating to patients' concerns about
11  their own information sourcing, what their information requirements are and the consequences
12  of poor communication. The 9 themes were:

13  14.Poor explanations of possible adverse events or side effects of medications.

14  15.Non-medical sources of information.

15  16.Management and communication with regards to ADRs.

16  17.Implications of poor communication for patients and carers.

17  18.Feelings about the experience of having an ADR.

18  19.Information needs.

19  20.Communication skills.

20  21.Linking signs and symptoms to a possible ADR.

1 22.Problems with patient information literature.

2 The themes that were identified by 4 out of 8 studies were 'non-medical sources of information',
3 'implications of poor communication', and 'communication skills'. All other themes were reported
4 in only 1 or 2 studies.

5 **Economic**

6 • No relevant economic evaluations were identified.

7 ## 9.7 Recommendations and link to evidence

| | |
|---|---|
| **Recommendations** | **17.Discuss the person's suspected drug allergy with them, and their parents or carers if appropriate, and provide written information (see recommendation 10). Record the name of the clinician and the date the information was given.**<br><br>**18.Ensure that the person (and their parents or carers if appropriate) is aware of the drug or drug classes that they need to avoid, and advise them to check with a pharmacist before taking any over-the-counter drugs.**<br><br>**19.Advise people (and their parents or carers if appropriate) to carry information they are given about their drug allergy at all times and to share this whenever they visit a healthcare professional or are prescribed, dispensed or are about to be administered a new drug.**<br><br>**20.Allergy specialists should give the following written information to people who have undergone specialist drug allergy investigation:**<br>• **the diagnosis – whether they had an allergic or non-allergic reaction**<br>• **the drug name and a description of their reaction**<br>• **the investigations used to confirm or exclude the diagnosis**<br>• **drugs to avoid in future**<br>• **any safe alternative drugs that may be used.**<br><br>**21.Inform people in whom allergy to a drug or drug class has been excluded by specialist investigation that they can now take this drug or drug class safely.**<br><br>**22.Provide information in line with the recommendations in Patient experience in adult NHS services (NICE clinical guidance 138).** |
| Relative values of different outcomes | The outcomes identified by the GDG as most important for decision-making were examples of information or support that led to an improvement in care and the management of drug allergy.<br><br>The studies included in the review examined many different types of interventions and describe a variety of resulting outcomes. However |

| | some common themes emerged around information needs and methods of communication which demonstrated both good and bad practice. The GDG considered both the positive and negative outcomes reported in the studies when drawing up recommendations on what information should be given to support patients and the method of communication. |
|---|---|
| Trade-off between clinical benefits and harms | The GDG agreed that information about drug allergy given to patients is often ad hoc and written information is rarely given. |
| | Providing information that would result in prescribing errors prevented and inappropriate medication being avoided would enable patients to avoid future drug allergic reactions and reduce the number of visits to their GP and emergency admissions to hospital. |
| | Providing information on details of the drug taken and the reaction along with any subsequent specialist investigations undertaken would improve communication between healthcare professionals and both help to prevent people without a drug allergy being incorrectly labelled as having an allergy, and ensure that people with a drug allergy avoid drugs to which they may be allergic. The gathering of this information is necessary in order to complete the patient's medical record (see Documentation, Chapter 8), but once collected it should also be shared with the patient. |
| | The importance of communication with patients who have had a suspected or confirmed drug allergy was highlighted by studies which described the fear of having a repeat reaction and the anxiety experienced by parents of children with a suspected drug allergy. The group agreed that a dialogue between the healthcare professional and the patient who has had a suspected or confirmed allergic reaction, or their carer, is important to ensure that opportunities are given to ask questions and to provide reassurance as well as practical advice. |
| Economic considerations | No relevant economic evidence was identified. The GDG did not prioritise this question for original economic analysis. |
| | The GDG expected that the impact on time and resource use of providing information to patients would be very small, and would be likely to be offset by an improvement in quality of life. Specifically, provision of information will help people to avoid the suspected allergen in the future, thereby reducing future costs to the health service and future impacts on quality of life through inadvertent repeat exposure. Good provision of information and discussion with a patient at the first opportunity may also reduce time spent by healthcare professionals in providing additional information and explanation to people on future occasions. |
| Quality of evidence | All of the included studies were qualitative research studies. The quality of each study was assessed in terms of confidence in the study, measured against 14 quality criteria specific to qualitative studies. Seven of the 8 included studies were given a 'moderate' level of confidence and 1 was given 'low' confidence. The 3 most frequently reported themes were non-medical sources of information, the implications of poor communication and how to communicate. The GDG acknowledged the implications of poor communication with patients, especially the fear felt by patients, and stressed the importance of providing clear and comprehensive information at both non-specialist and specialist visits. The GDG also referred to the recommendations given in the NICE clinical guideline 'Patient experience in adult NHS services'114 to emphasise good patient experience. Recommendations on checking to ensure that patients have the necessary knowledge, and on giving patients the responsibility to carry and share their drug allergy information are intended to minimise patients' fear, enhance communication between patients, clinicians and pharmacists, and enable the patient to better manage their confirmed or suspected drug allergy. |

| | |
|---|---|
| Other considerations | This review is closely connected with the review on documentation strategies (see Chapter 8). The quality of patient information can be improved through better documentation strategies and vice versa. The recommendations given here therefore advocate completion and maintenance of drug allergy documentation by healthcare professionals, provision of information to patients with effective communication and retention of that information by the patients. |

1

# 10 Non-specialist management

## 10.1 Introduction

In the non-specialist setting a doctor assessing a patient with a suspected allergy to a drug must decide if the drug is the cause of the new symptoms and whether the drug should be continued, the dose altered, or the drug stopped and the person advised to avoid taking the drug again. The course of action taken will be determined by both the severity and nature of the symptoms. If the symptoms are considered expected from the pharmacological profile of the drug, the dose may be altered, which may lead to the symptoms either ceasing or reducing sufficiently to allow the prescription to continue. In some circumstances, treatment may be managed by prescribing an alternative drug. If the allergic reaction to the drug was severe or the person is likely to need the same or a similar drug in future,  then referral for specialist investigation may be appropriate as part of the person's continuing management (see Chapter 11).

An area of management where there is some uncertainty is in the provision of an anti-inflammatory drug for people with a suspected allergy to a non-selective non-steroidal anti-inflammatory drug (NSAID). Current usual practice is for people with a suspected allergy to an NSAID to be prescribed an alternative NSAID which may provoke a similar allergic reaction or to use other analgesic agents such as opioids which do not have anti-inflammatory actions and can cause adverse effects. In some cases the individual may be referred to specialist services, giving rise to additional costs. If selective cyclooxygenase 2 (COX-2) inhibitors were found to be a safe alternative to non-selective NSAIDs they could be prescribed in primary care and may avoid the need to refer some people for specialist evaluation and drug challenge.

### 10.1.1 Selective COX-2 inhibitors

Commonly encountered side effects of NSAIDs include urticaria, angioedema and bronchospasm which affect susceptible patients, such as those with eosinophilic asthma and a history of nasal polyps. These drugs can be prescribed, and some, including aspirin and ibuprofen are also available over the counter, alone and included in a number of compound formulations for common ailments. NSAIDs are some of the most commonly used drugs on account of their anti-inflammatory, analgesic and antipyretic actions. All NSAIDs act on the prostaglandin pathway by inhibiting the enzyme cyclooxygenase. There are 2 main isoforms of cyclooxygenase – COX-1 and COX-2 – and both are inhibited to varying degrees by the available NSAIDs in a ratio that is unique to each drug. Inhibition of COX-1 is considered responsible for many of the allergic and some of the adverse reactions associated with these drugs.

Since the introduction of selective COX-2 inhibitors a number of studies have sought to examine whether patients reporting allergic reaction to non-selective NSAIDs will nonetheless tolerate selective COX-2 inhibitors. Experience from UK specialist drug allergy centres indicates that the majority of patients with a clinical history of allergy to non-selective NSAIDs tolerate selective COX-2 inhibitors, but each patient has usually received a hospital drug challenge under close monitoring to confirm tolerance.

## 10.2 Review question: In patients who have had allergic reactions to NSAIDs what are the factors that indicate whether they can or cannot tolerate selective COX-2 inhibitors?

For full details see review protocol in Appendix C.

Table 28:   Characteristics of review question

| Population | Patients who have had a previous allergic reaction to NSAIDs |
|---|---|
| Presence of factors or defining characteristics | • History of an allergy to more than 1 type of NSAIDs<br>• History of concurrent allergies<br>• History of comorbidities<br>   o Chronic urticaria (with or without angioedema)<br>   o History of asthma<br>   o History of nasal polyps<br>   o History of chronic rhinosinusitis<br>• Eosinophilia<br>• Age of the patient<br>• Severity of the original reaction<br>• Concurrent medications |
| Outcomes | • Incidence and severity of reaction to selective COX-2 inhibitors (coxibs), such as the following:<br>   o Asthma<br>   o Angiodema<br>   o Urticaria<br>• Incidence of other adverse events |
| Study design | Systematic reviews (SRs), prospective cohort studies, case control studies, randomised controlled studies |

## 10.3   Clinical evidence

We searched for any study that reported on tolerance and safety of COX-2 inhibitors in people who have had a previous allergic reaction to an NSAID (including aspirin). Studies that included only COX-2 inhibitors not licenced in the UK (such as nimesulide, rofecoxib, and valdecoxib) were excluded. We also excluded retrospective case reviews. Thirty-five observational studies[4,7,10,11,25,26,28,35,37,39,51,53,55,70,78,80,94,102,108,111,119,120,125,128,130-132,134,140,141,156,160,161,164] were identified. All studies were prospective cohort studies using either single or multiple drug COX-2 challenges, and were by study design mainly single blinded. They usually used incremental dosages (with a washout period between different drugs to prevent carry-over effects). There was considerable variation in study populations. Those could be divided into the following categories:

- Studies including only participants with a history of cutaneous reactions to NSAIDs.
- Studies including only participants who had asthma exacerbated by NSAIDs.
- Studies with mixed populations.
- One study restricted to people with anaphylactoid reactions to NSAIDs.

Results are described according to the COX-2 inhibitor used in the challenge test. The following drugs were tested:

Selective COX-2 inhibitors:

- celecoxib
- etoricoxib
- parecoxib (administered intravenously).

Preferential COX-2 inhibitors:

- etodolac
- meloxicam

- nabumetone.

In the vast majority of studies incremental dosages were used for oral challenges. At which dosage the reaction occurred was therefore also noted.

Table 30 summarises the evidence with regards to tolerance to those drugs. See also the study selection flow chart in Appendix E and exclusion list in Appendix K.

**Summary of included studies**

The characteristics of included studies are briefly outlined in Table 29 – for details please see Appendix H.

**Table 29:  Summary of studies included in the review**

| Study | Population | Drug and dose, mg | NSAID sensitivity confirmed | Protocol | Patients reacting n (%) |
|---|---|---|---|---|---|
| Andri & Falagiani, 2007[4] | Patients with previous cutaneous reactions to NSAIDs (asthma induced by NSAIDs excluded) | Celecoxib 50 mg or 75 mg or 100 mg | No | Single-blind prospective cohort | 3/32 (0.9%) |
| Asero, 2007[7] | Patients with chronic urticaria with NSAID intolerance | Etoricoxib 30–60 mg | No | Single-blind prospective cohort | 0/17 (0%) |
| Bavbek et al. 2004[10] | Patients with a history of urticaria or angioedema, naso-ocular symptoms, bronchospasm or anaphylactoid reactions to NSAIDs. | Meloxicam 7.5 mg | No | Single-blind prospective cohort | 5/61 (8.1%) |
| Bavbek et al. 2007[11] | Patients with asthma or nasal polyps who are hypersensitive to aspirin | Meloxicam 7.5 mg | Yes | Single-blind prospective cohort | 1/21 (4.8%) |
| Celik et al. 2005[25] | Patients with a history of urticaria or angioedema, naso-ocular symptoms, bronchospasm or anaphylactoid reactions to NSAIDs. | Celecoxib 200 mg in divided doses | No | Single-blind prospective cohort | 0/75 (0%) |
| Colanardi et al. 2008[26] | Patients with previous cutaneous reactions to NSAIDs | Parecoxib 40 mg | No | Single-blind prospective cohort | 0/79 (0%) |
| Confino et al. 2003[28] | Patients with a history of hypersensitivity reaction to at least 2 different NSAIDs (patients suffering from asthma or chronic urticaria were not included) | Nabumetone 1000 mg | No | Prognostic cohort study; open oral challenge | 2/24 (8.3%) |
| Domingo et al. 2006[35] | Patients with a history of any type of allergic reaction, reactions to at least 2 different NSAIDs, or positive oral challenge to aspirin | Meloxicam 7.5 mg | No | Single-blind prospective cohort | 5/108 (5%) |

| Study | Population | Drug and dose, mg | NSAID sensitivity confirmed | Protocol | Patients reacting n (%) |
|---|---|---|---|---|---|
| Dona et al. 201137 | Group A with any type of intolerance to NSAIDs and paracetamol and Group B with sensitivity to NSAIDs only | Etoricoxib 15 mg, 15 mg and 30 mg | Yes | Single-blind prospective cohort | Group A: 12/47 (25.53%) Group B: 3/50 (6%) |
| El Miedany et al. 200639 | Patients with a history of asthma induced by aspirin and at least 1 other NSAID | Etoricoxib 60 mg or 90 mg or 120 mg | No | Single-blind prospective cohort | 0/77 (0%) |
| Garcia-Rodriguez, 200251 | Patients with a history of urticaria or angioedema after ingestion of at least 2 different NSAIDs (separate episodes) | Celecoxib 200 mg | No | Single-blind prospective cohort | 0/20 (0%) |
| Goksel et al. 201053 | Patients with a history of urticaria or angioedema triggered by 1 or more NSAIDs | Meloxicam 7.5 mg | No | Single-blind prospective cohort | 10/116 (8.6%) |
| Gyllfors et al. 200355 | Patients with asthma and aspirin intolerance | Celecoxib, 10 mg or 30 mg or 100 mg or 200 mg | No | Double-blind placebo-controlled crossover oral challenge followed by an open challenge | 0/33 (0%) |
| Inomata et al. 200770 | Patients with a history of urticaria or angioedema after NSAID intake | Etodolac 200 mg Meloxicam 10 mg | Yes | Single-blind prospective cohort | Etodolac 8/15 (53.3%) Meloxicam 2/6 (33.3%) |
| Kleinhans et al. 200278 | Patients with a history of any type of allergic reaction NSAID sensitivity | Celecoxib 200 mg | No | Prospective comparative cohort, 2 phase approach: 1) scratch and patch test; 2) single-blind placebo-controlled oral challenge protocol | 0/14 (0%) |
| Koschel et al. 201380 | Patients with a history of respiratory disease exacerbated by aspirin | Etoricoxib 10 mg or 30 mg or 60 mg | Yes | Single-blind prospective cohort | 3/104 (3%) |
| Liccardi et al. 200595 | History of cutaneous reactions to paracetamol and NSAIDs. | Celecoxib 200 mg | Yes | Single-blind prospective cohort | 1/29 (3.4%) |
| Llanora et al. 200396 | Patients with a history of any type of allergic reaction NSAID sensitivity | Etoricoxib Cumulative dose of 120 mg but | No | Prospective cohort | 4/74 (5.4%) |

| Study | Population | Drug and dose, mg | NSAID sensitivity confirmed | Protocol | Patients reacting n (%) |
|---|---|---|---|---|---|
| | | given in separate doses, 30 minutes apart | | | |
| Martin-Garcia et al. 2003102 | Patients with asthma exacerbated by aspirin | Celecoxib 50 mg or 75 mg or 100 mg | No | Single-blind prospective cohort | 0/33 (0%) |
| Mihaela et al. 2012108 | Patients with a history of urticaria or angioedema triggered by 1 or more NSAIDs | Etoricoxib 60 mg | No | Single-blind prospective cohort | 2/118 (1.69%) |
| Muratore et al. 2007111 | Patients with a history of urticaria or angioedema after the ingestion of 2 or more different NSAIDs (on different occasions) | Etoricoxib 100 mg | No | Single-blind prospective cohort | 3/37 (8%) |
| Nettis et al. 2005120 | Patients with a history of urticaria or angioedema in reaction to NSAIDs | Etoricoxib 100 mg | No | Single-blind prospective cohort | 2/141 (1.4%) |
| Nettis et al. 2001119 | Patients with a history of cutaneous reactions triggered by 1 or more NSAIDs | Meloxicam 7.5 mg | No | Single-blind prospective cohort | 2/148 (1.35%) |
| Pagani et al. 2010125 | Patients with a history of any type of allergic reaction NSAID sensitivity | Etoricoxib 90 mg | No | Single-blind prospective cohort | 4/139 (2.8%) |
| Prieto et al. 2007128 | Patients with either respiratory or cutaneous reactions to NSAIDs | Nabumetone 1–2g Meloxicam 7.5–15 mg | Yes | Single-blind prospective cohort | 9/55 (16.4%) tolerated 2 g dose Nabumetone 2/51 (3.9%) tolerated 15 mg Meloxicam |
| Quaratino et al. 2000130 | Patients with a history of any hypersensitivity reactions to 1 or more NSAIDs | Meloxicam 7.5 mg | No | Single-blind prospective cohort | 2/177 (1.1%) |
| Quiralte et al. 2004131 | Patients with a history of anaphylactoid reactions to NSAIDs | Celecoxib 200 mg | Yes | Single-blind prospective cohort | 0/25 (0%) |
| Roll et al. 2006132 | Patients with a history of hypersensitivity reactions to 1 or more NSAIDs | Celecoxib 175 mg cumulative dose | Yes | Single-blind prospective cohort | 5/106 (4.7%) |
| Sanchez Borges et al. 2007134 | Patients with a history of NSAID induced urticaria or angioedema | Meloxicam 15 mg, Celecoxib 200 mg, Etoricoxib 120 mg | Yes | Single-blind prospective cohort | Meloxicam 6/29 (20.6%) Celecoxib: 14/76 (18.4%) Etoricoxib: |

| Study | Population | Drug and dose, mg | NSAID sensitivity confirmed | Protocol | Patients reacting n (%) |
|-------|-----------|-------------------|----------------------------|----------|-------------------------|
| | | | | | 7/62 (11.2%) |
| Senna et al. 2003141 | Patients with a history of at least 1 allergic reaction of any kind to 1 or more NSAIDs | Meloxicam 7.5–15 mg | No | Single-blind prospective cohort | 4/381 (1%) |
| Senna et al. 2004140 | Patients with a history of at least 1 allergic reaction to 1 or more NSAIDs – divided into 3 groups: NSAID-induced rhinitis and asthma Multiple NSAID-induced urticaria or angioedema Single NSAID-induced urticaria or angioedema | Celecoxib 100–200 mg Meloxicam 7.5–15 mg | No | Single-blind prospective cohort | Celecoxib: 4/72 (6.56%) Meloxicam 3/73 (4.1%) |
| Valero et al. 2011156 | Patients with asthma exacerbated by aspirin | Parecoxib 40 mg | No | Single-blind prospective cohort | 0/10 (0%) |
| Viola et al. 2005160 | Patients with a history of any hypersensitivity reaction to 1 or more NSAIDs | Celecoxib 50–200 mg | No | Single-blind prospective cohort | 1/120 (0.8%) |
| Viola et al. 2007161 | Patients with a history of any hypersensitivity reaction to 1 or more NSAIDs | Etoricoxib 120 mg | Yes | Single-blind prospective cohort | 0/31 (0%) |
| Woessner et al. 2002164 | Patients with asthma exacerbated by aspirin | Celecoxib 100–200 mg | Yes | Double-blind prospective cohort | 0/60 (0%) |

## 10.3.1 Summary of events induced by COX-2 inhibitors in NSAID-sensitive patients according to the specific drug administered

Table 30: COX-2 reactions, mode and severity and evidence quality

| Drug | Number of studies | n | Reactors (mean %; median % across studies) | Type of events | | | | | | | Severity | Quality [a] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | Urticaria | Angioedema | Rhinitis | Airway obstruction | Gastro-intestinal | Pruritus | Erythema | | |
| Celecoxib | 13 | 749 | 29 (3.8; 0) | 16 | 9 | | 1 | | 2 | 1 | All apart from 1 (a case of moderate angioedema of the lips[b]) described as non-severe | VERY LOW |
| Etoricoxib | 10 | 823 | 36 (4.3; 2.3) | 10 | 7 | | 4 (see severity column) | | 15 | | Mainly non-severe – 4 cases described as moderate or severe (3 of those asthma attacks and 1 had an asthma attack with tachycardia) | VERY LOW |
| Parecoxib | 2 | 89 | 0 | | | | | | | | | VERY LOW |
| Etodolac | 1 | 15 | 8 (53.3; n/a) | 4 | 2 | | 2 (see severity column) | | | | Described as non-severe (dyspnea and bronchial asthma and urticaria or | VERY LOW |

| Drug | Number of studies | n | Reactors (mean %; median % across studies) | Type of events | | | | | | | Severity | Quality [a] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | Urticaria | Angioedema | Rhinitis | Airway obstruction | Gastro-intestinal | Pruritus | Erythema | | |
| | | | | | | | | | | | angioedema) | |
| Meloxicam | 10 | 878 | 42 (4.8; 4.6) | 20 | 10 | 1 | 3 (see severity column) | 1 | 2 | 5 | Mainly non-severe (2 asthma attacks and 1 severe bronchial obstruction) | VERY LOW |
| Nabumetone | 2 | 94 | 15 (16; 8.3) | 7 | 1 | | 3 (see severity column) | | 2 | 2 | Mainly moderate to severe (nasal or bronchial symptoms with PEF decreases by more than 15%) | VERY LOW |

(a) Evidence quality was assessed according to NICE cohort quality criteria. Weight was given to double-blinding, and also to patient selection (clear description or grouping of patients according to prognostic criteria). Quality was then assessed across studies for each COX-2 drug. All evidence can be considered indirect since prognostic factors were not the objective of the majority of studies.

(b) Described by authors as moderate, symptoms resolved in less than 2 hours after administration of oral cetirizine (10 mg) and intravenous methyl prednisolone (40 mg).

## 10.3.2 Prognostic factors

**History of asthma versus history of cutaneous reactions**

Seven studies[11,39,55,80,102,156,164] investigated tolerance to COX-2 inhibitors in people who have asthma that is exacerbated by aspirin and NSAID use. Twelve other studies[4,7,26,37,53,70,108,111,120,134,135,160] addressed tolerance to COX-2 inhibitors restricted to people who have had a previous cutaneous reaction to NSAIDs. In the asthma studies 4 people from an overall 338 (1.1%) had an allergic reaction (0/126 to celecoxib, 3/181 to etoricoxib, 1/21 to meloxicam, and 0/10 to parecoxib) compared to 74 (7.4%) out of 999 in the cutaneous studies (19/282 to celecoxib, 29/472 to etoricoxib, 18/151 to meloxicam, and 0/79 to parecoxib).

**History of allergic reaction to single versus multiple drugs**

Four studies[36,94,125,140] separated people into groups of people who had a single drug reaction and people with multiple drug reactions or restricted the population to people with multiple drug reactions.

- Liccardi and colleagues (2005)[94] administered an oral challenge with celecoxib to people who had an allergy to NSAIDs as well as to paracetamol. Of the 29 people in this study 1 (3.4%) person experienced a moderate reaction (angioedema of the lips) to the COX-2 inhibitor. Cross-intolerance with paracetamol was also investigated by Dona et al. (2011)[36] in a study with 2 participant groups. In group A, people were intolerant to NSAIDs as well as paracetamol whereas group B was intolerant to NSAIDs only. Reactions to an etoricoxib challenge were more frequent in group A (12/47, 25.5%) compared to group B (3/50, 6%).

- In the study by Pagani et al. (2010)[125] patients were divided into people with previous reactions to a single NSAID (n=83) and people who had previous reactions to multiple NSAIDs (n=56). The tolerability of etoricoxib was evaluated in these groups. The COX-2 inhibitor was not tolerated in 3 of the single reactors (causing wheals in the face area) and in 1 of the multiple reactor group (a severe generalised reaction occurring 3 hours after drug intake).

- Senna and colleagues (2004)[140] divided people into 3 groups of those with a history of NSAID-induced asthma and rhinitis (group A, n=24), a history of multiple drug- (including NSAID-) induced urticaria or angioedema (group B, n=34) and people with NSAID-induced urticaria or angioedema (Group C, n=18). Patients underwent challenge tests with celecoxib and meloxicam. All people in group A tolerated these drugs whereas 3 people in group B, had a skin reaction (2 after celecoxib and 1 after meloxicam) and 4 people in group C (2 to celecoxib and 2 to meloxicam).

**Severity of initial reaction to NSAIDs**

One study (Quiralte et al. 2004[131]) focused on tolerance to COX-2 inhibitors in people who had had an anaphylactoid reaction (urticaria or angioedema plus hypotension or laryngeal oedema) after NSAID intake on admission to the emergency department. None of the 25 patients who were challenged with celecoxib experienced an allergic reaction.

**Mixed population studies**

In the remaining studies COX-2 inhibitor challenges were carried out in patients with any previous reactions to NSAIDs. Apart from an overall rate of tolerance, it was unclear which prognostic factors may indicate who may experience COX-2 hypersensitivity in these studies.

# 10.4 Economic evidence

**Published literature**

No relevant economic evaluations were identified.

See also the economic article selection flow chart in Appendix F.

**Unit costs**

The GDG considered the unit costs of selective COX-2 inhibitors and their alternatives – see Table 40 in Chapter 11 (Referral).

# 10.5 Evidence statements

**Clinical**

***Tolerance to different types of COX-2 inhibitors in people with a history of hypersensitivity to NSAIDs divided by drug***

Selective COX-2 inhibitors:

- Celecoxib – Very low quality evidence from 13 observational studies of people with a history of allergic reactions to NSAIDs (n=749) indicate a low rate of people reacting to celecoxib (mean 4.1%, median 0.4%). The majority of reactions were urticaria and angioedema. One reaction was described as a case of moderate angioedema of the lips, but apart from this all were described as non-severe.

- Etoricoxib – Very low quality evidence from 10 observational studies (n=823) showed a low rate of reactions to etoricoxib (mean 4%, median 2.3%). Drug reactions were mainly described as non-severe. However, there were 4 people who had a moderate to severe reactions, 3 of those had asthma attacks and 1 had an asthma attack with tachycardia.

- Parecoxib – Very low quality evidence from 2 observational studies (n=89) did not report any allergic reactions to parecoxib.

Preferential COX-2 inhibitors:

- Etodolac – Very low quality evidence from 1 observational study (n=15) reported 8 people (>50%) who reacted to etodolac. All reactions were described in the study as non-severe but included dyspnoea, bronchial asthma and urticaria or angioedema.

- Meloxicam – Very low quality evidence from 11 observational studies (n=895) showed that meloxicam had a low rate of allergic reactions (mean 5%, median 4.6%). The majority of reactions were urticaria. However, 1 person (0.1%) had a severe bronchial obstruction.

- Nabumetone – Very low quality evidence from 2 observational studies (n=94) indicated a comparatively higher rate of drug reaction to nabumetone (16%). Reactions were described as moderate or moderate to severe (mainly respiratory).

***Prognostic factors***

History of asthma exacerbated by NSAIDs versus history of cutaneous reactions to NSAIDs:

- Very low quality evidence from 7 observational studies with participants with asthma exacerbated by NSAIDs (n=338) and 12 observational studies with participants who had previous cutaneous reactions to NSAIDs (n=1070) indicate that there were fewer overall drug allergic reactions to

COX-2 inhibitors associated with the studies conducted with people with asthma compared to the overall rate of studies restricted to people with a history of cutaneous reactions to NSAIDs.

History of single versus multiple drug allergies:

- Very low quality evidence from 1 study (n=29) reported a rate of 3.4% (1/29) of people who had a history of allergic reactions to NSAIDs and also paracetamol, had a reaction to celecoxib.

- Very low quality evidence from 1 observational study (n=139) showed similar rates of allergic reactions to etoricoxib in people with prior reactions to single NSAID drugs versus people with prior reactions to multiple NSAIDs. However, the 3.6% (3/83) of people in the single NSAID group who reacted, experienced mild reactions whereas the 1.8% (1/56) of people in the multiple NSAID group who reacted, had a severe drug reaction.

- Very low quality evidence from 1 observational study of people with a history of asthma and rhinitis induced by NSAIDs (n=76) using a drug challenge with celecoxib and meloxicam and showed a zero rate of reactions. In a group with a history of multiple drug-induced urticaria or angioedema, 6% reacted to celecoxib and 3% to meloxicam; whereas 11% reacted in the group with NSAID-induced urticaria or angioedema (to either celecoxib or meloxicam).

Severity of initial reaction:

- Very low quality evidence from 1 observational study (n=25) showed good tolerance to celecoxib in people with a history of anaphylactic reactions to NSAIDs with none of the study participants reacting to the drug challenge.

**Economic**

- No relevant economic evaluations were identified.

## 10.6 Recommendations and link to evidence

| Recommendations | **General** |
|---|---|
| | **23. If drug allergy is suspected:** |
| | • **consider stopping the drug suspected to have caused the allergic reaction and advise the person to avoid that drug in future** |
| | • **treat the symptoms arising from the acute reaction if needed; send people with severe reactions to hospital** |
| | • **document details of the suspected drug allergy in the person's medical records (see recommendation 10)** |
| | • **provide information to the person (see section 9).** |
| | **24. Refer to a specialist drug allergy service people who have had:** |
| | • **a suspected anaphylactic reaction (also see Anaphylaxis, NICE clinical guideline 134) or** |
| | • **a severe non-immediate cutaneous reaction (for example, drug reaction with eosinophilia and systemic symptoms [DRESS], Stevens–Johnson Syndrome, toxic epidermal necrolysis).** |
| | **25. Inform people with a suspected allergy to a non-selective non-steroidal anti-inflammatory drug (NSAID) (and their parents or** |

carers if appropriate) that in future they need to avoid all other non-selective NSAIDs, including over-the-counter preparations.

26. Consider a selective cyclooxygenase 2 (COX-2) inhibitor for people who have had mild reactions to a non-selective NSAID if an anti-inflammatory is needed. Discuss the benefits and low risk of introducing a selective COX-2 inhibitor, and then offer the lowest starting dose and only give a single dose on the first day.

27. Do not offer a selective COX-2 inhibitor in a non-specialist setting to people who have had severe reactions, such as anaphylaxis, severe angioedema or asthmatic reactions, to non-selective NSAIDs.

| | |
|---|---|
| Relative values of different outcomes | The following outcomes were identified by the GDG as important for decision-making: the incidence and severity of reactions to selective COX-2 inhibitors including asthma, angioedema and urticaria, and the incidence of other adverse events. |
| | Although reactions to selective COX-2 inhibitors in the asthmatic group were shown to be less frequent than in the cutaneous group, the GDG agreed that the clinical consequences of an asthmatic reaction were greater than those of a cutaneous reaction. |
| Trade-off between clinical benefits and harms | On average, across all studies, more than 95% of people with a history of allergy to non-selective NSAIDs were shown to tolerate selective COX-2 inhibitors. Reactions described were generally of mild to moderate severity. The studies demonstrated that celecoxib, etoricoxib and meloxicam were tolerated by people with a history of allergy to NSAIDs (% reactors ≤5%). The GDG noted that meloxicam is a preferential COX-2 inhibitor (only partially selective) and therefore there is a theoretical risk of allergic reaction at higher doses in people with a history of allergic reaction to non-selective NSAIDs. The majority of the studies assessing the use of meloxicam used a single dose challenge with a low dose of 7.5 mg. |
| | Two studies considered parecoxib which reported no adverse reactions but these were both very small studies. Parecoxib is only used perioperatively and is usually administered intravenously. |
| | The studies frequently reported the level of severity in those who had an adverse reaction, and they were on the whole described as mild to moderate. The severity of an allergic reaction to an NSAID correlates with the dose, and although the risk of a reaction to a selective COX-2 inhibitor appears low, the GDG concluded that people receiving selective COX-2 inhibitors should begin treatment with a single dose taken at the lowest possible starting dose on the first day. It was noted that most studies included in the review all used a sub-therapeutic dose level to start with and increased the dose up to a therapeutic level when the lower dosage was tolerated. |
| | In studies with people who had asthma exacerbated by NSAIDs there were lower numbers of reactions to selective COX-2 inhibitors than in studies of people who had a history of cutaneous reactions to NSAIDs. |
| Economic considerations | No relevant economic evidence was identified. The GDG did not prioritise the use of specific COX-2 inhibitors for original economic analysis. The economics of broader aspects of non-specialist management were |

|  | considered in relation to the reviews of referral to specialist drug allergy services (see Section 11.9). |
|  | The GDG discussed that if an anti-inflammatory is required, an individual with a suspected allergy to a non-selective NSAID would need either to be referred to specialist drug allergy services or to take a selective COX-2 inhibitor. Provision of selective COX-2 inhibitors is substantially less costly than referral, and given the low risk of a reaction identified by the clinical evidence, the GDG did not feel that referral would offer great clinical benefit. Therefore a strategy of offering a selective COX-2 inhibitor to patients who require an anti-inflammatory but have a suspected non-severe allergy to non-selective NSAIDs would be cost effective, but a strategy of referring all individuals with suspected allergy to non-selective NSAIDs to specialist drug allergy services would not be. (If an anti-inflammatory is not required, then the individual should use an alternative painkiller rather than either a selective or a non-selective NSAID – see Section 11.10 in the review of referral to specialist care.) |
|  | People who have had a severe reaction to a non-selective NSAID should still be referred to specialist services on grounds of clinical safety. |
| Quality of evidence | The aim of the included studies was to assess the rate of reactions after a challenge with a non-selective COX-2 inhibitor. The majority of the studies were not designed to address the characteristics that indicate tolerance to selective COX-2 inhibitors. The quality of evidence was rated as very low. However, the quantity of evidence and consistency of results across the included studies increased the GDG's confidence in the findings. |
|  | None of the studies were randomised and the majority were single-blind, placebo-controlled, single group designs. Many studies did not prove NSAID sensitivity before drug challenges. The evidence demonstrated that there were fewer reactors to selective COX-2 inhibitors in studies restricted to people with prior asthmatic reactions than studies with people with a history of cutaneous reactions to NSAIDs. However, the picture was less clear when comparing people with a history of reactions to those with reactions to multiple NSAIDs. |
| Other considerations | People who have had a reaction to a drug, for example a cutaneous reaction, would have a similar cutaneous reaction on subsequent exposure. The GDG agreed it is important for people to be advised that they should not take any other type of NSAID (including over-the-counter preparations), other than those they are prescribed. The GDG noted that paracetamol is well tolerated in the majority of people who have had an allergic reaction to non-selective NSAIDs. |
|  | The GDG acknowledged that this was an important area of management in which to conduct a systematic review. Current practice is for people with a history of allergy to non-selective NSAIDs to be referred for specialist assessment, whereas the review has demonstrated that the majority of this group, other than those who have had severe reactions to NSAIDs, are able to tolerate selective COX-2 inhibitors. |
|  | The GDG concluded that selective COX-2 inhibitors should be considered for people who have had a previous suspected drug allergic reaction to a non-selective NSAID when there is a need for an anti-inflammatory effect; as a simple analgesic is not adequate to treat symptoms, and when the benefits outweigh the low risk of a cutaneous reaction. The benefits and harms should be fully discussed between the GP and the individual when making a joint decision on whether to prescribe. |
|  | There were lower numbers of reactions to selective COX-2 inhibitors in studies of people who had asthma exacerbated by NSAIDs than in studies of people who had a history of cutaneous reactions to NSAIDs. The GDG |

agreed people with asthma are a higher risk group and therefore they should not be prescribed any NSAID in primary care, including selective COX-2 inhibitors.

The GDG thought that selective COX-2 inhibitors would not be an appropriate treatment for people with rheumatoid arthritis who require long-term treatment that impacts on the severity of the disease and there are treatments specific for rheumatoid arthritis which are preferred.

The GDG discussed the need to make general management recommendations for non-specialist settings. Whilst acknowledging that these would state what was already common practice amongst GPs and other healthcare professionals, it was agreed that not providing general principles of management would leave a gap within the guideline.

1

# 11 Referral to specialist drug allergy services

## 11.1 Introduction

Within each drug class a significant proportion of patients develop adverse drug reactions, but the proportion who experience an allergic reaction is considerably lower. For example up to 10% of the population consider themselves to be allergic to penicillin, however it is likely that only a small percentage (perhaps 10%) of those with a label of penicillin allergy are truly allergic, with the remainder having experienced non-allergic side effects or viral exanthems mislabelled as allergy. Referral for specialist investigation should allow either confirmation of the allergy or to have the drug allergy excluded, enabling the patient to have the same and related drugs in future. Even when drug allergy is confirmed, in many cases it will be possible to identify alternative drugs that the patient is able to take safely.

Referral of all patients with a label of drug allergy is not necessarily the appropriate action, as this would be very costly and would overwhelm specialist drug allergy services, while some patients may receive only very small benefits from referral. Therefore, an evidence review has been conducted of the drugs most commonly leading to a referral for further investigation to consider who should be referred to specialist drug allergy services.

## 11.2 Review question 1: What is the clinical and cost effectiveness of referral to specialist drug allergy services for people with suspected allergy to beta-lactam antibiotics?

## 11.3 Review question 2: What is the clinical and cost effectiveness of referral to specialist drug allergy services for people with suspected allergy to NSAIDs?

## 11.4 Review question 3: What is the clinical and cost effectiveness of referral to specialist drug allergy services for people with suspected allergy to local anaesthetics?

## 11.5 Review question 4: What is the clinical and cost effectiveness of referral to specialist drug allergy services for people with suspected anaphylaxis due to drug allergy during general anaesthesia?

A single search was conducted for the review questions relating to referral of patients with suspected drug allergy.

For full details see review protocol in Appendix C.

**Table 31:  Main common characteristics of the review question protocol**

| Population | Patients presenting with suspected drug allergy to beta-lactam antibiotics, NSAIDs or local anaesthetics, or anaphylaxis due to drug allergy to general anaesthesia |
|---|---|
| Intervention | Referral to specialist drug allergy services (for diagnosis, further investigations to |

| | |
|---|---|
| | identify safe alternatives or other management strategies) |
| **Comparison** | No referral |
| **Outcome** | The benefit associated with referral as assessed by:<br>1. Mortality<br>2. Number of repeat drug allergic reactions (including patient reported episodes)<br>3. Length of hospital stay<br>4. Inappropriate avoidance of drugs.<br>5. Health-related quality of life<br>Any outcomes that may indicate who should be identified for referral |

# 11.6 Clinical evidence

The aim of the current review was twofold:

1. To assess the benefit of referral plus management by specialist allergy services versus management in primary care.

2. To identify who should be referred to specialist allergy services.

No direct high quality evidence was identified to answer the review questions. Only 1 study (Frigas 2008[49]) was identified which provided indirect evidence for the benefits of referral; see Table 32, GRADE Table 33 and Appendix J for forest plots. The quality of this evidence was assessed as 'Very Low.'

## 11.6.1 Benefit of referral

**Table 32:** **Benefits of referral to specialist clinics compared to other methods of evaluation for patients with suspected drug allergy to beta-lactam antibiotics**

| Reference | Population and setting | Aims of study | Effect sizes | Quality of evidence |
|---|---|---|---|---|
| Frigas E, Park MA, Narr BJ, Volcheck GW, Danielson DR, Markus PJ et al. Preoperative evaluation of patients with history of allergy to penicillin: comparison of 2 models of practice. Mayo Clinic Proceedings Mayo Clinic. 2008; 83(6):651-662 | Patients at the Mayo Clinic attending the Preoperation Evaluation Clinic (POEC) with HOAP who were evaluated and skin tested by an allergist and a team of allergy nurses before the decision of which antibiotic to use for POABP was made. Compared to OPES where there was no consultation or testing. | To compare the selection of the antibiotic for POABP in the POEC and OPES setting | Patients with history of beta-lactam allergy:<br>Screened at POEC: 68% cephalosporin, 26% vancomycin, 22% other<br>Screened at OPES: 33% cephalosporin, 26% vancomycin, 41% other.<br>No patients were skin test positive. | Strengths: Study conducted prospectively. There was a baseline difference in age with people screened in non-preoperative evaluation clinics being older than those who received preoperative specialist screening. The analysis was then adjusted for this difference.<br>Quality: Very Low |

*Abbreviations: HOAP: history of allergy to penicillin; OPES: other preoperative evaluation settings: POABP: perioperative antibacterial prophylaxis; POEC: Preoperation Evaluation Clinic*

**Table 33:   GRADE quality assessment: referral to specialist drug allergy services**

| | Quality assessment | | | | | | Summary of Findings Effect | | | | Quality | Importance |
| Number of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Screened at 'Preoperative Evaluation Clinic (POEC)' setting Event rate (%) | Screened at 'Other non-POEC (OPES)' settings Event rate (%) | Relative Risk (95% CI) | Absolute effect (95% CI) | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Referral for suspected penicillin allergy (Frigas 2008[49]) |||||||||||||
| Use of cephalosporin for preoperative prophylaxis in patients with history of beta-lactam allergy (6-month follow-up; assessed with: Mayo Clinic records) |||||||||||||
| 1 | observational study | very serious[a] | no serious inconsistency | very serious indirectness[b] | no serious imprecision | none | 280/412 (68%) | 23/69 (33.3%) | RR 2.04 (1.45 to 2.87) | 347 more per 1000 (from 150 more to 623 more) | ⊕◯◯◯ VERY LOW | IMPORTANT |
| Use of vancomycin for preoperative prophylaxis in patients with history of beta-lactam allergy (6-month follow-up; assessed with: Mayo Clinic records) |||||||||||||
| 1 | observational study | very serious[a] | no serious inconsistency | very serious indirectness[b] | no serious imprecision[c] | none | 42/412 (10.2%) | 18/69 (26.1%) | RR 0.39 (0.24 to 0.64) | 159 fewer per 1000 (from 94 fewer to 198 fewer) | ⊕◯◯◯ VERY LOW | IMPORTANT |
| Use of cephalosporin for preoperative prophylaxis in patients with penicillin allergy (6-month follow-up; assessed with: Mayo Clinic records) |||||||||||||
| 1 | observational study | very serious[a] | no serious inconsistency | very serious indirectness[b] | serious imprecision | none | 254/365 (69.6%) | 18/46 (39.1%) | RR 1.78 (1.23 to 2.57) | 305 more per 1000 (from 90 more to 614 more) | ⊕◯◯◯ VERY LOW | IMPORTANT |
| Use of vancomycin for preoperative prophylaxis in patients with penicillin allergy (6-month follow-up; assessed with: Mayo Clinic records) |||||||||||||
| 1 | observational study | very serious[a] | no serious inconsistency | very serious indirectness[b] | no serious imprecision | none | 36/365 (9.9%) | 13/46 (28.3%) | RR 0.35 (0.20 to 0.61) | 184 fewer per 1000 (from 110 fewer to 226 fewer) | ⊕◯◯◯ VERY LOW | IMPORTANT |

(a)  This is an observational study with limited baseline data and only 2 possible confounders are adjusted in the analysis.

(b)  The study does not directly address the benefits of referral as such, but seems to indicate that specialist clinics are better than non-specialist services at identifying who has an allergy.

(c)  The confidence interval crossed the default MID of 1.25 RR (from benefit to no effect) and was therefore downgraded once.

# 11.7 Economic evidence

## 11.7.1 People with suspected allergy to beta-lactam antibiotics

**Published literature**

No relevant economic evaluations were identified.

See also the economic article selection flow chart in Appendix F.

### 11.7.1.1 Cost-effectiveness analysis

In the absence of cost-effectiveness evidence, unit costs were collected to inform qualitative discussions of the cost effectiveness of referral compared to non-specialist management (see Table 34 and Table 35). Hypothetical scenarios were also constructed to further facilitate the GDG's consideration of cost effectiveness in common scenarios (see Table 36–Table 39).

**Costs of non-specialist management**

In order to calculate the cost of non-specialist management (that is, avoiding drugs to which there is a possible allergy and treating with alternative drugs instead), the GDG considered the costs of the alternative drugs which would be prescribed instead of beta-lactam antibiotics for a person with a suspected allergy to a beta-lactam (see Table 34).

**Table 34: Unit costs of beta-lactam and alternative antibiotics**

| Antibiotic | Group or class | Dosage (adult unless stated)[a] | Duration | Cost per course |
|---|---|---|---|---|
| Beta-lactams | | | | |
| Penicillin V | Penicillin | 500 mg every 6 hours | 7 days | £2.80 |
| Amoxicillin | Penicillin | 500 mg every 8 hours | 7 days | £1.61 |
| Flucloxacillin | Penicillin | 500 mg every 6 hours | 7 days | £2.49 |
| Cefalexin | First generation cephalosporin | 500 mg every 8 hours | 7 days | £1.90 |
| Cefaclor | Second generation cephalosporin | 250 mg every 8 hours | 7 days | £6.80 |
| Cefixime | Third generation cephalosporin | 400 mg once daily | 7 days | £26.46 |
| Piperacillin with tazobactam | Penicillin | 4000 mg piperacillin with 500 mg tazabactam every 8 hours | 14 days | £352.80 |
| Aztreonam | Monobactam | 2000 mg every 8 hours | 14 days | £790.44 |
| Alternatives to beta-lactams | | | | |
| Azithromycin | Macrolide | 500 mg once daily | 3 days | £4.51 |
| Clarithromycin | Macrolide | 250 mg every 12 hours | 7 days | £1.89 |
| Erythromycin | Macrolide | 500 mg every 6 hours | 7 days | £3.38 |
| Erythromycin ethyl succinate | Macrolide | 40 mg/kg daily (divided into 3 doses)[b] | 3 days(b) | £2.57 |
| Doxycycline | Tetracycline | 200 mg once on first day; then 100 mg once daily | 1 day; 6 days | £1.11 |
| Oxytetracycline | Tetracycline | 500 mg every 6 hours | 7 days | £2.46 |
| Metronidazole | Nitroimidazole | 400 mg every 8 hours | 7 days | £1.46 |

2    *(a) Where BNF gives a range of appropriate dosages, the highest dosage applicable for standard conditions has been*
3    *chosen, but not any increased doses which may be used, for example, in the case of severe infections. Where durations*
4    *are not stated in BNF they are as advised by GDG members.*
5    *(b) GDG assumption for children with otitis media. Calculations assume a child of 30 kg.*

6    To allow accurate comparison with the costs of referral, these costs must be calculated over a
7    person's lifetime. The cost of non-specialist management ($Cost_{2nd\ line}$) is therefore calculated using the
8    following formula:

$$Cost_{2nd\ line} = cost\ of\ second\ line\ antibiotic\ \times lifetime\ episodes$$

9    This formula requires an estimate of the number of times an individual will require a beta-lactam
10   over the course of their life (lifetime episodes), which is hugely variable. Therefore, for each scenario,
11   the costs were calculated using 3 different estimates of the number of lifetime episodes (see Table
12   36–Table 38).

13   Note that the cost of non-specialist management calculated here is likely to be an underestimate of
14   the true full cost, as it does not take into account higher rates of antibiotic resistance with some
15   second-line treatments, or additional costs incurred due to second-line treatments being less
16   effective at treating the initial infection. The GDG agreed that in some cases this would lead to
17   requirement for a longer course of treatment or the additional use of a third-line antibiotic. The GDG
18   also noted that beta-lactams are generally well tolerated, whereas some second- or third-line
19   antibiotics may cause adverse effects resulting in prolongation of treatment and ill health.

20   **Costs of referral to specialist drug allergy services**

21   Table 35 shows the costs of referral appointments with a drug allergy specialist, which include
22   various components. Generally, if more than 1 test is conducted, the cost to the NHS of that
23   appointment is the cost associated with the most expensive test conducted during that appointment.
24   Therefore, if all 3 tests are conducted, the cost is £499.89, whereas if only the skin prick test is
25   conducted, the cost is £486.08. Table 35 shows that appointments that include intradermal testing
26   are the most expensive and will be undertaken in 95% of cases, and appointments that include a skin
27   prick test will be the most expensive in the remaining 5% of cases. Therefore, we can calculate the
28   total expected cost of a referral appointment ($Cost_{appointment}$) using the following formula:

$$Cost_{appointment} = 0.95\ \times £499.89\ + 0.05\ \times £486.08\ =\ £499.20$$

29   **Table 35:   Costs of referral appointments with a drug allergy specialist**

| Component | Unit cost | Probability test conducted[d] |
|---|---|---|
| Skin prick test | £486.08[a] | 100% |
| Intradermal test | £499.89[b] | 95% |
| Drug challenge | £380.22[c] | 95% |

30   *(a) NHS reference costs[33] for day case procedures JC11Z*
31   *(b) NHS reference costs[33] for day case procedures JC18Z*
32   *(c) NHS reference costs[33] for day case procedures WA20Y*
33   *(d) Based on GDG assumptions*

34   However, the cost of the referral appointment is not the full cost of referral as the person will still
35   receive antibiotics when needed in future – whether they can now safely take some or all beta-
36   lactams again or need to use alternatives. People who are found to be truly allergic will still require
37   alternative drugs, and will therefore still incur the additional cost and quality of life impact associated
38   with second-line treatments. The GDG noted that the proportion of people with suspected allergy
39   who are found to be truly allergic is low, estimated to be around 10%. The remaining people are able

to resume taking first-line beta-lactam treatments. Assuming this is correct, the true cost of referral ($Cost_{referral}$) can be estimated as:

$$Cost_{referral} = Cost_{appointment} + 0.9 \times (cost\ of\ first\ line\ antibiotic \times lifetime\ episodes) \\ + 0.1 \times Cost_{2nd\ line}$$

For each scenario the cost of referral ($Cost_{referral}$) is calculated, and compared to the cost of non-specialist management ($Cost_{2nd\ line}$). The gain per episode in quality of life required for referral to be cost effective at the £20,000 per QALY gained threshold is then calculated based on the following formula:

$$QALY\ gain\ required\ per\ episode \\ = incremental\ cost\ of\ referral \div £20,000 \div lifetime\ episodes$$

This gives the number of additional QALYs that someone who has had a referral appointment (and hence now has a 90% chance of being able to take a first-line beta-lactam antibiotic, and a 10% chance of taking a second-line alternative antibiotic during future episodes requiring antibiotics) would gain during each future episode requiring an antibiotic compared to the quality of life of someone under non-specialist management who would take a second-line antibiotic during the same episode. This figure is also presented in terms of quality-adjusted life days (QALDs).

**Scenario 1**

An adult presents with an acute throat infection. The first-line treatment is assumed to be penicillin V, and the second-line treatment is assumed to be erythromycin. Results of the analysis are reported in Table 36.

**Table 36:  Scenario 1: acute throat infection**

| Lifetime episodes | Cost of non-specialist management | Cost of referral to a drug allergy specialist | Incremental cost of referral | QALYs (QALDs) required per episode for referral to be cost effective at a threshold of £20,000 per QALY gained |
|---|---|---|---|---|
| 2 | £6.76 | £504.91 | £498.15 | 0.0125 (4.5) |
| 5 | £16.90 | £513.49 | £486.59 | 0.0050 (1.8) |
| 10 | £33.80 | £527.78 | £483.98 | 0.0025 (0.9) |

**Scenario 2**

A child presents with otitis media. The first-line treatment is assumed to be amoxicillin, and the second-line treatment is assumed to be erythromycin ethyl succinate. Results of the analysis are reported in Table 37.

**Table 37:  Scenario 2: otitis media in children**

| Lifetime episodes | Cost of non-specialist management | Cost of referral to a drug allergy specialist | Incremental cost of referral | QALYs (QALDs) required per episode for referral to be cost effective at a threshold of £20,000 per QALY gained |
|---|---|---|---|---|
| 2 | £5.14 | £502.61 | £497.47 | 0.0124 (4.5) |
| 5 | £12.85 | £507.73 | £494.88 | 0.0049 (1.8) |
| 10 | £25.70 | £516.26 | £490.56 | 0.0025 (0.9) |

1 **Scenario 3**

2 An adult presents with bronchiectasis and associated respiratory exacerbation. The first-line
3 treatment is assumed to be amoxicillin (although note this is assumed to be taken for 14 days rather
4 than the standard 7-day course), and the second-line treatment is assumed to be clarithromycin.
5 Results of the analysis are reported in Table 38. Scenario 3 differs from the preceding scenarios as
6 bronchiectasis can lead to recurrent respiratory exacerbation, which sometimes requires specialist
7 treatment, and on occasion may lead to hospital admission and the need for intravenous antibiotics.
8 The doses required are higher than the standard dose (clarithromycin 500 mg twice daily) and each
9 treatment course would last for 14 days not 7 days. An individual who has bronchiectasis may
10 require antibiotics multiple times in a year, leading to a significant impact on quality of life, and
11 increased costs, if amoxicillin cannot be used due to a suspected drug allergy. Also note that the
12 additional cost per course of antibiotics is higher in this scenario than in the preceding scenarios.

13 **Table 38:  Scenario 3: bronchiectasis leading to recurrent respiratory sepsis**

| Lifetime episodes | Cost of non-specialist management | Cost of referral to a drug allergy specialist | Incremental cost of referral | QALYs (QALDs) required per episode for referral to be cost effective at a threshold of £20,000 per QALY gained |
|---|---|---|---|---|
| 5 | £37.80 | £517.47 | £479.67 | 0.0048 (1.8) |
| 10 | £75.60 | £535.74 | £460.14 | 0.0023 (0.8) |
| 20 | £151.20 | £572.28 | £421.08 | 0.0011 (0.4) |

14 **Scenario 4**

15 An adult with cystic fibrosis presents with a respiratory infection. The first-line treatment is assumed
16 to be piperacillin with tazobactam, and the second-line treatment is assumed to be aztreonam. Note
17 that these are both beta-lactam antibiotics, however there is thought to be little cross-reactivity
18 between these drugs. Regardless of the class of antibiotic, referral is still required to investigate
19 whether the first-line treatment needs to be avoided. Results of the analysis are reported in Table
20 39. In this scenario, the referral strategy is cheaper than providing the expensive second-line
21 treatment. Referral is also expected to increase quality of life compared to no referral, therefore
22 referral is expected to dominate no referral in this scenario. The QALYs required for referral to be
23 cost effective at the threshold of £20,000 per QALY gained would therefore be negative, and so are
24 not calculated.

25 **Table 39:  Scenario 4: cystic fibrosis**

| Lifetime episodes | Cost of non-specialist management | Cost of referral to a drug allergy specialist | Incremental cost of referral | QALYs (QALDs) required per episode for referral to be cost effective at a threshold of £20,000 per QALY gained |
|---|---|---|---|---|
| 5 | £3,952.20 | £2,482.02 | −£1,470.18 | Not applicable – referral dominates |
| 10 | £7,904.40 | £4,464.84 | −£3,439.56 | Not applicable – referral dominates |
| 20 | £15,808.80 | £8,430.48 | −£7,378.32 | Not applicable – referral dominates |

26 **Other considerations**

27 Note that this cost comparison does not calculate the QALY gains associated with either referral or
28 non-specialist management. The GDG stressed that second-line treatments are not only more costly
29 than most first-line treatments, but are generally less effective at treating infections and have worse
30 side effect profiles. In cases where second-line treatments are not tolerated well this may lead to
31 third-line treatment, which is likely to be even less effective at treating the initial infection. Second-
32 and third-line treatments are likely to lead to longer recovery times and reduced quality of life during
33 recovery compared to first-line antibiotics. Consequently referral is likely to lead to improvement in

quality of life compared to non-specialist management, as 90% of individuals will be able to resume taking first-line treatments.

Where second-line treatments are not tolerated well this may also lead to additional GP appointments, and additional interventions may also be required to counter side effects associated with second- and third-line treatments, the costs of which have not been included here. Consequently, the true cost of non-specialist management is likely to be higher than calculated here, and the incremental cost of referral lower.

The GDG also noted that this analysis does not account for the possibility that bacteria may be resistant to second-line antibiotics. This is more common with second-line treatments than with first-line treatments, and again may necessitate the use of less effective third-line treatments.

### 11.7.2 People with suspected allergy to NSAIDs

**Published literature**

No relevant economic evaluations were identified.

See also the economic article selection flow chart in Appendix F.

**Unit costs**

In the absence of cost-effectiveness evidence, unit costs were collected to inform qualitative discussions of the cost effectiveness of referral compared to non-specialist management.

**Costs of non-specialist management**

In order to consider the cost of non-specialist management (that is, avoiding drugs to which there is a possible allergy and treating with alternative drugs instead), the GDG noted the costs of the alternative drugs which would be prescribed instead of NSAIDs for a person with a suspected allergy to NSAIDs (see Table 40).

**Table 40: Costs of selected NSAIDs and alternatives**

| Drug | Maximum daily dose (adult) | Maximum daily cost |
|---|---|---|
| **NSAIDs – non-selective** | | |
| Aspirin | 4000 mg | £0.52 |
| Ibuprofen | 2400 mg | £0.23 |
| Naproxen | 1000 mg | £0.12 |
| **NSAIDs – selective COX-2 inhibitors** | | |
| Celecoxib (Celebrex) | 400 mg | £1.44 |
| Etoricoxib (Arcoxia) | 90 mg | £0.82 |
| Parecoxib (Dynastat) | 80 mg (intramuscular or intravenous injections) | £9.92 |
| **NSAIDs – preferential COX-2 inhibitors** | | |
| Etodolac | 600 mg | £0.27 |
| Meloxicam | 15 mg | £0.04 |
| Nabumetone | 2000 mg | £0.56 |
| **Alternative painkillers** | | |
| Paracetamol | 4000 mg | £0.22 |
| Co-dydramol | 80 mg dihydrocodeine | £0.26 |

| Drug | Maximum daily dose (adult) | Maximum daily cost |
|------|----------------------------|--------------------|
|      | 4000 mg paracetamol        |                    |
| Co-codamol (8/500) | 64 mg codeine<br>4000 mg paracetamol | £0.13 |
| Co-codamol (30/500) | 240 mg codeine<br>4000 mg paracetamol | £0.37 |
| Codeine | 240 mg | £0.40 |
| Dihydrocodeine | 120 mg | £0.17 |
| Tramadol | 400 mg | £0.28 |

1    *Source:    Doses and prices from British National Formulary, March 2014[71]*

2    To allow accurate comparison with the costs of referral, these costs would need to be calculated over
3    a person's lifetime. As the frequency of use of NSAIDs varies widely depending on the condition and
4    individual the GDG did not think it was appropriate to create scenarios for NSAIDs, but considered
5    the costs of NSAIDs and alternative drugs along with the likely frequency of their use when
6    formulating the recommendations relating to NSAIDs.

7    Alternative painkillers listed in this table do not have direct anti-inflammatory effects, will not be
8    appropriate alternatives for all conditions for which an NSAID may be used, and will have different
9    side effect profiles to NSAIDs.

10   **Costs of referral to specialist drug allergy services**

11   Table 41 shows the costs of referral appointments with a drug allergy specialist that include various
12   components. Generally, if more than 1 test is conducted, the cost to the NHS of that appointment is
13   the cost associated with the most expensive test conducted during that appointment. Therefore, if all
14   3 tests are conducted, the cost is £499.89, whereas if only the skin prick test is conducted, the cost is
15   £486.08. Table 41 shows that appointments that include intradermal testing are the most expensive
16   and will be undertaken in 95% of cases, and appointments that include a skin prick test will be the
17   most expensive in the remaining 5% of cases. Therefore, we can calculate the total expected cost of a
18   referral appointment ($Cost_{appointment}$) using the following formula:

$$Cost_{appointment} = 0.95 \times £499.89 + 0.05 \times £486.08 = £499.20$$

19   **Table 41:   Costs of referral appointments with a drug allergy specialist**

| Component | Unit cost | Probability test conducted[d] |
|-----------|-----------|-------------------------------|
| Skin prick test | £486.08[a] | 100% |
| Intradermal test | £499.89[b] | 95% |
| Drug challenge | £380.22[c] | 95% |

20   *(a) NHS reference costs[33] for day case procedures JC11Z*
21   *(b) NHS reference costs[33] for day case procedures JC18Z*
22   *(c) NHS reference costs[33] for day case procedures WA20Y*
23   *(d) Based on GDG assumptions*

24   Note that the cost of the referral appointment is not the full cost of referral. People who are found to
25   be truly allergic will still require treatment with alternative drugs, and will therefore still incur the
26   additional costs and quality of life impact associated with second-line treatments. The GDG noted
27   that the proportion of people with suspected allergy who are found to be truly allergic is low,
28   estimated to be around 10%. The remaining 90% of people are able to resume taking NSAIDs.

**11.7.3 People with suspected allergy to local anaesthetics**

**Published literature**

No relevant economic evaluations were identified.

See also the economic article selection flow chart in Appendix F.

**11.7.4 People with suspected anaphylaxis due to drug allergy during general anaesthesia**

**Published literature**

No relevant economic evaluations were identified.

See also the economic article selection flow chart in Appendix F.

# 11.8 Evidence statements

**Clinical**

- Very low quality evidence from 1 observational study (n=485) showed a significant increase in the use of cephalosporin and a decrease in the use of vancomycin in a model of practice that used an allergy consultation and skin testing in the selection of the antibiotic compared with a model that did not. Negative skin tests did not preclude the use of alternative drugs.

**Economic**

- No relevant economic evaluations were identified.

# 11.9 Recommendations and link to evidence: beta-lactam antibiotics

**What is the clinical and cost effectiveness of referral to specialist drug allergy services for people with suspected allergy to beta-lactam antibiotics?**

| Recommendations | 28.Refer to a specialist drug allergy service people with a suspected allergy to beta-lactam antibiotics who:<br><br>• **need treatment for a disease that can only be treated by a beta-lactam antibiotic or**<br>• **have a high likelihood of frequent future need for beta-lactam antibiotics, for example, people with recurrent bacterial infections or immune deficiency.**<br><br>29.Consider referring to a specialist drug allergy service people who are not able to take beta-lactam antibiotics and at least 1 other class of antibiotic because of suspected allergy to these antibiotics. |
|---|---|
| Relative values of different outcomes | The following outcomes were identified by the GDG as important for decision-making: mortality, repeat drug allergic reactions, length of hospital stay, inappropriate avoidance of drugs, and health-related quality of life.<br>However, these outcomes were not provided in the study reviewed. |

| | |
|---|---|
| | Indirect evidence for these outcomes came from included rates of referral, rates of positive testing and plausibility of adverse drug reactions. |
| Trade-off between clinical benefits and harms | The evidence presented to the GDG did not provide a sufficient number of outcomes to form the basis for a discussion on the trade-off between clinical benefits and harms. The benefits and harms were therefore discussed based on the experience of the GDG members. |
| | The systematic review focussed on beta-lactams, NSAIDs and local and general anaesthetics. However the GDG considered that if a person had experienced anaphylactic or severe cutaneous reactions such as DRESS or Stevens–Johnson Syndrome after taking any drug the person should be referred to specialist services for further investigation. In addition to the serious harm that may be caused to the person, the nature of such a severe reaction would be extremely alarming for the person concerned (and their parent or carer, where relevant), and it would be important to conduct further investigations in order to prevent a repeat occurrence. The GDG agreed that the guideline should provide a clear general recommendation that if these reactions are observed the person needs to be referred. |
| | The GDG agreed that for some conditions penicillin is the most effective and safest antibiotic and is associated with fewer side effects than alternative drugs. The GDG noted that in pregnancy penicillin has a good safety profile and some other classes of antibiotics would be contraindicated. |
| | The GDG agreed the risk of sensitising people to beta-lactams through carrying out investigations was extremely low. |
| | The GDG considered whether there were particular considerations for the referral of children with regards to benefits and safety outcomes. The consensus was that these recommendations apply to all age groups. |
| Economic considerations | No relevant economic evidence was identified. |
| | The GDG identified referral to specialist drug allergy services or alternative management strategies within primary care for patients who are not referred as the highest priority area for original economic analysis. The GDG believed that economic modelling in this area would be informative if feasible, but concluded that modelling was unfortunately not feasible as information was not available on the relative effectiveness of referral or non-specialist management on outcomes such as the number of future allergic reactions or the number of occasions alternative drugs are used. This was due both to the fact that as specialist management is outside the scope of this guideline the referral pathway is undefined, and to the lack of applicable published economic research on the areas that are within the scope. Therefore any model would necessarily have to be built largely upon estimates and assumptions. In particular, sufficient data were not available to allow modelling of different subgroups, which would be necessary to identify which individuals should or should not be referred to specialist drug allergy services. |
| | Instead of conducting a full economic evaluation, 4 cost-effectiveness scenarios were constructed for the case of suspected allergy to beta-lactam antibiotics. These calculated the potential costs of both referral to specialist drug allergy services and of non-specialist management for multiple frequencies of future need for antibiotics. They presented the magnitude of difference in quality of life which referral would need to be expected to yield for it to be cost effective compared to non-specialist management. The GDG used these scenarios to inform their recommendations regarding which people should and should not be |

referred to specialist drug allergy services, as discussed below.

People who have experienced a suspected anaphylactic reaction or a severe non-immediate cutaneous reaction

The GDG considered this to be an issue of patient safety: severe reactions need to be investigated and referral is necessary for appropriate future treatment to be identified. Appropriate investigation of an allergy after anaphylaxis or a severe non-immediate cutaneous reaction will allow safe treatments to be identified and given in future, and will therefore avoid the large cost and quality of life impacts of further reactions. The GDG agreed that these recommendations would be appropriate across drug allergy generally, and should not be restricted only to people who have had such severe reactions to beta-lactams. The GDG noted that this represents a small patient group, and is therefore not expected to have a large impact on resources.

People who need treatment for a disease which can only be treated by a beta-lactam

The GDG considered that referral was the only appropriate option for this group of patients as it is crucial to determine which drugs they can take safely. This is an issue of patient safety.

People with a high likelihood of future need for beta-lactams

The GDG discussed the economic implications of referral and non-referral. It was noted that if patients are not referred they typically remain under an assumed positive diagnosis and will in future be given second-line antibiotics which are often more expensive and less effective than first-line beta-lactams. Referral, on the other hand, leads to the cost of a specialist appointment and allergy investigations. If upon referral a patient is found not to have a drug allergy, they can return to taking the first-line treatment, and thus some savings and improvements in quality of life would be realised.

The GDG considered several hypothetical scenarios in which patients present with a range of infections for which beta-lactams are typically considered first-line treatments. The GDG considered the cost of a referral strategy compared to a non-specialist management strategy for each scenario, as well as the QALYs required for the referral strategy to be cost effective at a cost-effectiveness threshold of £20,000 per QALY gained. The GDG also discussed the limitations of this approach, notably that the analysis did not account for the higher rates of antibiotic resistance associated with some second-line treatments, nor did it quantitatively measure the decrease in quality of life associated with taking second-line treatments. The analysis was therefore considered to underestimate the benefits of referral.

The analysis confirmed that second-line treatments are often more expensive than first-line beta-lactams, and showed that a key driver of cost effectiveness was the number of times in an individual's life they would require beta-lactams. For example, a patient who has an acute throat infection and would only require beta-lactam treatment twice more over their lifetime would need to gain 0.0124 QALYs (or 4.52 quality-adjusted life days) from referral during each future treatment episode compared to treatment with second-line drugs, which was not considered likely. However, a patient with bronchiectasis who requires beta-lactams 20 times over their lifetime would only need to gain 0.0011 QALYs (or 0.41 quality adjusted life days) per treatment episode as a result of being referred for referral to be considered cost effective compared to treatment with second-line drugs. The GDG agreed that the QALY gain in the latter case would be likely to be reached. Therefore the GDG concluded that referral is likely to be cost effective for patients who

| | |
|---|---|
| | have a high likelihood of frequent need for beta-lactams. |
| | **People with suspected allergy to beta-lactams and another class of antibiotics** |
| | It is important to establish which antibiotics are safe for people in this population group to take. This can only be done reliably and safely through referral, therefore the GDG considered that referral was the only appropriate strategy for this group of patients, and is necessary to ensure patient safety. The GDG also noted that whilst there is a cost of referral, this will be partially offset by a reduction in the number of patients taking third-line treatments, which can be considerably more expensive, and could be counteracted by an increase in quality of life. |
| Quality of evidence | Overall the evidence is sparse and of very low quality and only provides indirect evidence to the question of benefits of referral and characteristics of people who might benefit from referral. |
| Other considerations | The aim of the review was to assess the benefit of referral and to determine who should be referred to specialist drug allergy services. As only indirect evidence was found the recommendations are based on the cost-effectiveness scenarios and the consensus view of the GDG. |
| | The GDG did not consider that patients who have a history of allergy should be automatically investigated unless a beta-lactam was the drug of choice and no suitable alternative was available. There is a case for investigating particular groups such as people with immune deficiencies or recurrent infections who have a greater need for antibiotic drugs. Similarly people with a history of adverse reactions or allergy to more than one class of antibiotic have a restricted choice of antibiotic and therefore specialist referral for this group was considered necessary as otherwise alternative antibiotics may be less effective, more expensive or have greater side effects. The GDG agreed that patients who are allergic to 2 or more classes of antibiotics also have increased anxiety and this may impact on their quality of life. The GDG also observed that alternative antibiotics are sometimes more complicated to administer and monitor and may sometimes require prolonged hospital admission for intravenous administration. |
| | The GDG noted that, in UK practice, it would not be usual to give cephalosporins (which have low levels of cross-reactivity with other beta-lactams) to people allergic to beta-lactams for pre-surgical prophylaxis; however they are used fairly widely on hospital wards. |

## 1 11.10    Recommendations and link to evidence: NSAIDs

2 **What is the clinical and cost effectiveness of referral to specialist drug allergy services for people**
3 **with suspected allergy to NSAIDs?**

| | |
|---|---|
| | **30.Refer to a specialist drug allergy service people who have had suspected allergic reactions to NSAIDs with symptoms such as severe angioedema or asthmatic reactions but who need treatment with an NSAID.** |
| | **31.Be aware that people with asthma who also have nasal polyps are likely to have NSAID-sensitive asthma unless they are known to have tolerated NSAIDs in the last 12 months.** |
| **Recommendations** | |
| Relative values of different | The following outcomes were identified by the GDG as important for |

| | |
|---|---|
| outcomes | decision-making: mortality, repeat drug allergic reactions, length of hospital stay, inappropriate avoidance of drugs, and health-related quality of life.<br><br>No clinical studies were identified for this question. |
| Trade-off between clinical benefits and harms | The GDG discussed the following benefits and harms associated with referral for NSAID allergies. This discussion was based on the experience of guideline members as no direct evidence was identified.<br><br>Although many people can avoid NSAIDs or take an alternative analgesic drug such as paracetamol or an opiate, some people require an NSAID for their anti-inflammatory properties. Someone who is allergic to one NSAID should be assumed to be allergic to all other non-selective NSAIDs as well, so should not take any without undergoing specialist investigations to assess which NSAIDs can be safely taken.<br><br>Those people who have experienced only a mild reaction to a non-selective NSAID should be recommended to take a selective COX-2 inhibitor (see Chapter 10). For those who have experienced a severe reaction and for whom an NSAID would be the preferred treatment option referral is required to determine which NSAID(s) may be safely taken. The GDG noted that patients are also extremely anxious after experiencing a severe reaction and confirmation of whether they can use an NSAID again, now or in the future, can have benefits for the person's quality of life. |
| Economic considerations | No relevant economic evidence was identified.<br><br>People who have had a suspected allergic reaction with severe symptoms and require treatment with NSAIDs<br><br>No cost-effectiveness evidence was identified. The GDG discussed the economic implications of referral compared to a non-specialist management strategy; it was noted that if patients are not referred they typically remain under an assumed positive diagnosis and are given alternative treatments. The GDG therefore considered the unit costs of NSAIDs and their alternatives. The cost differences between these are small, with alternatives being cheaper in some cases, and referral comes at a much higher cost. The GDG considered that in some cases the alternative treatments are not as effective, and therefore referral may lead to gains in quality of life (many patients are found not to be allergic following specialist investigation and can resume taking any NSAID). It was also noted that the cost of referral to a drug allergy specialist would only be incurred once, yet the benefits of a confirmed diagnosis would be felt on multiple occasions during a lifetime.<br><br>The GDG agreed that when NSAIDs are required and selective COX-2 inhibitors cannot be taken the quality of life gained from through referral by identifying NSAID(s) which are safe to take are likely to be substantial, and referral is likely to be cost effective. The GDG noted that this represents only a small group of patients, as alternatives painkillers or selective COX-2 inhibitors can be given in the majority of cases, meaning that non-selective NSAIDs are usually not required. The GDG judged that it would not be cost effective to refer people who do not require treatment with NSAIDs.<br><br>Patients with asthma and nasal polyps<br><br>It is believed that people with asthma who also have nasal polyps are likely to be intolerant of NSAIDs. The GDG agreed that, as with the general population, referral would only be cost effective for this group if NSAIDs were required for treatment. In the majority of cases an alternative painkiller could be given instead. |
| Quality of evidence | No relevant studies were identified for this clinical question. |

| Other considerations | The recommendations are based on the consensus of the GDG. |
|---|---|
| | The GDG were aware of asthma patients being admitted to hospital because they had taken an NSAID and agreed that it is important to ensure this group of patients receive appropriate information to prevent repeated reactions potentially leading to readmission and patient death. The GDG estimated that 5–10% of people with asthma are affected, but agreed further investigation through a drug challenge was not always necessary. People with asthma who have had a reaction to an NSAID should have this flagged within their notes and the patient informed that they should avoid the use of all NSAIDs in future. |
| | The GDG were aware that advice provided to all patients with asthma is generally to avoid using an NSAID. However, the group agreed that the presence of particular comorbidities can identify those asthma patients at a higher level of risk such as the presence of chronic rhinosinusitis, a history of nasal polyps, or eosinophilia. The GDG believed that these patients should be provided with written advice on avoidance of NSAIDs but that they should be referred to specialist drug allergy services only if NSAIDs were required for future management of an existing condition. |

# 11.11 Recommendations and link to evidence: local anaesthetics

**What is the clinical and cost effectiveness of referral to specialist drug allergy services for people with suspected allergy to local anaesthetics?**

| Recommendations | **32. Refer to a specialist drug allergy service people who need procedures involving local anaesthetics but are unable to have them because of previous suspected allergic reactions to local anaesthetics.** |
|---|---|
| Relative values of different outcomes | The following outcomes were identified by the GDG as important for decision-making: mortality, repeat drug allergic reactions, length of hospital stay, inappropriate avoidance of drugs, and health-related quality of life. |
| | No evidence was found for these outcomes in this review. |
| Trade-off between clinical benefits and harms | In the absence of direct evidence for this review questions recommendations were based on GDG consensus. |
| | A patient who has experienced a suspected drug allergic reaction following the previous use of a local anaesthetic would in some cases be able to receive an alternative local anaesthetic from a different class. |
| | However, the healthcare professional (doctor, dentist or anaesthetist) concerned may not recommend an alternative local anaesthetic, depending on which alternative drugs would be appropriate for the required usage and the severity of the previous reaction. In addition some people may be unwilling to receive an alternative local anaesthetic due to their previous experience, even if informed that the likelihood of a reaction with a different class of drug is low. |
| | In the case of most procedures using local anaesthetics, the alternative to using a different local anaesthetic is to carry out the procedure under general anaesthesia, although it is noted that in the case of some dental procedures some individuals may choose to undergo the procedure without any anaesthetic. |
| | Procedures carried out under general anaesthesia are likely to have similar clinical outcomes, but longer recovery times and an increased rate of adverse events. Dental procedures carried out without anaesthetic will |

| | result in increased pain for the individual. |
|---|---|
| Economic considerations | No relevant economic evidence was identified. |
| | The GDG considered the cost of referral to a specialist and weighed this against the alternative strategy of no referral, in which the patient remains under an assumed positive diagnosis. The GDG judged that if a patient was unable to undergo a procedure with local anaesthetic due to a suspected allergy they may suffer substantial decreases in quality of life, or be referred for the procedure under general anaesthetic at a much greater cost. The GDG therefore agreed that in such cases it would be very likely to be cost effective to refer patients to a specialist drug allergy service, as this would allow identification of local anaesthetics which would be safe for the individual to use, thereby avoiding the substantial impact on quality of life of non-treatment or the increased costs of general anaesthetic. The GDG highlighted that patients may need local anaesthetics multiple times over their lifetime, and whilst the cost of referral to a drug allergy specialist would only be incurred once, the benefits of a confirmed diagnosis could be realised on multiple occasions. |
| | For those people who are able and willing to receive an alternative local anaesthetic there is no need for referral to a specialist service, and so referral would not be a cost effective strategy. |
| Quality of evidence | No relevant studies were identified for this clinical question. |
| Other considerations | GPs do not have the tools to enable them to determine if a patient has an allergy to one or more local anaesthetics. The only way of determining this is to refer to specialist drug allergy services for investigation. |
| | In the majority of suspected cases of allergy the patient is found not to be allergic when investigations have been completed and will therefore be able to take the same local anaesthetic. In most other cases the investigation will conclude that the patient may safely take an alternative local anaesthetic. Referral to specialist care therefore enables patients to receive treatment with local anaesthetic as planned, without the need for general anaesthesia. |
| | The GDG agreed it is inappropriate to advise a general anaesthetic on the basis of a previous suspected allergic reaction to a local anaesthetic that has not been investigated. |

## 11.12 Recommendations and link to evidence: general anaesthesia

**What is the clinical and cost effectiveness of referral to specialist drug allergy services for people with suspected anaphylaxis due to drug allergy during general anaesthesia?**

| Recommendations | 33. Refer to a specialist drug allergy service people who have had a suspected allergic reaction or anaphylaxis during or immediately after general anaesthesia. |
|---|---|
| Relative values of different outcomes | The following outcomes were identified by the GDG as important for decision-making: mortality, repeat drug allergic reactions, length of hospital stay, inappropriate avoidance of drugs, and health-related quality of life. |
| | No evidence was found for these outcomes in this review. |
| Trade-off between clinical benefits and harms | In the absence of evidence the GDG discussed risks and benefits based on their experience. |
| | If a patient has experienced a suspected allergic reaction or anaphylaxis to a drug during or immediately following general anaesthesia, then it is not safe for the patient to undergo further general anaesthesia until the patient has |

| | |
|---|---|
| | undergone investigation to determine the cause of the reaction and an alternative combination of drugs is identified that may be safely administered to the patient. |
| | Referral to specialist care therefore gives benefit in enabling treatment for the original condition to be completed, enabling the patient to undergo procedures under general anaesthesia in future, and in reducing anxiety or stress induced in the patient by uncertainty regarding their condition and concern that they would be unable to undergo emergency procedures in future. These are substantial benefits and most likely outweigh the potential risk of having an allergic reaction to the tests used in specialist investigations. |
| Economic considerations | No relevant economic evidence was identified. |
| | The GDG stressed that this is an issue of patient safety. It is crucial to establish whether or not an individual is allergic to general anaesthesia as there is often no alternative, and this can only be accurately determined through referral to specialist drug allergy services. |
| | The GDG also noted that suspected allergy to general anaesthesia can lead to cancelled or postponed surgery or to prolonged hospital stays, either of which would have a large impact on both hospital costs and quality of life. Some people may require general anaesthesia more than once over their lifetime; the cost of referral to a drug allergy specialist would only be incurred once, whilst the benefits of a confirmed diagnosis could be realised on multiple occasions. The GDG therefore considered that referral is very likely to be cost effective for people with a suspected allergy to general anaesthesia. |
| Quality of evidence | No relevant clinical studies were identified for this review question. |
| Other considerations | A large proportion of people will require general anaesthesia at some point in their lives, often in an emergency situation, and in most cases such procedures have no alternative to general anaesthesia. Consequently, if the cause of a suspected allergic reaction or anaphylaxis is not investigated then the patient is at risk of being unable to receive necessary emergency treatment at some future point in their life. |
| | In addition, in many cases where a patient experiences anaphylaxis or a suspected allergic reaction during general anaesthesia the procedure will immediately be terminated, and a further procedure under general anaesthesia may hence be required to complete the original treatment. |
| | GPs do not have diagnostic tools to enable them to determine if a patient has an allergy to a drug used in general anaesthesia, or to which of the drugs involved the patient is allergic. The only way of determining this is to refer the patient for investigation by drug allergy specialists. The investigation will normally conclude that the patient may undergo general anaesthetic using an alternative combination of drugs which have been found to be safe for that person. There is limited availability of specialists who can comprehensively investigate allergic drug reactions during general anaesthesia and the GDG noted the particular requirement for highly specialised investigation. |
| | The GDG noted that lesser reactions should also be referred, not just life-threatening reactions, and recognised that in current practice a referral may sometimes not be made due to a problem not being identified or lack of knowledge regarding where referrals should be directed. The GDG recognised that it is likely that there is currently under-referral of people with reactions during anaesthesia. |

1

2

# 12 Acronyms and glossaries of terms used in the guideline

## 12.1 Acronyms and abbreviations

| Acronym or abbreviation | Description |
|---|---|
| ADE | Adverse drug event |
| ADR | Adverse drug reaction |
| AMP | Ampicillin |
| AX | Amoxicillin |
| AXO | Amoxicilloyl c6 |
| BP | Benzyl penicillin |
| BPO | Benzylpenicilloyl c1 |
| CAP | Pharmacia CAP system |
| CDS | Clinical decision support |
| CDR | Challenge–dechallenge–rechallenge |
| COX-1 | Cyclooxygenase 1 |
| COX-2 | Cyclooxygenase 2 |
| CPOE | Computerised physician (or prescriber) order entry |
| DST | Decision support tool |
| ED | Emergency department |
| EID | Extent of information desired |
| FEIA | Fluoroenzymoimmunoassay |
| FN | False negative |
| FP | False positive |
| HOAP | History of allergy to penicillin |
| ICD | International Classification of Diseases |
| IgE | Immunoglobulin E |
| MDM | Minor determinant mixture |
| MPE | Medication prescribing error |
| NMBA | Neuromuscular blocking agent |
| NPV | Negative predictive value |
| NRLS | The National Reporting and Learning System |
| NSAIDs | Non-steroidal anti-inflammatory drugs |
| OPES | Other preoperative evaluation settings |
| POABP | Perioperative antibacterial prophylaxis |
| POEC | Preoperative Evaluation Clinic |
| PPV | Positive predictive value |
| QALY | Quality-adjusted life year |
| QALD | Quality-adjusted life day |
| QUADAS-2 | Quality Assessment of Diagnostic Accuracy Studies checklist |
| RAST | A radioallergosorbent test |
| RIA | Radioimmunoassay |
| SD | Standard deviation |

| Acronym or abbreviation | Description |
|---|---|
| SPL | Structured Product Labelling |
| TEN | Toxic epidermal necrolysis |
| TN | True positive |
| TP | True negative |

## 12.2 Glossary of medical terms

| Term | Definition |
|---|---|
| Allergological | Relating to the study of allergies. |
| Anaphylaxis | A serious allergic reaction that is rapid in onset and may cause death. It typically causes a number of symptoms including an itchy rash, throat swelling, and low blood pressure. Common causes include insect bites and stings, foods, and medications. |
| Angioedema | The rapid swelling (oedema) of the dermis, subcutaneous tissue, mucosa and submucosal tissues. |
| Bronchospasm | A sudden constriction of the muscles in the walls of the bronchioles. It is caused by the release (degranulation) of substances from mast cells or basophils under the influence of anaphylatoxins. It causes difficulty in breathing which can be mild to severe. |
| Cutaneous | Relating to, or affecting the skin. |
| Dechallenge | A medical testing protocol in which an administered medicine or drug is withdrawn while the patient is being monitored for adverse effects at each stage |
| Eosinophilic asthma | A type of asthma that is characterised by increased levels of eosinophils (a type of white blood cell) in the airways. |
| Exanthemic | A disease or condition, accompanied by a skin eruption. |
| Extrapyramidal effects or symptoms | Extrapyramidal symptoms (EPS) are various movement disorders such as acute dystonic reactions, pseudoparkinsonism, or akathisia suffered as a result of taking dopamine antagonists, usually antipsychotic (neuroleptic) drugs, which are often used to control psychosis. It can also be a symptom of a metabolic disease. |
| Hypotension | Low blood pressure, especially in the arteries of the systemic circulation. |
| IgE | Immunoglobulin E (IgE) is an antibody related to allergic reactions present in the blood, usually in very low concentrations or found on the surface of cells such as mast cells. |
| IgE testing | A test that measures the blood level of IgE, 1 of the 5 subclasses of antibodies. The IgE test is often performed as part of an initial screen for allergies. |
| IgE-mediated | Immunoglobulin E (IgE) is an antibody present in the blood, usually in small concentrations. When triggered by an allergen (usually proteins in certain food) the body releases antibodies to fight what it thinks are offending cells. This leads to an increase in histamine levels in the body and the classic allergic reactions (such as inflammation of the face and limbs and anaphylaxis). This reaction can be measured by blood tests as there will be an increase of IgE levels in the blood; these are known as IgE-mediated allergies. |
| Maculopapular | A maculopapular rash is a type of rash characterised by a flat, red area on the skin that is covered with small confluent bumps. |
| Nasal polyps | Abnormal tissue growths that grow inside the nasal passages and sinuses. |

| Term | Definition |
|---|---|
| Naso-ocular | Of or pertaining to the nose and eyes. |
| Non-IgE-mediated | In non-IgE allergies the person suffers with some of the same symptoms, but does not make IgE antibodies against the allergens. |
| Parmacia Uni CAP FEIA system | Serum Allergy Test |
| Peri-anesthetic anaphylaxis | Anaphylaxis during surgical and interventional procedures involving anesthetic. |
| Pharmacia CAP system | New solid-phase immunoassay, fully automated, used for the volumetric analysis of specific IgE antibodies. |
| Pharmacovigilance | Also known as Drug Safety, is the pharmacological science relating to the collection, detection, assessment, monitoring, and prevention of adverse effects with pharmaceutical products. |
| Prostaglandin pathway | The route of alteration and chemical breakdown of prostaglandins in the human body. |
| Radioallergosorbent test (REIA) | A blood test used to determine to what substances a person is allergic. |
| Rechallenge | A medical testing protocol in which an administered medicine or drug is re-administered while the patient is being monitored for adverse effects at each stage |
| Rhinosinusitis | Inflammation of the para-nasal sinuses. It can be due to infection, allergy, or autoimmune problems. |
| Serum tryptase | Tryptase is a trypsin-like proteinase that is most abundant in human mast cells and basophils. |
| Skin prick tests | The skin prick test introduces a tiny amount of allergen into the skin, eliciting a small, localised allergic response, in the form of a wheal (bump) and flare (redness) at the site of testing. |
| Stevens–Johnson syndrome | A life-threatening skin condition, in which cell death causes the epidermis to separate from the dermis. The syndrome is thought to be a hypersensitivity complex that affects the skin and the mucous membranes. The most well-known causes are certain medications, but it can also be due to infections, or more rarely, cancers. |
| Tachpnoea | Also known as or related to hyperpnoea, rapid respiration, rapid shallow breathing, breathing fast, tachypneic, respiratory rate raised |
| Tryptase | The most abundant secretory granule-derived serine proteinase contained in mast cells and has been used as a marker for mast cell activation. |
| UniCAP | A highly sensitive laboratory method for detection of serum tryptase using fluorescence linked to an antibody |
| Urticaria | Urticaria (also known as hives, welts or nettle rash) is a raised, itchy rash that appears on the skin. The rash can be limited to one part of the body or spread across large areas of the body. |
| Viral exanthems | A widespread rash usually occurring in children. Exanthems can be caused by toxins or drugs, microorganisms, or can result from autoimmune disease. |

1

## 12.3 Glossary of methodological terms

| Term | Definition |
|---|---|
| Abstract | Summary of a study, which may be published alone or as an introduction to a full scientific paper. |

| Term | Definition |
|---|---|
| Algorithm (in guidelines) | A flow chart of the clinical decision pathway described in the guideline, where decision points are represented with boxes, linked with arrows. |
| Allocation concealment | The process used to prevent advance knowledge of group assignment in an RCT. The allocation process should be impervious to any influence by the individual making the allocation, by being administered by someone who is not responsible for recruiting participants. |
| Applicability | How well the results of a study or NICE evidence review can answer a clinical question or be applied to the population being considered. |
| Arm (of a clinical study) | Subsection of individuals within a study who receive a particular intervention, for example placebo arm |
| Association | Statistical relationship between 2 or more events, characteristics or other variables. The relationship may or may not be causal. |
| Baseline | The initial set of measurements at the beginning of a study (after run-in period where applicable), with which subsequent results are compared. |
| Before-and-after study | A study that investigates the effects of an intervention by measuring particular characteristics of a population both before and after taking the intervention, and assessing any change that occurs. |
| Bias | Influences on a study that can make the results look better or worse than they really are. (Bias can even make it look as if a treatment works when it does not.) Bias can occur by chance, deliberately or as a result of systematic errors in the design and execution of a study. It can also occur at different stages in the research process, for example, during the collection, analysis, interpretation, publication or review of research data. For examples see selection bias, performance bias, information bias, confounding factor, and publication bias. |
| Blinding | A way to prevent researchers, doctors and patients in a clinical trial from knowing which study group each patient is in so they cannot influence the results. The best way to do this is by sorting patients into study groups randomly. The purpose of 'blinding' or 'masking' is to protect against bias. A single-blinded study is one in which patients do not know which study group they are in (for example whether they are taking the experimental drug or a placebo). A double-blinded study is one in which neither patients nor the researchers or doctors know which study group the patients are in. A triple blind study is one in which neither the patients, clinicians or the people carrying out the statistical analysis know which treatment patients received. |
| Carer (caregiver) | Someone who looks after family, partners or friends in need of help because they are ill, frail or have a disability. |
| Case–control study | A study to find out the cause(s) of a disease or condition. This is done by comparing a group of patients who have the disease or condition (cases) with a group of people who do not have it (controls) but who are otherwise as similar as possible (in characteristics thought to be unrelated to the causes of the disease or condition). This means the researcher can look for aspects of their lives that differ to see if they may cause the condition. For example, a group of people with lung cancer might be compared with a group of people the same age that do not have lung cancer. The researcher could compare how long both groups had been exposed to tobacco smoke. Such studies are retrospective because they look back in time from the outcome to the possible causes of a disease or condition. |
| Case series | Report of a number of cases of a given disease, usually covering the course of the disease and the response to treatment. There is no comparison (control) group of patients. |

| Term | Definition |
|------|------------|
| Clinical efficacy | The extent to which an intervention is active when studied under controlled research conditions. |
| Clinical effectiveness | How well a specific test or treatment works when used in the 'real world' (for example, when used by a doctor with a patient at home), rather than in a carefully controlled clinical trial. Trials that assess clinical effectiveness are sometimes called management trials.<br>Clinical effectiveness is not the same as efficacy. |
| Clinician | A healthcare professional that provides patient care. For example, a doctor, nurse or physiotherapist. |
| Cochrane Review | The Cochrane Library consists of a regularly updated collection of evidence-based medicine databases including the Cochrane Database of Systematic Reviews (reviews of randomised controlled trials prepared by the Cochrane Collaboration). |
| Cohort study | A study with 2 or more groups of people – cohorts – with similar characteristics. One group receives a treatment, is exposed to a risk factor or has a particular symptom and the other group does not. The study follows their progress over time and records what happens. See also observational study. |
| Comorbidity | A disease or condition that someone has in addition to the health problem being studied or treated. |
| Comparability | Similarity of the groups in characteristics likely to affect the study results (such as health status or age). |
| Concordance | This is a recent term whose meaning has changed. It was initially applied to the consultation process in which doctor and patient agree therapeutic decisions that incorporate their respective views, but now includes patient support in medicine taking as well as prescribing communication. Concordance reflects social values but does not address medicine-taking and may not lead to improved adherence. |
| Confidence interval (CI) | There is always some uncertainty in research. This is because a small group of patients is studied to predict the effects of a treatment on the wider population. The confidence interval is a way of expressing how certain we are about the findings from a study, using statistics. It gives a range of results that is likely to include the 'true' value for the population.<br>The CI is usually stated as '95% CI', which means that the range of values has a 95 in a 100 chance of including the 'true' value. For example, a study may state that 'based on our sample findings, we are 95% certain that the 'true' population blood pressure is not higher than 150 and not lower than 110'. In such a case the 95% CI would be 110 to 150.<br>A wide confidence interval indicates a lack of certainty about the true effect of the test or treatment – often because a small group of patients has been studied. A narrow confidence interval indicates a more precise estimate (for example, if a large number of patients have been studied). |
| Confounding factor | Something that influences a study and can result in misleading findings if it is not understood or appropriately dealt with.<br>For example, a study of heart disease may look at a group of people that exercises regularly and a group that does not exercise. If the ages of the people in the 2 groups are different, then any difference in heart disease rates between the 2 groups could be because of age rather than exercise. Therefore age is a confounding factor. |
| Consensus methods | Techniques used to reach agreement on a particular issue. Consensus methods may be used to develop NICE guidance if there is not enough good quality research evidence to give a clear answer to a question. Formal consensus methods include Delphi and nominal group techniques. |

| Term | Definition |
|---|---|
| Control group | A group of people in a study who do not receive the treatment or test being studied. Instead, they may receive the standard treatment (sometimes called 'usual care') or a dummy treatment (placebo). The results for the control group are compared with those for a group receiving the treatment being tested. The aim is to check for any differences.<br><br>Ideally, the people in the control group should be as similar as possible to those in the treatment group, to make it as easy as possible to detect any effects due to the treatment. |
| Cost–benefit analysis (CBA) | Cost–benefit analysis is one of the tools used to carry out an economic evaluation. The costs and benefits are measured using the same monetary units (for example, pounds sterling) to see whether the benefits exceed the costs. |
| Cost–consequences analysis (CCA) | Cost–consequences analysis is one of the tools used to carry out an economic evaluation. This compares the costs (such as treatment and hospital care) and the consequences (such as health outcomes) of a test or treatment with a suitable alternative. Unlike cost–benefit analysis or cost-effectiveness analysis, it does not attempt to summarise outcomes in a single measure (like the quality-adjusted life year) or in financial terms. Instead, outcomes are shown in their natural units (some of which may be monetary) and it is left to decision-makers to determine whether, overall, the treatment is worth carrying out. |
| Cost-effectiveness analysis (CEA) | Cost-effectiveness analysis is one of the tools used to carry out an economic evaluation. The benefits are expressed in non-monetary terms related to health, such as symptom-free days, heart attacks avoided, deaths avoided or life years gained (that is, the number of years by which life is extended as a result of the intervention). |
| Cost-effectiveness model | An explicit mathematical framework, which is used to represent clinical decision problems and incorporate evidence from a variety of sources in order to estimate the costs and health outcomes. |
| Cost–utility analysis (CUA) | Cost–utility analysis is one of the tools used to carry out an economic evaluation. The benefits are assessed in terms of both quality and duration of life, and expressed as quality-adjusted life years (QALYs). See also utility. |
| Credible interval (CrI) | The Bayesian equivalent of a confidence interval. |
| Decision analysis | An explicit quantitative approach to decision-making under uncertainty, based on evidence from research. This evidence is translated into probabilities, and then into diagrams or decision trees which direct the clinician through a succession of possible scenarios, actions and outcomes. |
| Discounting | Costs and perhaps benefits incurred today have a higher value than costs and benefits occurring in the future. Discounting health benefits reflects individual preference for benefits to be experienced in the present rather than the future. Discounting costs reflects individual preference for costs to be experienced in the future rather than the present. |
| Dominance | A health economics term. When comparing tests or treatments, an option that is both less effective and costs more is said to be 'dominated' by the alternative. |
| Drop-out | A participant who withdraws from a trial before the end. |
| Economic evaluation | An economic evaluation is used to assess the cost effectiveness of healthcare interventions (that is, to compare the costs and benefits of a healthcare intervention to assess whether it is worth doing). The aim of an economic evaluation is to maximise the level of benefits – health effects – relative to the resources available. It should be used to inform and support the decision-making process; it is not supposed to replace the judgement of healthcare professionals. |

| Term | Definition |
|---|---|
|  | There are several types of economic evaluation: cost–benefit analysis, cost–consequences analysis, cost-effectiveness analysis, cost–minimisation analysis and cost–utility analysis. They use similar methods to define and evaluate costs, but differ in the way they estimate the benefits of a particular drug, programme or intervention. |
| Effect<br>(as in effect measure, treatment effect, estimate of effect, effect size) | A measure that shows the magnitude of the outcome in one group compared with that in a control group.<br>For example, if the absolute risk reduction is shown to be 5% and it is the outcome of interest, the effect size is 5%.<br>The effect size is usually tested, using statistics, to find out how likely it is that the effect is a result of the treatment and has not just happened by chance (that is, to see if it is statistically significant). |
| Effectiveness | How beneficial a test or treatment is under usual or everyday conditions, compared with doing nothing or opting for another type of care. |
| Efficacy | How beneficial a test, treatment or public health intervention is under ideal conditions (for example, in a laboratory), compared with doing nothing or opting for another type of care. |
| Epidemiological study | The study of a disease within a population, defining its incidence and prevalence and examining the roles of external influences (for example, infection, diet) and interventions. |
| EQ-5D (EuroQol 5 dimensions) | A standardised instrument used to measure health-related quality of life. It provides a single index value for health status. |
| Evidence | Information on which a decision or guidance is based. Evidence is obtained from a range of sources including randomised controlled trials, observational studies, expert opinion (of clinical professionals or patients). |
| Exclusion criteria (literature review) | Explicit standards used to decide which studies should be excluded from consideration as potential sources of evidence. |
| Exclusion criteria (clinical study) | Criteria that define who is not eligible to participate in a clinical study. |
| Extended dominance | If Option A is both more clinically effective than Option B and has a lower cost per unit of effect, when both are compared with a do-nothing alternative then Option A is said to have extended dominance over Option B. Option A is therefore more cost effective and should be preferred, other things remaining equal. |
| Extrapolation | An assumption that the results of studies of a specific population will also hold true for another population with similar characteristics. |
| Follow-up | Observation over a period of time of an individual, group or initially defined population whose appropriate characteristics have been assessed in order to observe changes in health status or health-related variables. |
| Generalisability | The extent to which the results of a study hold true for groups that did not participate in the research. See also external validity. |
| Gold standard | A method, procedure or measurement that is widely accepted as being the best available to test for or treat a disease. |
| GRADE, GRADE profile | A system developed by the GRADE Working Group to address the shortcomings of present grading systems in healthcare. The GRADE system uses a common, sensible and transparent approach to grading the quality of evidence. The results of applying the GRADE system to clinical trial data are displayed in a table known as a GRADE profile. |
| Harms | Adverse effects of an intervention. |
| Health economics | Study or analysis of the cost of using and distributing healthcare resources. |
| Health-related quality of life | A measure of the effects of an illness to see how it affects someone's day- |

| Term | Definition |
|------|-----------|
| (HRQoL) | to-day life. |
| Heterogeneity or Lack of homogeneity | The term is used in meta-analyses and systematic reviews to describe when the results of a test or treatment (or estimates of its effect) differ significantly in different studies. Such differences may occur as a result of differences in the populations studied, the outcome measures used or because of different definitions of the variables involved. It is the opposite of homogeneity. |
| Imprecision | Results are imprecise when studies include relatively few patients and few events and thus have wide confidence intervals around the estimate of effect. |
| Inclusion criteria (literature review) | Explicit criteria used to decide which studies should be considered as potential sources of evidence. |
| Incremental analysis | The analysis of additional costs and additional clinical outcomes with different interventions. |
| Incremental cost | The extra cost linked to using one test or treatment rather than another. Or the additional cost of doing a test or providing a treatment more frequently. |
| Incremental cost-effectiveness ratio (ICER) | The difference in the mean costs in the population of interest divided by the differences in the mean outcomes in the population of interest for one treatment compared with another. |
| Incremental net benefit (INB) | The value (usually in monetary terms) of an intervention net of its cost compared with a comparator intervention. The INB can be calculated for a given cost-effectiveness (willingness to pay) threshold. If the threshold is £20,000 per QALY gained then the INB is calculated as: (£20,000 × QALYs gained) minus Incremental cost. |
| Indirectness | The available evidence is different to the review question being addressed, in terms of PICO (population, intervention, comparison and outcome). |
| Intention-to-treat analysis (ITT) | An assessment of the people taking part in a clinical trial, based on the group they were initially (and randomly) allocated to. This is regardless of whether or not they dropped out, fully complied with the treatment or switched to an alternative treatment. Intention-to-treat analyses are often used to assess clinical effectiveness because they mirror actual practice: that is, not everyone complies with treatment and the treatment people receive may be changed according to how they respond to it. |
| Intervention | In medical terms this could be a drug treatment, surgical procedure, diagnostic or psychological therapy. Examples of public health interventions could include action to help someone to be physically active or to eat a more healthy diet. |
| Intraoperative | The period of time during a surgical procedure. |
| Kappa statistic | A statistical measure of inter-rater agreement that takes into account the agreement occurring by chance. |
| Length of stay | The total number of days a participant stays in hospital. |
| Licence | See 'Product licence'. |
| Life years gained | Mean average years of life gained per person as a result of the intervention compared with an alternative intervention. |
| Likelihood ratio | The likelihood ratio combines information about the sensitivity and specificity. It tells you how much a positive or negative result changes the likelihood that a patient would have the disease. The likelihood ratio of a positive test result (LR+) is sensitivity divided by (1 minus specificity). |
| Long-term care | Residential care in a home that may include skilled nursing care and help with everyday activities. This includes nursing homes and residential homes. |
| Loss to follow up | Participants in a study who were lost to follow up. |

| Term | Definition |
|---|---|
| Markov model | A method for estimating long-term costs and effects for recurrent or chronic conditions, based on health states and the probability of transition between them within a given time period (cycle). |
| Meta-analysis | A method often used in systematic reviews. Results from several studies of the same test or treatment are combined to estimate the overall effect of the treatment. |
| Multivariate model | A statistical model for analysis of the relationship between 2 or more predictor (independent) variables and the outcome (dependent) variable. |
| Negative predictive value (NPV) | In screening or diagnostic tests: A measure of the usefulness of a screening or diagnostic test. It is the proportion of those with a negative test result who do not have the disease, and can be interpreted as the probability that a negative test result is correct. |
| Number needed to treat (NNT) | The average number of patients who need to be treated to get a positive outcome. For example, if the NNT is 4, then 4 patients would have to be treated to ensure 1 of them gets better. The closer the NNT is to 1, the better the treatment.

For example, if you give a stroke prevention drug to 20 people before 1 stroke is prevented, the number needed to treat is 20. See also number needed to harm, absolute risk reduction. |
| Observational study | Individuals or groups are observed or certain factors are measured. No attempt is made to affect the outcome. For example, an observational study of a disease or treatment would allow 'nature' or usual medical care to take its course. Changes or differences in one characteristic (for example, whether or not people received a specific treatment or intervention) are studied without intervening.

There is a greater risk of selection bias than in experimental studies. |
| Odds ratio | Odds are a way to represent how likely it is that something will happen (the probability). An odds ratio compares the probability of something in one group with the probability of the same thing in another.

An odds ratio of 1 between 2 groups would show that the probability of the event (for example a person developing a disease, or a treatment working) is the same for both. An odds ratio greater than 1 means the event is more likely in the first group. An odds ratio less than 1 means that the event is less likely in the first group.

Sometimes probability can be compared across more than 2 groups – in this case, one of the groups is chosen as the 'reference category', and the odds ratio is calculated for each group compared with the reference category. For example, to compare the risk of dying from lung cancer for non-smokers, occasional smokers and regular smokers, non-smokers could be used as the reference category. Odds ratios would be worked out for occasional smokers compared with non-smokers and for regular smokers compared with non-smokers. See also confidence interval, relative risk, risk ratio. |
| Opportunity cost | The loss of other healthcare programmes displaced by investment in or introduction of another intervention. This may be best measured by the health benefits that could have been achieved had the money been spent on the next best alternative healthcare intervention. |
| Outcome | The impact that a test, treatment, policy, programme or other intervention has on a person, group or population. Outcomes from interventions to improve the public's health could include changes in knowledge and behaviour related to health, societal changes (for example, a reduction in crime rates) and a change in people's health and wellbeing or health status. In clinical terms, outcomes could include the number of patients who fully recover from an illness or the number of hospital admissions, and an |

| Term | Definition |
|------|-----------|
| | improvement or deterioration in someone's health, functional ability, symptoms or situation. Researchers should decide what outcomes to measure before a study begins. |
| P value | The p value is a statistical measure that indicates whether or not an effect is statistically significant.<br><br>For example, if a study comparing 2 treatments found that one seems more effective than the other, the p value is the probability of obtaining these results by chance. By convention, if the p value is below 0.05 (that is, there is less than a 5% probability that the results occurred by chance) it is considered that there probably is a real difference between treatments. If the p value is 0.001 or less (less than a 1% probability that the results occurred by chance), the result is seen as highly significant.<br><br>If the p value shows that there is likely to be a difference between treatments, the confidence interval describes how big the difference in effect might be. |
| Perioperative | The period from admission through surgery until discharge, encompassing the preoperative and postoperative periods. |
| Placebo | A fake (or dummy) treatment given to participants in the control group of a clinical trial. It is indistinguishable from the actual treatment (which is given to participants in the experimental group). The aim is to determine what effect the experimental treatment has had – over and above any placebo effect caused because someone has received (or thinks they have received) care or attention. |
| Polypharmacy | The use or prescription of multiple medications. |
| Positive predictive value (PPV) | In screening or diagnostic tests: A measure of the usefulness of a screening or diagnostic test. It is the proportion of those with a positive test result who have the disease, and can be interpreted as the probability that a positive test result is correct. |
| Postoperative | Pertaining to the period after patients leave the operating theatre, following surgery. |
| Post-test probability | In diagnostic tests: The proportion of patients with that particular test result who have the target disorder (post-test odds/[1 plus post-test odds]). |
| Power (statistical) | The ability to demonstrate an association when one exists. Power is related to sample size; the larger the sample size, the greater the power and the lower the risk that a possible association could be missed. |
| Preoperative | The period before surgery commences. |
| Pre-test probability | In diagnostic tests: The proportion of people with the target disorder in the population at risk at a specific time point or time interval. Prevalence may depend on how a disorder is diagnosed. |
| Primary care | Healthcare delivered outside hospitals. It includes a range of services provided by GPs, nurses, health visitors, midwives and other healthcare professionals and allied health professionals such as dentists, pharmacists and opticians. |
| Primary outcome | The outcome of greatest importance, usually the one in a study that the power calculation is based on. |
| Product licence | An authorisation from the MHRA to market a medicinal product. |
| Prognosis | A probable course or outcome of a disease. Prognostic factors are patient or disease characteristics that influence the course. Good prognosis is associated with low rate of undesirable outcomes; poor prognosis is associated with a high rate of undesirable outcomes. |
| Prospective study | A research study in which the health or other characteristic of participants is monitored (or 'followed up') for a period of time, with events recorded as |

| Term | Definition |
|------|------------|
| | they happen. This contrasts with retrospective studies. |
| Publication bias | Publication bias occurs when researchers publish the results of studies showing that a treatment works well and don't publish those showing it did not have any effect. If this happens, analysis of the published results will not give an accurate idea of how well the treatment works. This type of bias can be assessed by a funnel plot. |
| Quality of life | See 'Health-related quality of life'. |
| Quality-adjusted life year (QALY) | A measure of the state of health of a person or group in which the benefits, in terms of length of life, are adjusted to reflect the quality of life. One QALY is equal to 1 year of life in perfect health. |
| | QALYS are calculated by estimating the years of life remaining for a patient following a particular treatment or intervention and weighting each year with a quality of life score (on a scale of 0 to 1). It is often measured in terms of the person's ability to perform the activities of daily life, freedom from pain and mental disturbance. |
| Randomisation | Assigning participants in a research study to different groups without taking any similarities or differences between them into account. For example, it could involve using a random numbers table or a computer-generated random sequence. It means that each individual (or each group in the case of cluster randomisation) has the same chance of receiving each intervention. |
| Randomised controlled trial (RCT) | A study in which a number of similar people are randomly assigned to 2 (or more) groups to test a specific drug or treatment. One group (the experimental group) receives the treatment being tested, the other (the comparison or control group) receives an alternative treatment, a dummy treatment (placebo) or no treatment at all. The groups are followed up to see how effective the experimental treatment was. Outcomes are measured at specific times and any difference in response between the groups is assessed statistically. This method is also used to reduce bias. |
| RCT | See 'Randomised controlled trial'. |
| Receiver operated characteristic (ROC) curve | A graphical method of assessing the accuracy of a diagnostic test. Sensitivity is plotted against 1 minus specificity. A perfect test will have a positive, vertical linear slope starting at the origin. A good test will be somewhere close to this ideal. |
| Reference standard | The test that is considered to be the best available method to establish the presence or absence of the outcome – this may not be the one that is routinely used in practice. |
| Relative risk (RR) | The ratio of the risk of disease or death among those exposed to certain conditions compared with the risk for those who are not exposed to the same conditions (for example, the risk of people who smoke getting lung cancer compared with the risk for people who do not smoke). |
| | If both groups face the same level of risk, the relative risk is 1. If the first group had a relative risk of 2, subjects in that group would be twice as likely to have the event happen. A relative risk of less than one means the outcome is less likely in the first group. Relative risk is sometimes referred to as risk ratio. |
| Reporting bias | See 'Publication bias'. |
| Resource implication | The likely impact in terms of finance, workforce or other NHS resources. |
| Retrospective study | A research study that focuses on the past and present. The study examines past exposure to suspected risk factors for the disease or condition. Unlike prospective studies, it does not cover events that occur after the study group is selected. |

| Term | Definition |
|---|---|
| Review question | In guideline development, this term refers to the questions about treatment and care that are formulated to guide the development of evidence-based recommendations. |
| Secondary outcome | An outcome used to evaluate additional effects of the intervention deemed a priori as being less important than the primary outcomes. |
| Selection bias | Selection bias occurs if:<br><br>a) The characteristics of the people selected for a study differ from the wider population from which they have been drawn, or<br><br>b) There are differences between groups of participants in a study in terms of how likely they are to get better. |
| Sensitivity | How well a test detects the thing it is testing for.<br><br>If a diagnostic test for a disease has high sensitivity, it is likely to pick up all cases of the disease in people who have it (that is, give a 'true positive' result). But if a test is too sensitive it will sometimes also give a positive result in people who don't have the disease (that is, give a 'false positive').<br><br>For example, if a test were developed to detect if a woman is 6-months pregnant, a very sensitive test would detect everyone who was 6-months pregnant, but would probably also include those who are 5- and 7-months pregnant.<br><br>If the same test were more specific (sometimes referred to as having higher specificity), it would detect only those who are 6 months pregnant, and someone who was 5-months pregnant would get a negative result (a 'true negative'). But it would probably also miss some people who were 6-months pregnant (that is, give a 'false negative').<br><br>Breast screening is a 'real-life' example. The number of women who are recalled for a second breast screening test is relatively high because the test is very sensitive. If it were made more specific, people who don't have the disease would be less likely to be called back for a second test but more women who have the disease would be missed. |
| Sensitivity analysis | A means of representing uncertainty in the results of economic evaluations. Uncertainty may arise from missing data, imprecise estimates or methodological controversy. Sensitivity analysis also allows for exploring the generalisability of results to other settings. The analysis is repeated using different assumptions to examine the effect on the results.<br><br>One-way simple sensitivity analysis (univariate analysis): each parameter is varied individually in order to isolate the consequences of each parameter on the results of the study.<br><br>Multi-way simple sensitivity analysis (scenario analysis): 2 or more parameters are varied at the same time and the overall effect on the results is evaluated.<br><br>Threshold sensitivity analysis: the critical value of parameters above or below which the conclusions of the study will change are identified.<br><br>Probabilistic sensitivity analysis: probability distributions are assigned to the uncertain parameters and are incorporated into evaluation models based on decision analytical techniques (for example, Monte Carlo simulation). |
| Significance (statistical) | A result is deemed statistically significant if the probability of the result occurring by chance is less than 1 in 20 (p<0.05). |
| Specificity | The proportion of true negatives that are correctly identified as such. For example in diagnostic testing the specificity is the proportion of non-cases correctly diagnosed as non-cases.<br><br>See related term 'Sensitivity'.<br><br>In terms of literature searching a highly specific search is generally narrow and aimed at picking up the key papers in a field and avoiding a wide range |

| Term | Definition |
|---|---|
|  | of papers. |
| Stakeholder | An organisation with an interest in a topic that NICE is developing a clinical guideline or piece of public health guidance on. Organisations that register as stakeholders can comment on the draft scope and the draft guidance. Stakeholders may be:<br>• manufacturers of drugs or equipment<br>• national patient and carer organisations<br>• NHS organisations<br>• organisations representing healthcare professionals. |
| Systematic review | A review in which evidence from scientific studies has been identified, appraised and synthesised in a methodical way according to predetermined criteria. It may include a meta-analysis. |
| Time horizon | The time span over which costs and health outcomes are considered in a decision analysis or economic evaluation. |
| Treatment allocation | Assigning a participant to a particular arm of a trial. |
| Univariate | Analysis which separately explores each variable in a data set. |
| Utility | In health economics, a 'utility' is the measure of the preference or value that an individual or society places upon a particular health state. It is generally a number between 0 (representing death) and 1 (perfect health). The most widely used measure of benefit in cost–utility analysis is the quality-adjusted life year, but other measures include disability-adjusted life years (DALYs) and healthy year equivalents (HYEs). |

1
2

# 13 References

1   Abramson EL, Barron Y, Quaresimo J, Kaushal R. Electronic prescribing within an electronic health record reduces ambulatory prescribing errors. Joint Commission Journal on Quality and Patient Safety. 2011; 37(10):470-478

2   Academy of Medical Royal Colleges. i-care: information, communication and technology in the NHS. London. Academy of Medical Royal Colleges, 2013

3   Agbabiaka TB, Savovic J, Ernst E. Methods for causality assessment of adverse drug reactions: a systematic review. Drug Safety. 2008; 31(1):21-37

4   Andri L, Falagiani P. Safety of celecoxib in patients with cutaneous reactions due to ASA-NSAIDs intolerance. Allergologia Et Immunopathologia. 2007; 35(4):126-129

5   Arimone Y, Bidault I, Dutertre JP, Gerardin M, Guy C, Haramburu F et al. Updating the French method for the causality assessment of adverse drug reactions. Therapie. 2013; 68(2):69-76

6   Arnott J, Hesselgreaves H, Nunn AJ, Peak M, Pirmohamed M, Smyth RL et al. Enhancing communication about paediatric medicines: lessons from a qualitative study of parents' experiences of their child's suspected adverse drug reaction. PloS One. 2012; 7(10):e46022

7   Asero R. Etoricoxib challenge in patients with chronic urticaria with NSAID intolerance. Clinical and Experimental Dermatology. 2007; 32(6):661-663

8   Bates DW, Leape LL, Cullen DJ, Laird N, Petersen LA, Teich JM et al. Effect of computerized physician order entry and a team intervention on prevention of serious medication errors. JAMA. 1998; 280(15):1311-1316

9   Bates DW, Teich JM, Lee J, Seger D, Kuperman GJ, Ma'Luf N et al. The impact of computerized physician order entry on medication error prevention. Journal of the American Medical Informatics Association. 1999; 6(4):313-321

10  Bavbek S, Celik G, Ozer F, Mungan D, Misirligil Z. Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib. Journal of Asthma. 2004; 41(1):67-75

11  Bavbek S, Dursun AB, Dursun E, Eryilmaz A, Misirligil Z. Safety of meloxicam in aspirin-hypersensitive patients with asthma and/or nasal polyps. A challenge-proven study. International Archives of Allergy and Immunology. 2007; 142(1):64-69

12  Begaud B, Evreux JC, Jouglard J, Lagier G. [Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France]. Therapie. 1985; 40(2):111-118

13  Benahmed S, Picot MC, Hillaire-Buys D, Blayac JP, Dujols P, Demoly P. Comparison of pharmacovigilance algorithms in drug hypersensitivity reactions. European Journal of Clinical Pharmacology. 2005; 61(7):537-541

14  Benichou C, Danan G. Causality assessment in the European pharmaceutical industry: presentation of the preliminary results of a new method. Drug Information Journal. 1992; 26:589-592

15 Benkhaial A, Kaltschmidt J, Weisshaar E, Diepgen TL, Haefeli WE. Prescribing errors in patients with documented drug allergies: comparison of ICD-10 coding and written patient notes. Pharmacy World and Science. 2009; 31(4):464-472

16 Blanc S, Leuenberger P, Berger JP, Brooke EM, Schelling JL. Judgments of trained observers on adverse drug reactions. Clinical Pharmacology and Therapeutics. 1979; 25(5 Pt 1):493-498

17 Blanca M, Mayorga C, Torres MJ, Reche M, Moya MC, Rodriguez JL et al. Clinical evaluation of Pharmacia CAP System RAST FEIA amoxicilloyl and benzylpenicilloyl in patients with penicillin allergy. Allergy. 2001; 56(9):862-870

18 Bousquet PJ, Demoly P, Romano A, Aberer W, Bircher A, Blanca M et al. Pharmacovigilance of drug allergy and hypersensitivity using the ENDA-DAHD database and the GALEN platform. The Galenda project. Allergy. 2009; 64(2):194-203

19 Brown S, Black K, Mrochek S, Wood A, Bess T, Cobb J et al. RADARx: Recognizing, Assessing, and Documenting Adverse Rx events. Proceedings. 2000;101-105

20 Busto U, Naranjo CA, Sellers EM. Comparison of two recently published algorithms for assessing the probability of adverse drug reactions. British Journal of Clinical Pharmacology. 1982; 13(2):223-227

21 Butt TF, Cox AR, Lewis H, Ferner RE. Patient experiences of serious adverse drug reactions and their attitudes to medicines: a qualitative study of survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK. Drug Safety. 2011; 34(4):319-328

22 Butt TF, Cox AR, Oyebode JR, Ferner RE. Internet accounts of serious adverse drug reactions: a study of experiences of Stevens-Johnson syndrome and toxic epidermal necrolysis. Drug Safety. 2012; 35(12):1159-1170

23 Caimmi S, Caimmi D, Bousquet PJ, Demoly P. How can we better classify NSAID hypersensitivity reactions?--validation from a large database. International Archives of Allergy and Immunology. 2012; 159(3):306-312

24 Castle WM. Assessment of causality in industrial settings. Drug Information Journal. 1984; 18:297-302

25 Celik G, Pasaoglu G, Bavbek S, Abadoglu O, Dursun AB, Mungan D et al. Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance. Journal of Asthma. 2005; 42(2):127-131

26 Colanardi MC, Nettis E, Traetta P, Daprile C, Fitto C, Aloia AM et al. Safety of parecoxib in patients with nonsteroidal anti-inflammatory drug-induced urticaria or angioedema. Annals of Allergy, Asthma and Immunology. 2008; 100(1):82-85

27 Colpaert K, Claus B, Somers A, Vandewoude K, Robays H, Decruyenaere J. Impact of computerized physician order entry on medication prescription errors in the intensive care unit: a controlled cross-sectional trial. Critical Care. 2006; 10(1):R21

28 Confino-Cohen R, Goldberg A. Safe full-dose one-step nabumetone challenge in patients with nonsteroidal anti-inflammatory drug hypersensitivity. Allergy and Asthma Proceedings. 2003; 24(4):281-284

29 Coombes ID, Stowasser DA, Reid C, Mitchell CA. Impact of a standard medication chart on prescribing errors: a before-and-after audit. Quality and Safety in Health Care. 2009; 18(6):478-485

30 Cornelli U. The phase IV monitoring studies: example of Na-proxen Na multi-centre Italian trial. In: Crescioni C, James JM (eds), Postmarketing clinical trials - the phase V studies, Paris: Editions de Sante, 1984: 89-105

31 Danan G, Benichou C. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. Journal of Clinical Epidemiology. 1993; 46(11):1323-1330

32 Dangoumau J, Evreux JC, Jouglard J. Method for determination of undesirable effects of drugs. Therapie. 1978; 33:373-381

33 Department of Health. NHS reference costs 2011-2012. 2013. Available from: https://www.gov.uk/government/publications/nhs-reference-costs-financial-year-2011-to-2012 [Last accessed: 1 August 2013]

34 Doeglas HM. Reactions to aspirin and food additives in patients with chronic urticaria, including the physical urticarias. British Journal of Dermatology. 1975; 93(2):135-144

35 Domingo MV, Marchuet MJC, Culla MTD, Joanpere RS, Guadano EM. Meloxicam tolerance in hypersensitivity to nonsteroidal anti-inflammatory drugs. Journal of Investigational Allergology and Clinical Immunology. 2006; 16(6):364-366

36 Dona I, Blanca-Lopez N, Cornejo-Garcia JA, Torres MJ, Laguna JJ, Fernandez J et al. Characteristics of subjects experiencing hypersensitivity to non-steroidal anti-inflammatory drugs: patterns of response. Clinical and Experimental Allergy. 2011; 41(1):86-95

37 Dona I, Blanca-Lopez N, Jagemann LR, Torres MJ, Rondon C, Campo P et al. Response to a selective COX-2 inhibitor in patients with urticaria/angioedema induced by nonsteroidal anti-inflammatory drugs. Allergy.: Allergy Service, Carlos Haya Hospital, Malaga, Spain. 2011; 66(11):1428-1433

38 Du W, Lehr VT, Lieh-Lai M, Koo W, Ward RM, Rieder MJ et al. An algorithm to detect adverse drug reactions in the neonatal intensive care unit. Journal of Clinical Pharmacology. 2013; 53(1):87-95

39 El Miedany Y, Youssef S, Ahmed I, El Gaafary M. Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease. Annals of Allergy, Asthma and Immunology. 2006; 97(1):105-109

40 Emanueli A, Sacchetti G. An algorithm for the classification of untoward events in large scale clinical trials. Agents and Actions Supplements. 1980; 7:318-322

41 Eneh O, Fahy S. Audit of documentation of allergies in a psychiatric inpatient unit. Irish Journal of Psychological Medicine. 2011; 28(4):213-216

42 Evans RS, Classen DC, Pestotnik SL, Clemmer TP, Weaver LK, Burke JP. A decision support tool for antibiotic therapy. Proceedings of the Annual Symposium on Computer Application in Medical Care Symposium on Computer Applications in Medical Care. 1995;651-655

43  Evans RS, Pestotnik SL, Classen DC, Clemmer TP, Weaver LK, Orme JF, Jr. et al. A computer-assisted management program for antibiotics and other antiinfective agents. New England Journal of Medicine. 1998; 338(4):232-238

44  Evans RS, Pestotnik SL, Classen DC, Horn SD, Bass SB, Burke JP. Preventing adverse drug events in hospitalized patients. Annals of Pharmacotherapy. 1994; 28(4):523-527

45  Evreux JC, Loupi E, Descotes J, Ventre JJ. [Evaluation of the documentation on adverse effects of drugs. Proposition. 2. Imputability]. Therapie. 1982; 37(6):657-670

46  Fisher MM, Baldo BA. Immunoassays in the diagnosis of anaphylaxis to neuromuscular blocking drugs: the value of morphine for the detection of IgE antibodies in allergic subjects. Anaesthesia and Intensive Care. 2000; 28(2):167-170

47  Fontaine C, Mayorga C, Bousquet PJ, Arnoux B, Torres MJ, Blanca M et al. Relevance of the determination of serum-specific IgE antibodies in the diagnosis of immediate beta-lactam allergy. Allergy. 2007; 62(1):47-52

48  Franic DM, Pathak DS. Communicating the frequency of adverse drug reactions to female patients. Drug Information Journal. 2000; 34(1):251-272

49  Frigas E, Park MA, Narr BJ, Volcheck GW, Danielson DR, Markus PJ et al. Preoperative evaluation of patients with history of allergy to penicillin: comparison of 2 models of practice. Mayo Clinic Proceedings Mayo Clinic. 2008; 83(6):651-662

50  Gallagher RM, Kirkham JJ, Mason JR, Bird KA, Williamson PR, Nunn AJ et al. Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool. PloS One. 2011; 6(12):e28096

51  Garcia-Rodriguez RM, Hinojosa M, Camacho-Garrido E, Berges-Gimeno MP, Martin-Garcia C. Celecoxib, safe in NSAID intolerance. Allergy. 2002; 57(11):1085-1086

52  Garvey LH, Kroigaard M, Poulsen LK, Skov PS, Mosbech H, Venemalm L et al. IgE-mediated allergy to chlorhexidine. Journal of Allergy and Clinical Immunology. 2007; 120(2):409-415

53  Goksel O, Aydin O, Misirligil Z, Demirel YS, Bavbek S. Safety of meloxicam in patients with aspirin/non-steroidal anti-inflammatory drug-induced urticaria and angioedema. Journal of Dermatology. 2010; 37(11):973-979

54  Gonzalez J, Guerra F, Moreno C, Miguel R, Daza JC, Sanchez Guijo P. Assessment of a self-designed protocol on patients with adverse reactions to beta-lactam antibiotics. Allergologia Et Immunopathologia. 1992; 20(5):184-189

55  Gyllfors P, Bochenek G, Overholt J, Drupka D, Kumlin M, Sheller J et al. Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib. Journal of Allergy and Clinical Immunology. 2003; 111(5):1116-1121

56  Hackl WO, Ammenwerth E, Marcilly R, Chazard E, Luyckx M, Leurs P et al. Clinical evaluation of the ADE scorecards as a decision support tool for adverse drug event analysis and medication safety management. British Journal of Clinical Pharmacology. 2013; 76(S1):78-90

57  Harboe T, Guttormsen AB, Irgens A, Dybendal T, Florvaag E. Anaphylaxis during anesthesia in Norway: a 6-year single-center follow-up study. Anesthesiology. 2005; 102(5):897-903

58 Harris MF, Giles A, O'Toole BI. Communication across the divide. A trial of structured communication between general practice and emergency departments. Australian Family Physician. 2002; 31(2):197-200

59 Hedman J, Kaprio J, Poussa T, Nieminen MM. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. International Journal of Epidemiology. 1999; 28(4):717-722

60 Hippern LD, Halapy H. Assessing penicillin allergies with a structured assessment form. Canadian Journal of Hospital Pharmacy. 2000; 53(3):184-192

61 Holm A, Mosbech H. Challenge test results in patients with suspected penicillin allergy, but no specific iGE. Allergy. 2011; 3(2):118-122

62 Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Annals of Pharmacotherapy. 2007; 41(4):674-680

63 Hoskins W, Mannino S. Causality assessment of adverse drug reactions using decision support and infomatics tools. Pharmacoepidemiology and Drug Safety. 1992; 1992(1):-235

64 Hsieh TC, Kuperman GJ, Jaggi T, Hojnowski-Diaz P, Fiskio J, Williams DH et al. Characteristics and consequences of drug allergy alert overrides in a computerized physician order entry system. Journal of the American Medical Informatics Association. 2004; 11(6):482-491

65 Hsu P-H, Stoll RW. Causality assessment of adverse events in clinical trials: II. An algorithm for drug causality assessment. Drug Information Journal. 1993; 27(2):387-394

66 Hughes L, Whittlesea C, Luscombe D. Patients' knowledge and perceptions of the side-effects of OTC medication. Journal of Clinical Pharmacy and Therapeutics. 2002; 27(4):243-248

67 Hunteman L, Ward L, Read D, Jolly M, Heckman M. Analysis of allergy alerts within a computerized prescriber-order-entry system. American Journal of Health-System Pharmacy. 2009; 66(4):373-377

68 Hutchinson TA. Computerised Bayesian ADE assessment. Drug Information Journal. 1991; 25(2):235-241

69 Immunology Quality Services. Protein reference units. 2013. Available from: http://www.immqas.org.uk/pru.asp?ID=316 [Last accessed: 19 November 2013]

70 Inomata N, Osuna H, Yamaguchi J, Onoda M, Takeshita Y, Chiba Y et al. Safety of selective cyclooxygenase-2 inhibitors and a basic non-steroidal anti-inflammatory drug (NSAID) in Japanese patients with NSAID-induced urticaria and/or angioedema: Comparison of meloxicam, etodolac and tiaramide. Journal of Dermatology. 2007; 34(3):172-177

71 Joint Formulary Committee. British National Formulary (BNF). 67th edition. London: British Medical Association and The Royal Pharmaceutical Society of Great Britain; 2014. Available from: http://www.bnf.org

72 Jones JK. Adverse drug reactions in the community health setting: approaches to recognizing, counseling, and reporting. Family and Community Health. 1982; 5(2):58-67

73  Kane-Gill SL, Forsberg EA, Verrico MM, Handler SM. Comparison of three pharmacovigilance algorithms in the ICU setting: a retrospective and prospective evaluation of ADRs. Drug Safety. 2012; 35(8):645-653

74  Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. Clinical Pharmacology and Therapeutics. 1977; 21(3):247-254

75  Kasper L, Sladek K, Duplaga M, Bochenek G, Liebhart J, Gladysz U et al. Prevalence of asthma with aspirin hypersensitivity in the adult population of Poland. Allergy. 2003; 58(10):1064-1066

76  Kerr JR. Penicillin allergy: a study of incidence as reported by patients. British Journal of Clinical Practice. 1994; 48(1):5-7

77  Kitaguchi T, Nohiri T, Suzuki S. Some assesment systems for industry post marketing adverse drug reaction (ADR) information. Iyakuhin Kenkyu. 1983; 14:980-982

78  Kleinhans M, Linzbach L, Zedlitz S, Kaufmann R, Boehncke WH. Positive patch test reactions to celecoxib may be due to irritation and do not correlate with the results of oral provocation. Contact Dermatitis. 2002; 47(2):100-102

79  Koh Y, Shu CL. A new algorithm to identify the causality of adverse drug reactions. Drug Safety. 2005; 28(12):1159-1161

80  Koschel D, Ninck Weber C, Hoffken G. Tolerability to etoricoxib in patients with aspirin-exacerbated respiratory disease. Journal of Investigational Allergology and Clinical Immunology. 2013; 23(4):275-280

81  Kraft D, Roth A, Mischer P, Pichler H, Ebner H. Specific and total serum IgE measurements in the diagnosis of penicillin allergy. A long term follow-up study. Clinical Allergy. 1977; 7(1):21-28

82  Kraft D, Wide L. Clinical patterns and results of radioallergosorbent test (RAST) and skin tests in penicillin allergy. British Journal of Dermatology. 1976; 94(6):593-601

83  Kramer MS, Hutchinson TA. The Yale algorithm. Special workshop--clinical. Drug Information Journal. 1984; 18(3-4):283-291

84  Kramer MS, Leventhal JM, Hutchinson TA, Feinstein AR. An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use. JAMA. 1979; 242(7):623-632

85  Krska J, Anderson C, Murphy E, Avery AJ. How patient reporters identify adverse drug reactions: a qualitative study of reporting via the UK Yellow Card Scheme. Drug Safety. 2011; 34(5):429-436

86  Kuperman GJ, Gandhi TK, Bates DW. Effective drug-allergy checking: methodological and operational issues. Journal of Biomedical Informatics. 2003; 36(1-2):70-79

87  Laaksonen R, Duggan C, Bates I. Desire for information about drugs: relationships with patients' characteristics and adverse effects. Pharmacy World and Science. 2002; 24(5):205-210

88  Lagier G, Vincens M, Castot A. [Imputability in drug monitoring. Principles of the balanced drug reaction assessment method and principal errors to avoid]. Therapie. 1983; 38(3):303-318

89  Lanctot KL, Kwok MCO, Naranjo CA. Computerised Bayesian evaluation of adverse events. Drug Information Journal. 1995; 29:319-325

90  Lanctot KL, Naranjo CA. Comparison of the Bayesian approach and a simple algorithm for assessment of adverse drug events. Clinical Pharmacology and Therapeutics. 1995; 58(6):692-698

91  Lane DA, Kramer MS, Hutchinson TA, Jones JK, Naranjo C. The causality assessment of adverse drug reactions using a Bayesian approach. Pharmaceutical Medicine. 1987; 2(3):265-283

92  Laroche D, Chollet-Martin S, Leturgie P, Malzac L, Vergnaud MC, Neukirch C et al. Evaluation of a new routine diagnostic test for immunoglobulin e sensitization to neuromuscular blocking agents. Anesthesiology. 2011; 114(1):91-97

93  Leung AA, Keohane C, Lipsitz S, Zimlichman E, Amato M, Simon SR et al. Relationship between medication event rates and the leapfrog computerized physician order entry evaluation tool. Journal of the American Medical Informatics Association. 2013; 20(E1):e85-e90

94  Liccardi G, Cazzola M, De Giglio C, Manfredi D, Piscitelli E, D'Amato M et al. Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and other non-steroidal anti-inflammatory drugs. Journal of Investigational Allergology and Clinical Immunology. 2005; 15(4):249-253

95  Liccardi G, Salzillo A, Piccolo A, Senna GE, Piscitelli E, D'Amato M et al. Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs. European Annals of Allergy and Clinical Immunology. 2005; 37(2):50-53

96  Llanora GV, Loo EXL, Gerez IF, Cheng YK. Etoricoxib: a safe alternative for NSAID intolerance in Asian patients. Asian Pacific Journal of Allergy and Immunology. 2013; 31(4):330-333

97  Lorimer S, Cox A, Langford NJ. A patient's perspective: the impact of adverse drug reactions on patients and their views on reporting. Journal of Clinical Pharmacy and Therapeutics. 2012; 37(2):148-152

98  Mahoney CD, Berard-Collins CM, Coleman R, Amaral JF, Cotter CM. Effects of an integrated clinical information system on medication safety in a multi-hospital setting. American Journal of Health-System Pharmacy. 2007; 64(18):1969-1977

99  Malinovsky J-M, Decagny S, Wessel F, Guilloux L, Mertes PM. Systematic follow-up increases incidence of anaphylaxis during adverse reactions in anesthetized patients. Acta Anaesthesiologica Scandinavica. 2008; 52(2):175-181

100 Marco AP, Buchman D, Lancz C. Influence of form structure on the anesthesia preoperative evaluation. Journal of Clinical Anesthesia. 2003; 15(6):411-417

101 Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology. 1997; 26:664-669

102 Martin-Garcia C, Hinojosa M, Berges P, Camacho E, Garcia-Rodriguez R, Alfaya T. Celecoxib, a highly selective COX-2 inhibitor, is safe in aspirin-induced asthma patients. Journal of Investigational Allergology and Clinical Immunology. 2003; 13(1):20-25

103 Mashford ML. The Australian method of drug-event assessment. Special workshop--regulatory. Drug Information Journal. 1984; 18(3-4):271-273

104 Mead GE, Cunnington AL, Faulkner S, Russell KJ, Ford MJ. Can general practitioner referral letters for acute medical admissions be improved? Health Bulletin. 1999; 57(4):257-261

105 Menendez MD, Alonso J, Rancano I, Corte JJ, Herranz V, Vazquez F. Impact of computerized physician order entry on medication errors. Revista De Calidad Asistencial. 2012; 27(6):334-340

106 Mertes PM, Laxenaire M-C, Alla F, Groupe d'Etudes des Reactions Anaphylactoides Peranesthesiques. Anaphylactic and anaphylactoid reactions occurring during anesthesia in France in 1999-2000. Anesthesiology. 2003; 99(3):536-545

107 Michel DJ, Knodel LC. Comparison of three algorithms used to evaluate adverse drug reactions. American Journal of Hospital Pharmacy. 1986; 43(7):1709-1714

108 Mihaela TA, Popescu FD, Mariana V, Florica P. The safety profile of etoricoxib in autoreactive urticaria. Therapeutics, Pharmacology and Clinical Toxicology. 2012; 16(2):116-120

109 Moore-Robinson M, Warin RP. Effect of salicylates in urticaria. British Medical Journal. 1967; 4(5574):262-264

110 Mullett CJ, Evans RS, Christenson JC, Dean JM. Development and impact of a computerized pediatric antiinfective decision support program. Pediatrics. 2001; 108(4):E75

111 Muratore L, Ventura M, Calogiuri G, Calcagnile F, Quarta E, Muratore M et al. Tolerance to etoricoxib in 37 patients with urticaria and angioedema induced by nonsteroidal anti-inflammatory drugs. Annals of Allergy, Asthma & Immunology: Official Publication of the American College of Allergy, Asthma, & Immunology.: Allergology and Clinical Immunology Service, Vito Fazzi Hospital, Lecce, Italy. 2007; 98(2):168-171

112 Naccarelli GV, Panaccio MP, Cummins G, Tu N. CHADS2 and CHA2DS2-VASc risk factors to predict first cardiovascular hospitalization among atrial fibrillation/atrial flutter patients. American Journal of Cardiology. 2012; 109(10):1526-1533

113 Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA et al. A method for estimating the probability of adverse drug reactions. Clinical Pharmacology and Therapeutics. 1981; 30(2):239-245

114 National Clinical Guideline Centre. Patient experience in adult NHS services: improving the experience of care for people using adult NHS services. NICE clinical guideline 138. London. National Clinical Guideline Centre, 2012. Available from: http://www.nice.org.uk/CG138

115 National Institute for Health and Clinical Excellence. Social value judgements: principles for the development of NICE guidance. 2nd edition. London: National Institute for Health and Clinical Excellence; 2008. Available from: http://www.nice.org.uk/media/C18/30/SVJ2PUBLICATION2008.pdf

116 National Institute for Health and Clinical Excellence. Anaphylaxis: assessment to confirm an anaphylactic episode and the decision to refer after emergency treatment for a suspected anaphylactic episode. NICE clinical guideline 134. London. National Institute for Health and Clinical Excellence, 2011. Available from: http://guidance.nice.org.uk/CG134

117 National Institute for Health and Clinical Excellence. The guidelines manual. London: National Institute for Health and Clinical Excellence; 2012. Available from: http://publications.nice.org.uk/the-guidelines-manual-pmg6/

118 National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal 2013. 2nd Ed edition. London: National Institute for Health and Clinical Excellence; 2013. Available from: http://publications.nice.org.uk/pmg9

119 Nettis E, Di Paola R, Ferrannini A, Tursi A. Meloxicam in hypersensitivity to NSAIDs. *Allergy*. 2001; 56(8):803-804

120 Nettis E, Colanardi MC, Ferrannini A, Vacca A, Tursi A. Short-term tolerability of etoricoxib in patients with cutaneous hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. *Annals of Allergy, Asthma and Immunology*. 2005; 95(5):438-442

121 Neubert A, Dormann H, Prokosch HU, Burkle T, Rascher W, Sojer R et al. E-pharmacovigilance: development and implementation of a computable knowledge base to identify adverse drug reactions. *British Journal of Clinical Pharmacology*. 2013; 76 Suppl 1:69-77

122 NHS England. Drug allergies: an eight year review of NRLS medication incident reports 01 April 2005 to 31 March 2013 (unpublished), 2013

123 Organisation for Economic Co-operation and Development (OECD). Purchasing power parities (PPP). 2013. Available from: http://www.oecd.org/std/ppp [Last accessed: 16 January 2013]

124 Ortega A, Aguinagalde A, Lacasa C, Aquerreta I, Fernandez-Benitez M, Fernandez LM. Efficacy of an adverse drug reaction electronic reporting system integrated into a hospital information system. *Annals of Pharmacotherapy*. 2008; 42(10):1491-1496

125 Pagani M, Bonadonna P, Dama A, Senna GE, Vescovi PP, Antico A. Long-term tolerability of etoricoxib in different types of NSAID-intolerant subjects. *European Annals of Allergy and Clinical Immunology*. 2010; 42(6):216-220

126 Pere JC, Begaud B, Haramburu F, Albin H. Computerized comparison of six adverse drug reaction assessment procedures. *Clinical Pharmacology and Therapeutics*. 1986; 40(4):451-461

127 Porter SC, Manzi SF, Volpe D, Stack AM. Getting the data right: information accuracy in pediatric emergency medicine. *Quality and Safety in Health Care*. 2006; 15(4):296-301

128 Prieto A, De Barrio M, Martin E, Fernandez-Bohorquez M, de Castro FJ, Ruiz FJ et al. Tolerability to nabumetone and meloxicam in patients with nonsteroidal anti-inflammatory drug intolerance. *Journal of Allergy and Clinical Immunology*. 2007; 119(4):960-964

129 Qiao HL, Liu JH, Yang J, Dong ZM. Relationships between skin test, specific IgE and levels of cytokines in patients with penicillin allergy. *International Journal of Clinical Practice*. 2005; 59(8):895-899

130 Quaratino D, Romano A, Di Fonso M, Papa G, Perrone MR, D'Ambrosio FP et al. Tolerability of meloxicam in patients with histories of adverse reactions to nonsteroidal anti-inflammatory drugs. *Annals of Allergy, Asthma and Immunology*. 2000; 84(6):613-617

131 Quiralte J, Delgado J, Saenz de San Pedro B, Lopez-Pascual E, Nieto MA, Ortega N et al. Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs. *Annals of Allergy, Asthma and Immunology*. 2004; 93(4):360-364

132 Roll A, Wuthrich B, Schmid-Grendelmeier P, Hofbauer G, Ballmer-Weber BK. Tolerance to celecoxib in patients with a history of adverse reactions to nonsteroidal anti-inflammatory drugs. *Swiss Medical Weekly*. 2006; 136(43-44):684-690

133 Sala-Cunill A, Cardona V, Labrador-Horrillo M, Luengo O, Esteso O, Garriga T et al. Usefulness and limitations of sequential serum tryptase for the diagnosis of anaphylaxis in 102 patients. International Archives of Allergy and Immunology. 2013; 160(2):192-199

134 Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. Cutaneous hypersensitivity reactions to inhibitors of cyclooxygenase-2 - Results from 307 oral provocation tests and review of the literature. Allergy and Clinical Immunology International. 2007; 19(2):44-49

135 Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F, Perez CR. Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions. Annals of Allergy, Asthma and Immunology. 2001; 87(3):201-204

136 Sanz ML, Gamboa PM, De Weck AL. Clinical evaluation of in vitro tests in diagnosis of immediate allergic reactions to beta-lactam antibiotics. Allergy and Clinical Immunology International. 2002; 14(5):185-193

137 Sanz ML, Garcia BE, Prieto I, Tabar A, Oehling A. Specific IgE determination in the diagnosis of beta-lactam allergy. Journal of Investigational Allergology and Clinical Immunology. 1996; 6(2):89-93

138 Sard BE, Walsh KE, Doros G, Hannon M, Moschetti W, Bauchner H. Retrospective evaluation of a computerized physician order entry adaptation to prevent prescribing errors in a pediatric emergency department. Pediatrics. 2008; 122(4):782-787

139 Schadow G. Structured product labeling improves detection of drug-intolerance issues. Journal of the American Medical Informatics Association. 2009; 16(2):211-219

140 Senna G, Bilo MB, Antonicelli L, Schiappoli M, Crivellaro MA, Bonadonna P et al. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients. European Annals of Allergy and Clinical Immunology. 2004; 36(6):215-218

141 Senna GE, Passalacqua G, Dama A, Crivellaro M, Schiappoli M, Bonadonna P et al. Nimesulide and meloxicam are a safe alternative drugs for patients intolerant to nonsteroidal anti-inflammatory drugs. European Annals of Allergy and Clinical Immunology. 2003; 35(10):393-396

142 Silva R, Cruz L, Botelho C, Cadinha S, Castro E, Rodrigues J et al. Work up of patients with history of beta-lactam hypersensitivity. Allergologia Et Immunopathologia. 2009; 37(4):193-197

143 Silva R, Cruz L, Botelho C, Castro E, Cadinha S, Castel-Branco MG et al. Immediate hypersensitivity to penicillins with negative skin tests - The value of specific IgE. European Annals of Allergy and Clinical Immunology. 2009; 41(4):117-119

144 Simmonds M, Petterson J. Anaesthetists' records of pre-operative assessment. British Journal of Clinical Governance. 2000; 5(1):22-27

145 Soller RW, Shaheen C, Yen J, Rose J, Lightwood J. Improvement of the Drug Allergy Alert for Nonprescription NSAIDs. Drug Information Journal. 2012; 46(3):336-343

146 Son YM, Lee JR, Roh JY. Causality assessment of cutaneous adverse drug reactions. Annals of Dermatology. 2011; 23(4):432-438

147 Soto CM, Kleinman KP, Simon SR. Quality and correlates of medical record documentation in the ambulatorycare setting. BMC Health Services Research. 2002; 2:1-7

148 Spina JR, Glassman PA, Simon B, Lanto A, Lee M, Cunningham F et al. Potential safety gaps in order entry and automated drug alerts: a nationwide survey of VA physician self-reported practices with computerized order entry. Medical Care. 2011; 49(10):904-910

149 Stephens MD. Assesment of causality in industrial settings. special workshop - industrial. Drug Information Journal. 1984; 18:307-313

150 Stricker BHC. Diagnosis and causality assessment of drug-induced hepatic injury. In: Dukes MNG (eds), Drug-induced hepatic injury, Amsterdam: Elsevier, 1985: 1-13

151 Tamblyn R, Huang A, Taylor L, Kawasumi Y, Bartlett G, Grad R et al. A randomized trial of the effectiveness of on-demand versus computer-triggered drug decision support in primary care. Journal of the American Medical Informatics Association. 2008; 15(4):430-438

152 Theophile H, Andre M, Miremont-Salame G, Arimone Y, Begaud B. Comparison of three methods (an updated logistic probabilistic method, the naranjo and liverpool algorithms) for the evaluation of routine pharmacovigilance case reports using consensual expert judgement as reference. Drug Safety. 2013; 36(10):1033-1044

153 Trewin VF. The design of an algorithm for pharmacists to evaluate ADRs in the elderly. Journal of Clinical Pharmacy and Therapeutics. 1991; 16(1):45-53

154 Turner WM. The Food and Drug Administration algorithm. Special workshop--regulatory. Drug Information Journal. 1984; 18(3-4):259-266

155 University of Bristol. QUADAS-2. 2011. Available from: http://www.bris.ac.uk/quadas/quadas-2/ [Last accessed: 18 February 2014]

156 Valero A, Sanchez-Lopez J, Bartra J, Serrano C, Munoz-Cano R, Roca J et al. Safety of parecoxib in asthmatic patients with aspirin-exacerbated respiratory disease. International Archives of Allergy and Immunology. 2011; 156(2):221-223

157 Varkey P, Aponte P, Swanton C, Fischer D, Johnson SF, Brennan MD. The effect of computerized physician-order entry on outpatient prescription errors. Managed Care Interface. 2007; 20(3):53-57

158 Vega JM, Blanca M, Garcia JJ, Carmona MJ, Miranda A, Perez-Estrada M et al. Immediate allergic reactions to amoxicillin. Allergy. 1994; 49(5):317-322

159 Venulet J, Ciucci A, Berneker GC. Standardized assessment of drug-adverse reaction associations--rationale and experience. International Journal of Clinical Pharmacology, Therapy, and Toxicology. 1980; 18(9):381-388

160 Viola M, Quaratino D, Gaeta F, Caringi M, Valluzzi R, Caruso C et al. Celecoxib tolerability in patients with hypersensitivity (mainly cutaneous reactions) to nonsteroidal anti-inflammatory drugs. International Archives of Allergy and Immunology. 2005; 137(2):145-150

161 Viola M, Quaratino D, Gaeta F, Caruso C, Valluzzi R, Romano A. Etoricoxib tolerability in patients with hypersensitivity to nonsteroidal anti-inflammatory drugs. International Archives of Allergy and Immunology. 2007; 143(2):103-108

162 Vultaggio A, Matucci A, Virgili G, Rossi O, Fili L, Parronchi P et al. Influence of total serum IgE levels on the in vitro detection of beta-lactams-specific IgE antibodies. Clinical and Experimental Allergy. 2009; 39(6):838-844

163 Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine. 2011; 155(8):529-536

164 Woessner KM, Simon RA, Stevenson DD. The safety of celecoxib in patients with aspirin-sensitive asthma. Arthritis and Rheumatism. 2002; 46(8):2201-2206

165 Wolfstadt JI, Gurwitz JH, Field TS, Lee M, Kalkar S, Wu W et al. The effect of computerized physician order entry with clinical decision support on the rates of adverse drug events: a systematic review. Journal of General Internal Medicine. 2008; 23(4):451-458

166 World Health Organisation UMC. The use of the WHO_UMC system for standardised case causality assessment, 2007. Available from: http://who-umc.org/Graphics/24734.pdf

167 Zenk KE, Randall RJ, Fukumitsu CJ. Notation of allergies and body weight on patient profiles. Drug Intelligence and Clinical Pharmacy. 1984; 18(7-8):625-626